BINDING MOLECULES FOR BCMA AND CD3

Abstract

The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster 3 of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.

Claims

1. A chimeric human/murine BCMA extracellular domain consisting of SEQ ID NO: 1015.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0360] FIG. 1:

[0361] Sequence alignment of the extracellular domain (ECD) of human BCMA (amino acid residues 1-54 of the full-length protein) and murine BCMA (amino acid residues 1-49 of the full-length protein). Highlighted are the regions (domains or amino acid residues) which were exchanged in the chimeric constructs, as designated for the epitope clustering. Cysteines are depicted by black boxes. Disulfide bonds are indicated.

[0362] FIGS. 2A-B:

[0363] Epitope mapping of the BCMA constructs. Human and murine BCMA (FIG. 2A) as well as seven chimeric human-murine BCMA constructs (FIG. 2B) expressed on the surface of CHO cells as shown by flow cytometry. The expression of human BCMA on CHO was detected with a monoclonal anti-human BCMA antibody. Murine BCMA expression was detected with a monoclonal anti-murine BCMA-antibody. Bound monoclonal antibody was detected with an anti-rat IgG-Fc-gamma-specific antibody conjugated to phycoerythrin.

[0364] FIG. 3:

[0365] Examples of binding molecules specific for epitope cluster E3, as detected by epitope mapping of the chimeric BCMA constructs (see example 3).

[0366] FIGS. 4A-D:

[0367] Determination of binding constants of bispecific binding molecules (anti BCMA x anti CD3) on human and macaque BCMA using the Biacore system. Antigen was immobilized in low to intermediate density (100 RU) on CM5 chip. Dilutions of binders were floated over the chip surface and binding determined using BiaEval Software. Respective off-rates and the binding constant (KD) of the respective binders are depicted below every graph. FIG. 4A depicts the measured binding constant of BCMA-101×CD3 on human BCMA. FIG. 4B depicts the measured binding constant of BCMA-101×CD3 on macaque BCMA. FIG. 4C depicts the measured binding constant of BCMA-102×CD3 on human BCMA. FIG. 4D depicts the measured binding constant of BCMA-102×CD3 on macaque BCMA.

[0368] FIGS. 5A-B:

[0369] Cytotoxic activity of BCMA bispecific antibodies as measured in an 18-hour .sup.51chromium release assay. Effector cells: stimulated enriched human CD8 T cells. Target cells: Human BCMA transfected CHO cells (FIG. 5A) and macaque BCMA transfected CHO cells (FIG. 5B). Effector to target cell (E:T) ratio: 10:1.

[0370] FIGS. 6A-H:

[0371] Determination of binding constants of BCMA/CD3 bispecific antibodies of epitope cluster E3 on human and macaque BCMA and on human and macaque CD3 using the Biacore system. Antigen was immobilized in low to intermediate density (100-200 RU) on CM5 chip. Dilutions of bispecific antibodies were floated over the chip surface and binding determined using BiaEval Software. Respective on- and off-rates and the resulting binding constant (KD) of the respective bispecific antibodies are depicted below every graph. FIG. 6A depicts a measured binding constant of BCMA-34×CD3 on human BCMA. FIG. 6B depicts a measured binding constant of BCMA-34×CD3 on macaque BCMA. FIG. 6C depicts a measured binding constant of BCMA-34×CD3 on human CD3. FIG. 6D depicts a measured binding constant of BCMA-34×CD3 on macaque CD3. FIG. 6E depicts a measured binding constant of BCMA-98×CD3 on human BCMA. FIG. 6F depicts a measured binding constant of BCMA-98×CD3 on macaque BCMA. FIG. 6G depicts a measured binding constant of BCMA-98×CD3 on human CD3. FIG. 6H depicts a measured binding constant of BCMA-98×CD3 on macaque CD3.

[0372] FIGS. 7A-F:

[0373] FACS analysis of BCMA/CD3 bispecific antibodies of epitope cluster E3 on indicated cell lines: human BCMA transfected CHO cells (FIG. 7A), human CD3 positive human T cell line HBP-ALL (FIG. 7B), macaque BCMA transfected CHO cells (FIG. 7C), macaque T cell line 4119 LnPx (FIG. 7D), BCMA-positive human multiple myeloma cell line NCI-H929 (FIG. 7E), and untransfected CHO cells (FIG. 7F). Negative controls [for FIGS. 7A-F]: detection antibodies without prior BCMA/CD3 bispecific antibody.

[0374] FIGS. 8A-D:

[0375] Scatchard analysis of BCMA/CD3 bispecific antibodies on BCMA-expressing cells. Cells were incubated with increasing concentrations of monomeric antibody until saturation. Antibodies were detected by flow cytometry. Values of triplicate measurements were plotted as hyperbolic curves and as sigmoid curves to demonstrate a valid concentration range used. Maximal binding was determined using Scatchard evaluation, and the respective KD values were calculated. FIG. 8A depicts a Scatchard analysis of BCMA-20×CD3 on CHO cells expressing human BCMA as a hyperbolic curve. FIG. 8B depicts a Scatchard analysis of BCMA-20×CD3 on CHO cells expressing human BCMA as a sigmoid curve. FIG. 8C depicts a Scatchard analysis of BCMA-20×CD3 on CHO cells expressing macaque BCMA as a hyperbolic curve. FIG. 8D depicts a Scatchard analysis of BCMA-20×CD3 on CHO cells expressing macaque BCMA as a sigmoid curve.

[0376] FIGS. 9A-B:

[0377] Cytotoxic activity of BCMA/CD3 bispecific antibodies of epitope cluster E3, as measured in an 18-hour 51-chromium release assay against CHO cells transfected with human BCMA. Effector cells: stimulated enriched human CD8 T cells. Effector to target cell (E:T) ratio: 10:1. FIG. 9A depicts a measured 51-chromium release assay of BCMA-97×CD3, BCMA-98×CD3, BCMA-99×CD3, and BCMA-100×CD3 on CHO cells expressing human BCMA. FIG. 9B depicts a measured 51-chromium release assay of BCMA-82×CD3, BCMA-83×CD3, and BCMA-84×CD3 on CHO cells expressing human BCMA.

[0378] FIG. 10:

[0379] Cytotoxic activity of BCMA/CD3 bispecific antibodies of epitope cluster E3 as measured in a 48-hour FACS-based cytotoxicity assay. Effector cells: unstimulated human PBMC. Target cells: CHO cells transfected with human BCMA. Effector to target cell (E:T)-ratio: 10:1.

[0380] FIGS. 11A-H:

[0381] FACS analysis of BCMA/CD3 bispecific antibodies of epitope cluster E3 on BAFF-R and TACI transfected CHO cells. Cell lines: 1) human BAFF-R transfected CHO cells, 2) human TACI transfected CHO cells 3) multiple myeloma cell line L363; negative controls: detection antibodies without prior BCMA/CD3 bispecific antibody. Positive controls: BAFF-R detection: goat anti hu BAFF-R (R&D AF1162; 1:20) detected by anti-goat antibody-PE (Jackson 705-116-147; 1:50) TACI-detection: rabbit anti TACI antibody (abcam AB 79023; 1:100) detected by goat anti rabbit-antibody PE (Sigma P9757; 1:20). FIG. 11A depicts FACS analysis of CHO cells expressing human BAFF-R treated with BCMA-98. FIG. 11B depicts FACS analysis of CHO cells expressing human TACI treated with BCMA-98. FIG. 11C depicts FACS analysis of L393 cells treated with BCMA-98. FIG. 11D depicts FACS analysis of CHO cells expressing human BAFF-R treated with BCMA-34. FIG. 11E depicts FACS analysis of CHO cells expressing human TACI treated with BCMA-34. FIG. 11F depicts FACS analysis of L393 cells treated with BCMA-34. FIG. 11G depicts a positive control FACS analysis of CHO cells expressing human BAFF-R with an anti-BAFF-R antibody. FIG. 11H depicts a positive control FACS analysis of CHO cells expressing human TACI with an anti-TACI antibody.

[0382] FIG. 12:

[0383] Cytotoxic activity of BCMA/CD3 bispecific antibodies as measured in an 18-hour 51-chromium release assay. Effector cells: stimulated enriched human CD8 T cells. Target cells: BCMA-positive human multiple myeloma cell line L363 (i.e. natural expresser). Effector to target cell (E:T) ratio: 10:1.

[0384] FIG. 13:

[0385] Cytotoxic activity of BCMA/CD3 bispecific antibodies as measured in a 48-hour FACS-based cytotoxicity assay. Effector cells: unstimulated human PBMC. Target cells: human multiple myeloma cell line L363 (natural BCMA expresser). Effector to target cell (E:T)-ratio: 10:1.

[0386] FIG. 14:

[0387] Cytotoxic activity of BCMA/CD3 bispecific antibodies as measured in a 48-hour FACS-based cytotoxicity assay. Effector cells: unstimulated human PBMC. Target cells: BCMA-positive human multiple myeloma cell line NCI-H929. Effector to target cell (E:T)-ratio: 10:1.

[0388] FIG. 15:

[0389] Cytotoxic activity of BCMA/CD3 bispecific antibodies as measured in a 48-hour FACS-based cytotoxicity assay. Effector cells: macaque T cell line 4119LnPx. Target cells: CHO cells transfected with macaque BCMA. Effector to target cell (E:T) ratio: 10:1.

[0390] FIG. 16:

[0391] Anti-tumor activity of BCMA/CD3 bispecific antibodies of epitope cluster E3 in an advanced-stage NCI-H929 xenograft model (see Example 16).

[0392] FIGS. 17A-F:

[0393] FACS-based cytotoxicity assay using human multiple myeloma cell lines NCI-H929, L-363 and OPM-2 as target cells and human PBMC as effector cells (48 h; E:T=10:1). The figure depicts the cytokine levels [pg/ml] which were determined for 11-2, IL-6, IL-10, TNF and IFN-gamma at increasing concentrations of the BCMA/CD3 bispecific antibodies of epitope cluster E3 (see Example 22). FIG. 17A depicts a measured cytotoxicity assay of NCI-H929 cells treated with BCMA-98×CD3. FIG. 17B depicts a measured cytotoxicity assay of NCI-H929 cells treated with BCMA-34×CD3. FIG. 17C depicts a measured cytotoxicity assay of OPM-2 cells treated with BCMA-98×CD3. FIG. 17D depicts a measured cytotoxicity assay of OPM-2 cells treated with BCMA-34×CD3. FIG. 17E depicts a measured cytotoxicity assay of L-363 cells treated with BCMA-98×CD3. FIG. 17F depicts a measured cytotoxicity assay of L-363 cells treated with BCMA-34×CD3.

EXAMPLES

[0394] The following examples illustrate the invention. These examples should not be construed as to limit the scope of this invention. The examples are included for purposes of illustration, and the present invention is limited only by the claims.

Example 1

[0395] Generation of CHO Cells Expressing Chimeric BCMA

[0396] For the construction of the chimeric epitope mapping molecules, the amino acid sequence of the respective epitope domains or the single amino acid residue of human BCMA was changed to the murine sequence. The following molecules were constructed:

[0397] Human BCMA ECD/E1 murine (SEQ ID NO: 1009)

[0398] Chimeric extracellular BCMA domain: Human extracellular BCMA domain wherein epitope cluster 1 (amino acid residues 1-7 of SEQ ID NO: 1002 or 1007) is replaced by the respective murine cluster (amino acid residues 1-4 of SEQ ID NO: 1004 or 1008)

[0399] .fwdarw.deletion of amino acid residues 1-3 and G6Q mutation in SEQ ID NO: 1002 or 1007

[0400] Human BCMA ECD/E2 murine (SEQ ID NO: 1010)

[0401] Chimeric extracellular BCMA domain: Human extracellular BCMA domain wherein epitope cluster 2 (amino acid residues 8-21 of SEQ ID NO: 1002 or 1007) is replaced by the respective murine cluster (amino acid residues 5-18 of SEQ ID NO: 1004 or 1008)

[0402] .fwdarw.S9F, Q10H, and N11S mutations in SEQ ID NO: 1002 or 1007

[0403] Human BCMA ECD/E3 murine (SEQ ID NO: 1011)

[0404] Chimeric extracellular BCMA domain: Human extracellular BCMA domain wherein epitope cluster 3 (amino acid residues 24-41 of SEQ ID NO: 1002 or 1007) is replaced by the respective murine cluster (amino acid residues 21-36 of SEQ ID NO: 1004 or 1008)

[0405] .fwdarw.deletion of amino acid residues 31 and 32 and Q25H, S30N, L35A, and R39P mutation in SEQ ID NO: 1002 or 1007

[0406] Human BCMA ECD/E4 murine (SEQ ID NO: 1012)

[0407] Chimeric extracellular BCMA domain: Human extracellular BCMA domain wherein epitope cluster 4 (amino acid residues 42-54 of SEQ ID NO: 1002 or 1007) is replaced by the respective murine cluster (amino acid residues 37-49 of SEQ ID NO: 1004 or 1008)

[0408] .fwdarw.N42D, A43P, N47S, N53Y and A54T mutations in SEQ ID NO: 1002 or 1007

[0409] Human BCMA ECD/E5 murine (SEQ ID NO: 1013)

[0410] Chimeric extracellular BCMA domain: Human extracellular BCMA domain wherein the amino acid residue at position 22 of SEQ ID NO: 1002 or 1007 (isoleucine) is replaced by its respective murine amino acid residue of SEQ ID NO: 1004 or 1008 (lysine, position 19)

[0411] .fwdarw.122K mutation in SEQ ID NO: 1002 or 1007

[0412] Human BCMA ECD/E6 murine (SEQ ID NO: 1014)

[0413] Chimeric extracellular BCMA domain: Human extracellular BCMA domain wherein the amino acid residue at position 25 of SEQ ID NO: 1002 or 1007 (glutamine) is replaced by its respective murine amino acid residue of SEQ ID NO: 1004 or 1008 (histidine, position 22)

[0414] .fwdarw.Q25H mutation in SEQ ID NO: 1002 or 1007

[0415] Human BCMA ECD/E7 murine (SEQ ID NO: 1015)

[0416] Chimeric extracellular BCMA domain: Human extracellular BCMA domain wherein the amino acid residue at position 39 of SEQ ID NO: 1002 or 1007 (arginine) is replaced by its respective murine amino acid residue of SEQ ID NO: 1004 or 1008 (proline, position 34)

[0417] .fwdarw.R39P mutation in SEQ ID NO: 1002 or 1007

[0418] A) The cDNA constructs were cloned into the mammalian expression vector pEF-DHFR and stably transfected into CHO cells. The expression of human BCMA on CHO cells was verified in a FACS assay using a monoclonal anti-human BCMA antibody. Murine BCMA expression was demonstrated with a monoclonal anti-mouse BCMA-antibody. The used concentration of the BCMA antibodies was 10 μg/ml in PBS/2% FCS. Bound monoclonal antibodies were detected with an anti-rat-IgG-Fcy-PE (1:100 in PBS/2% FCS; Jackson-Immuno-Research #112-116-071). As negative control, cells were incubated with PBS/2% FCS instead of the first antibody. The samples were measured by flow cytometry on a FACSCanto II instrument (Becton Dickinson) and analyzed by FlowJo software (Version 7.6). The surface expression of human-murine BCMA chimeras, transfected CHO cells were analyzed and confirmed in a flow cytometry assay with different anti-BCMA antibodies (FIGS. 2A-B).

[0419] B) For the generation of CHO cells expressing human, macaque, mouse and human/mouse chimeric transmembrane BCMA, the coding sequences of human, macaque, mouse BCMA and the human-mouse BCMA chimeras (BCMA sequences as published in GenBank, accession numbers NM_001192 [human]; NM_011608 [mouse] and XM_001106892 [macaque]) were obtained by gene synthesis according to standard protocols. The gene synthesis fragments were designed as to contain first a Kozak site for eukaryotic expression of the constructs and the coding sequence of a 19 amino acid immunoglobulin leader peptide, followed in frame by the coding sequence of the BCMA proteins respectively in case of the chimeras with the respective epitope domains of the human sequence exchanged for the murine sequence.

[0420] Except for the human BCMA ECD/E4 murine and human BCMA constructs the coding sequence of the extracellular domain of the BCMA proteins was followed in frame by the coding sequence of an artificial Ser1-Gly4-Ser1-linker followed by the intracellular domain of human EpCAM (amino acids 226-314; sequence as published in GenBank accession number NM_002354).

[0421] All coding sequences were followed by a stop codon. The gene synthesis fragments were also designed as to introduce suitable restriction sites. The gene synthesis fragments were cloned into a plasmid designated pEF-DHFR (pEF-DHFR is described in Raum et al. Cancer Immunol Immunother 50 (2001) 141-150). All aforementioned procedures were carried out according to standard protocols (Sambrook, Molecular Cloning; A Laboratory Manual, 3rd edition, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, N.Y. (2001)). For each antigen a clone with sequence-verified nucleotide sequence was transfected into DHFR deficient CHO cells for eukaryotic expression of the constructs. Eukaryotic protein expression in DHFR deficient CHO cells was performed as described by Kaufman R. J. (1990) Methods Enzymol. 185, 537-566. Gene amplification of the constructs was induced by increasing concentrations of methotrexate (MTX) to a final concentration of up to 20 nM MTX.

Example 2

[0422] 2.1 Transient Expression in HEK 293 Cells

[0423] Clones of the expression plasmids with sequence-verified nucleotide sequences were used for transfection and protein expression in the FreeStyle 293 Expression System (Invitrogen GmbH, Karlsruhe, Germany) according to the manufacturer's protocol. Supernatants containing the expressed proteins were obtained, cells were removed by centrifugation and the supernatants were stored at −20 C.

[0424] 2.2 Stable Expression in CHO Cells

[0425] Clones of the expression plasmids with sequence-verified nucleotide sequences were transfected into DHFR deficient CHO cells for eukaryotic expression of the constructs. Eukaryotic protein expression in DHFR deficient CHO cells was performed as described by Kaufman R. J. (1990) Methods Enzymol. 185, 537-566. Gene amplification of the constructs was induced by increasing concentrations of methotrexate (MTX) to a final concentration of 20 nM MTX. After two passages of stationary culture the cells were grown in roller bottles with nucleoside-free HyQ PF CHO liquid soy medium (with 4.0 mM L-Glutamine with 0.1% Pluronic F—68; HyClone) for 7 days before harvest. The cells were removed by centrifugation and the supernatant containing the expressed protein was stored at −20 C.

[0426] 2.3 Protein Purification

[0427] Purification of soluble BCMA proteins was performed as follows: Äkta® Explorer System (GE Healthcare) and Unicorn® Software were used for chromatography. Immobilized metal affinity chromatography (“IMAC”) was performed using a Fractogel EMD chelate® (Merck) which was loaded with ZnCl2 according to the protocol provided by the manufacturer. The column was equilibrated with buffer A (20 mM sodium phosphate buffer pH 7.2, 0.1 M NaCl) and the filtrated (0.2 μm) cell culture supernatant was applied to the column (10 ml) at a flow rate of 3 ml/min. The column was washed with buffer A to remove unbound sample. Bound protein was eluted using a two-step gradient of buffer B (20 mM sodium phosphate buffer pH 7.2, 0.1 M NaCl, 0.5 M imidazole) according to the following procedure:

[0428] Step 1: 10% buffer B in 6 column volumes

[0429] Step 2: 100% buffer B in 6 column volumes

[0430] Eluted protein fractions from step 2 were pooled for further purification. All chemicals were of research grade and purchased from Sigma (Deisenhofen) or Merck (Darmstadt).

[0431] Gel filtration chromatography was performed on a HiLoad 16/60 Superdex 200 prep grade column (GE/Amersham) equilibrated with Equi-buffer (10 mM citrate, 25 mM lysine-HCl, pH 7.2 for proteins expressed in HEK cells and PBS pH 7.4 for proteins expressed in CHO cells). Eluted protein samples (flow rate 1 ml/min) were subjected to standard SDS-PAGE and Western Blot for detection. Protein concentrations were determined using OD280 nm.

[0432] Proteins obtained via transient expression in HEK 293 cells were used for immunizations. Proteins obtained via stable expression in CHO cells were used for selection of binders and for measurement of binding.

Example 3

[0433] Epitope Clustering of Murine scFv-Fragments

[0434] Cells transfected with human or murine BCMA, or with chimeric BCMA molecules were stained with crude, undiluted periplasmic extract containing scFv binding to human/macaque BCMA. Bound scFv were detected with 1 μg/ml of an anti-FLAG antibody (Sigma F1804) and a R-PE-labeled anti-mouse Fc gamma-specific antibody (1:100; Dianova #115-116-071). All antibodies were diluted in PBS with 2% FCS. As negative control, cells were incubated with PBS/2% FCS instead of the periplasmic extract. The samples were measured by flow cytometry on a FACSCanto II instrument (Becton Dickinson) and analyzed by FlowJo software (Version 7.6); see FIG. 3.

Example 4

[0435] Procurement of Different Recombinant Forms of Soluble Human and Macaque BCMA

[0436] A) The coding sequences of human and rhesus BCMA (as published in GenBank, accession numbers NM_001192 [human], XM_001106892 [rhesus]) coding sequences of human albumin, human Fcγ1 and murine albumin were used for the construction of artificial cDNA sequences encoding soluble fusion proteins of human and macaque BCMA respectively and human albumin, human IgG1 Fc and murine albumin respectively as well as soluble proteins comprising only the extracellular domains of BCMA. To generate the constructs for expression of the soluble human and macaque BCMA proteins, cDNA fragments were obtained by PCR mutagenesis of the full-length BCMA cDNAs described above and molecular cloning according to standard protocols.

[0437] For the fusions with human albumin, the modified cDNA fragments were designed as to contain first a Kozak site for eukaryotic expression of the constructs followed by the coding sequence of the human and rhesus (or Macaca mulatta) BCMA proteins respectively, comprising amino acids 1 to 54 and 1 to 53 corresponding to the extracellular domain of human and rhesus BCMA, respectively, followed in frame by the coding sequence of an artificial Ser1-Gly4-Ser1-linker, followed in frame by the coding sequence of human serum albumin, followed in frame by the coding sequence of a Flag tag, followed in frame by the coding sequence of a modified histidine tag (SGHHGGHHGGHH) and a stop codon.

[0438] For the fusions with murine IgG1, the modified cDNA fragments were designed as to contain first a Kozak site for eukaryotic expression of the constructs followed by the coding sequence of the human and macaque BCMA proteins respectively, comprising amino acids 1 to 54 and 1 to 53 corresponding to the extracellular domain of human and rhesus BCMA, respectively, followed in frame by the coding sequence of an artificial Ser1-Gly4-Ser1-linker, followed in frame by the coding sequence of the hinge and Fc gamma portion of human IgG1, followed in frame by the coding sequence of a hexahistidine tag and a stop codon.

[0439] For the fusions with murine albumin, the modified cDNA fragments were designed as to contain first a Kozak site for eukaryotic expression of the constructs followed by the coding sequence of the human and macaque BCMA proteins respectively, comprising amino acids 1 to 54 and 1 to 53 corresponding to the extracellular domain of human and rhesus BCMA, respectively, followed in frame by the coding sequence of an artificial Ser1-Gly4-Ser1-linker, followed in frame by the coding sequence of murine serum albumin, followed in frame by the coding sequence of a Flag tag, followed in frame by the coding sequence of a modified histidine tag (SGHHGGHHGGHH) and a stop codon.

[0440] For the soluble extracellular domain constructs, the modified cDNA fragments were designed as to contain first a Kozak site for eukaryotic expression of the constructs followed by the coding sequence of the human and macaque BCMA proteins respectively, comprising amino acids 1 to 54 and 1 to 53 corresponding to the extracellular domain of human and rhesus BCMA, respectively, followed in frame by the coding sequence of an artificial Ser1-Gly1-linker, followed in frame by the coding sequence of a Flag tag, followed in frame by the coding sequence of a modified histidine tag (SGHHGGHHGGHH) and a stop codon.

[0441] The cDNA fragments were also designed to introduce restriction sites at the beginning and at the end of the fragments. The introduced restriction sites, EcoRI at the 5′ end and SalI at the 3′ end, were utilized in the following cloning procedures. The cDNA fragments were cloned via EcoRI and SalI into a plasmid designated pEF-DHFR (pEF-DHFR is described in Raum et al. Cancer Immunol Immunother 50 (2001) 141-150). The aforementioned procedures were all carried out according to standard protocols (Sambrook, Molecular Cloning; A Laboratory Manual, 3rd edition, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, N.Y. (2001)).

[0442] B) The coding sequences of human and macaque BCMA as described above and coding sequences of human albumin, human Fcγ1, murine Fcγ1, murine Fcγ2a, murine albumin, rat albumin, rat Fcγ1 and rat Fcγ2b were used for the construction of artificial cDNA sequences encoding soluble fusion proteins of human and macaque BCMA respectively and human albumin, human IgG1 Fc, murine IgG1 Fc, murine IgG2a Fc, murine albumin, rat IgG1 Fc, rat IgG2b and rat albumin respectively as well as soluble proteins comprising only the extracellular domains of BCMA. To generate the constructs for expression of the soluble human and macaque BCMA proteins cDNA fragments were obtained by PCR mutagenesis of the full-length BCMA cDNAs described above and molecular cloning according to standard protocols.

[0443] For the fusions with albumins the modified cDNA fragments were designed as to contain first a Kozak site for eukaryotic expression of the constructs and the coding sequence of a 19 amino acid immunoglobulin leader peptide, followed in frame by the coding sequence of the extracellular domain of the respective BCMA protein followed in frame by the coding sequence of an artificial Ser1-Gly4-Ser1-linker, followed in frame by the coding sequence of the respective serum albumin, followed in frame by the coding sequence of a Flag tag, followed in frame by the coding sequence of a modified histidine tag (SGHHGGHHGGHH) and a stop codon.

[0444] For the fusions with IgG Fcs the modified cDNA fragments were designed as to contain first a Kozak site for eukaryotic expression of the constructs and the coding sequence of a 19 amino acid immunoglobulin leader peptide, followed in frame by the coding sequence of the extracellular domain of the respective BCMA protein followed in frame by the coding sequence of an artificial Ser1-Gly4-Ser1-linker, except for human IgG1 Fc where an artificial Ser1-Gly1-linker was used, followed in frame by the coding sequence of the hinge and Fc gamma portion of the respective IgG, followed in frame by the coding sequence of a Flag tag, followed in frame by the coding sequence of a modified histidine tag (SGHHGGHHGGHH) and a stop codon.

[0445] For the soluble extracellular domain constructs the modified cDNA fragments were designed as to contain first a Kozak site for eukaryotic expression of the constructs and the coding sequence of a 19 amino acid immunoglobulin leader peptide, followed in frame by the coding sequence of the extracellular domain of the respective BCMA protein followed in frame by the coding sequence of an artificial Ser1-Gly1-linker, followed in frame by the coding sequence of a Flag tag, followed in frame by the coding sequence of a modified histidine tag (SGHHGGHHGGHH) and a stop codon.

[0446] For cloning of the constructs suitable restriction sites were introduced. The cDNA fragments were all cloned into a plasmid designated pEF-DHFR (pEF-DHFR is described in Raum et al. 2001). The aforementioned procedures were all carried out according to standard protocols (Sambrook, 2001).

[0447] The following constructs were designed to enable directed panning on distinct epitopes. The coding sequence of murine-human BCMA chimeras and murine-macaque BCMA chimeras (mouse, human and macaque BCMA sequences as described above) and coding sequences of murine albumin and murine Fcγ1 were used for the construction of artificial cDNA sequences encoding soluble fusion proteins of murine-human and murine-macaque BCMA chimeras respectively and murine IgG1 Fc and murine albumin, respectively. To generate the constructs for expression of the soluble murine-human and murine-macaque BCMA chimeras cDNA fragments of murine BCMA (amino acid 1-49) with the respective epitope domains mutated to the human and macaque sequence respectively were obtained by gene synthesis according to standard protocols. Cloning of constructs was carried out as described above and according to standard protocols (Sambrook, 2001).

[0448] The following molecules were constructed: [0449] amino acid 1-4 human, murine IgG1 Fc [0450] amino acid 1-4 human, murine albumin [0451] amino acid 1-4 rhesus, murine IgG1 Fc [0452] amino acid 1-4 rhesus, murine albumin [0453] amino acid 5-18 human, murine IgG1 Fc [0454] amino acid 5-18 human, murine albumin [0455] amino acid 5-18 rhesus, murine IgG1 Fc [0456] amino acid 5-18 rhesus, murine albumin [0457] amino acid 37-49 human, murine IgG1 Fc [0458] amino acid 37-49 human, murine albumin [0459] amino acid 37-49 rhesus, murine IgG1 Fc [0460] amino acid 37-49 rhesus, murine albumin

Example 5

[0461] 5.1 Biacore-Based Determination of Bispecific Antibody Affinity to Human and Macaque BCMA and CD3

[0462] Biacore analysis experiments were performed using recombinant BCMA fusion proteins with human serum albumin (ALB) to determine BCMA target binding. For CD3 affinity measurements, recombinant fusion proteins having the N-terminal 27 amino acids of the CD3 epsilon (CD3e) fused to human antibody Fc portion were used. This recombinant protein exists in a human CD3e1-27 version and in a cynomolgous CD3e version, both bearing the epitope of the CD3 binder in the bispecific antibodies.

[0463] In detail, CM5 Sensor Chips (GE Healthcare) were immobilized with approximately 100 to 150 RU of the respective recombinant antigen using acetate buffer pH4.5 according to the manufacturer's manual. The bispecific antibody samples were loaded in five concentrations: 50 nM, 25 nM, 12.5 nM, 6.25 nM and 3.13 nM diluted in HBS-EP running buffer (GE Healthcare). Flow rate was 30 to 35 μl/min for 3 min, then HBS-EP running buffer was applied for 8 min again at a flow rate of 30 to 35 μl/ml. Regeneration of the chip was performed using 10 mM glycine 0.5 M NaCl pH 2.45. Data sets were analyzed using BiaEval Software (see FIGS. 4A-D). In general two independent experiments were performed.

[0464] 5.2 Binding Affinity to Human and Macaque BCMA

[0465] Binding affinities of BCMA/CD3 bispecific antibodies to human and macaque BCMA were determined by Biacore analysis using recombinant BCMA fusion proteins with mouse albumin (ALB).

[0466] In detail, CM5 Sensor Chips (GE Healthcare) were immobilized with approximately 150 to 200 RU of the respective recombinant antigen using acetate buffer pH4.5 according to the manufacturer's manual. The bispecific antibody samples were loaded in five concentrations: 50 nM, 25 nM, 12.5 nM, 6.25 nM and 3.13 nM diluted in HBS-EP running buffer (GE Healthcare). For BCMA affinity determinations the flow rate was 35 μl/min for 3 min, then HBS-EP running buffer was applied for 10, 30 or 60 min again at a flow rate of 35 μl/ml. Regeneration of the chip was performed using a buffer consisting of a 1:1 mixture of 10 mM glycine 0.5 M NaCl pH 1.5 and 6 M guanidine chloride solution. Data sets were analyzed using BiaEval Software (see FIGS. 6A-H). In general two independent experiments were performed.

[0467] Confirmative human and macaque CD3 epsilon binding was performed in single experiments using the same concentrations as applied for BCMA binding; off-rate determination was done for 10 min dissociation time.

[0468] All BCMA/CD3 bispecific antibodies of epitope cluster E3 showed high affinities to human BCMA in the sub-nanomolar range down to 1-digit picomolar range. Binding to macaque BCMA was balanced, also showing affinities in the 1-digit nanomolar down to subnanomolar range. Affinities and affinity gaps of BCMA/CD3 bispecific antibodies are shown in Table 2.

TABLE-US-00002 TABLE 2 Affinities of BCMA/CD3 bispecific antibodies of the epitope cluster E3 to human and macaque BCMA as determined by Biacore analysis, and calculated affinity gaps (ma BCMA:hu BCMA). BCMA/CD3 bispecific hu BCMA ma BCMA Affinity gap antibody [nM] [nM] ma BCMA:hu BCMA BCMA-83 0.031 0.077 2.5 BCMA-98 0.025 0.087 3.5 BCMA-71 0.60 2.2 3.7 BCMA-34 0.051 0.047 1:1.1 BCMA-74 0.088 0.12 1.4 BCMA-20 0.0085 0.016 1.9

[0469] 5.3 Biacore-Based Determination of the Bispecific Antibody Affinity to Human and Macaque BCMA

[0470] The affinities of BCMA/CD3 bispecific antibodies to recombinant soluble BCMA on CM5 chips in Biacore measurements were repeated to reconfirm KDs and especially off-rates using longer dissociation periods (60 min instead of 10 min as used in the previous experiment). All of the tested BCMA/CD3 bispecific antibodies underwent two independent affinity measurements with five different concentrations each.

[0471] The affinities of the BCMA/CD3 bispecific antibodies of the epitope cluster E3 were clearly subnanomolar down to 1-digit picomolar, see examples in Table 3.

TABLE-US-00003 TABLE 3 Affinities (KD) of BCMA/CD3 bispecific antibodies of the epitope cluster E3 from Biacore experiments using extended dissociation times (two independent experiments each). BCMA/CD3 KD [nM] KD [nM] bispecific antibody human BCMA macaque BCMA BCMA-83 0.053 ± 0.017 0.062 ± 0.011 BCMA-98 0.025 ± 0.003 0.060 ± 0.001 BCMA-71 0.242 ± 0.007 0.720 ± 0.028 BCMA-34 0.089 ± 0.019 0.056 ± 0.003 BCMA-74 0.076 ± 0.002 0.134 ± 0.010 BCMA-20 0.0095 ± 0.0050 0.0060 ± 0.0038

Example 6

[0472] Bispecific Binding and Interspecies Cross-Reactivity

[0473] For confirmation of binding to human and macaque BCMA and CD3, bispecific antibodies were tested by flow cytometry using CHO cells transfected with human and macaque BCMA, respectively, the human multiple myeloma cell line NCI-H929 expressing native human BCMA, CD3-expressing human T cell leukemia cell line HPB-ALL (DSMZ, Braunschweig, ACC483) and the CD3-expressing macaque T cell line 4119LnPx (Knappe A, et al., Blood, 2000, 95, 3256-3261). Moreover, untransfected CHO cells were used as negative control.

[0474] For flow cytometry 200,000 cells of the respective cell lines were incubated for 30 min on ice with 50 μl of purified bispecific antibody at a concentration of 5 μg/ml. The cells were washed twice in PBS/2% FCS and binding of the constructs was detected with a murine PentaHis antibody (Qiagen; diluted 1:20 in 50 μl PBS/2% FCS). After washing, bound PentaHis antibodies were detected with an Fc gamma-specific antibody (Dianova) conjugated to phycoerythrin, diluted 1:100 in PBS/2% FCS. Samples were measured by flow cytometry on a FACSCanto II instrument and analyzed by FACSDiva software (both from Becton Dickinson).

[0475] The BCMA/CD3 bispecific antibodies of epitope cluster E3 stained CHO cells transfected with human and macaque BCMA, the human BCMA-expressing multiple myeloma cell line NCI-H929 as well as human and macaque T cells. Moreover, there was no staining of untransfected CHO cells (see FIGS. 7A-F).

Example 7

[0476] Scatchard-Based Determination of Bispecific-Antibody Affinity to Human and Macaque BCMA

[0477] For Scatchard analysis, saturation binding experiments are performed using a monovalent detection system developed at Micromet (anti-His Fab/Alexa 488) to precisely determine monovalent binding of the bispecific antibodies to the respective cell line.

[0478] 2×10.sup.4 cells of the respective cell line (recombinantly human BCMA-expressing CHO cell line, recombinantly macaque BCMA-expressing CHO cell line) are incubated with each 50 μl of a triplet dilution series (eight dilutions at 1:2) of the respective BCMA bispecific antibody starting at 100 nM followed by 16 h incubation at 4° C. under agitation and one residual washing step. Then, the cells are incubated for further 30 min with 30 μl of an anti-His Fab/Alexa488 solution (Micromet; 30 μg/ml). After one washing step, the cells are resuspended in 150 μl FACS buffer containing 3.5% formaldehyde, incubated for further 15 min, centrifuged, resuspended in FACS buffer and analyzed using a FACS Cantoll machine and FACS Diva software. Data are generated from two independent sets of experiments. Values are plotted as hyperbole binding curves. Respective Scatchard analysis is calculated to extrapolate maximal binding (Bmax). The concentrations of bispecific antibodies at half-maximal binding are determined reflecting the respective KDs. Values of triplicate measurements are plotted as hyperbolic curves. Maximal binding is determined using Scatchard evaluation and the respective KDs are calculated.

[0479] The affinities of BCMA/CD3 bispecific antibodies to CHO cells transfected with human or macaque BCMA were determined by Scatchard analysis as the most reliable method for measuring potential affinity gaps between human and macaque BCMA.

[0480] Cells expressing the BCMA antigen were incubated with increasing concentrations of the respective monomeric BCMA/CD3 bispecific antibody until saturation was reached (16 h). Bound bispecific antibody was detected by flow cytometry. The concentrations of BCMA/CD3 bispecific antibodies at half-maximal binding were determined reflecting the respective KDs.

[0481] Values of triplicate measurements were plotted as hyperbolic curves and as S-shaped curves to demonstrate proper concentration ranges from minimal to optimal binding. Maximal binding (Bmax) was determined (FIGS. 8A-D) using Scatchard evaluation and the respective KDs were calculated. Values depicted in Table 4 were derived from two independent experiments per BCMA/CD3 bispecific antibody.

[0482] Cell based Scatchard analysis confirmed that the BCMA/CD3 bispecific antibodies of the epitope cluster E3 are subnanomolar in affinity to human BCMA and present with a small interspecies BCMA affinity gap of below five.

TABLE-US-00004 TABLE 4 Affinities (KD) of BCMA/CD3 bispecific antibodies of the epitope cluster E3 from cell based Scatchard analysis (two independent experiments each) with the calculated affinity gap KD macaque BCMA/KD human BCMA. BCMA/CD3 KD [nM] KD [nM] x-fold KD bispecific human macaque difference KD ma antibody BCMA BCMA vs. KD hu BCMA BCMA-83 0.40 ± 0.13 1.22 ± 0.25 3.1 BCMA-98 0.74 ± 0.02 1.15 ± 0.64 1.6 BCMA-71 0.78 ± 0.07 3.12 ± 0.26 4.0 BCMA-34 0.77 ± 0.11 0.97 ± 0.33 1.3 BCMA-74 0.67 ± 0.03 0.95 ± 0.06 1.4 BCMA-20 0.78 ± 0.10 0.85 ± 0.01 1.1

Example 8

[0483] Cytotoxic Activity

[0484] 8.1 Chromium Release Assay with Stimulated Human T Cells

[0485] Stimulated T cells enriched for CD8.sup.+ T cells were obtained as described below.

[0486] A petri dish (145 mm diameter, Greiner bio-one GmbH, Kremsmunster) was coated with a commercially available anti-CD3 specific antibody (OKT3, Orthoclone) in a final concentration of 1 μg/ml for 1 hour at 37° C. Unbound protein was removed by one washing step with PBS. 3—5×10.sup.7 human PBMC were added to the precoated petri dish in 120 ml of RPMI 1640 with stabilized glutamine/10% FCS/IL-2 20 U/ml (Proleukin®, Chiron) and stimulated for 2 days. On the third day, the cells were collected and washed once with RPMI 1640. IL-2 was added to a final concentration of 20 U/ml and the cells were cultured again for one day in the same cell culture medium as above.

[0487] CD8.sup.+ cytotoxic T lymphocytes (CTLs) were enriched by depletion of CD4.sup.+ T cells and CD56.sup.+ NK cells using Dynal-Beads according to the manufacturer's protocol.

[0488] Macaque or human BCMA-transfected CHO target cells were washed twice with PBS and labeled with 11.1 MBq .sup.51Cr in a final volume of 100 μl RPMI with 50% FCS for 60 minutes at 37° C. Subsequently, the labeled target cells were washed 3 times with 5 ml RPMI and then used in the cytotoxicity assay. The assay was performed in a 96-well plate in a total volume of 200 μl supplemented RPMI with an E:T ratio of 10:1. A starting concentration of 0.01-1 μg/ml of purified bispecific antibody and threefold dilutions thereof were used. Incubation time for the assay was 18 hours. Cytotoxicity was determined as relative values of released chromium in the supernatant relative to the difference of maximum lysis (addition of Triton-X) and spontaneous lysis (without effector cells). All measurements were carried out in quadruplicates. Measurement of chromium activity in the supernatants was performed in a Wizard 3″ gamma counter (Perkin Elmer Life Sciences GmbH, Köln, Germany). Analysis of the results was carried out with Prism 5 for Windows (version 5.0, GraphPad Software Inc., San Diego, Calif., USA). EC50 values calculated by the analysis program from the sigmoidal dose response curves were used for comparison of cytotoxic activity (see FIGS. 5A-B).

[0489] 8.2 Potency of Redirecting Stimulated Human Effector T Cells Against Human BCMA-Transfected CHO Cells

[0490] The cytotoxic activity of BCMA/CD3 bispecific antibodies was analyzed in a 51-chromium (.sup.51Cr) release cytotoxicity assay using CHO cells transfected with human BCMA as target cells, and stimulated enriched human CD8 T cells as effector cells. The experiment was carried out as described in Example 8.1.

[0491] All BCMA/CD3 bispecific antibodies of epitope cluster E3 showed very potent cytotoxic activity against human BCMA transfected CHO cells with EC50-values in the 1-digit pg/ml range or even below (FIGS. 9A-B and Table 5). So the epitope cluster E3 presents with a very favorable epitope-activity relationship supporting very potent bispecific antibody mediated cytotoxic activity.

TABLE-US-00005 TABLE 5 EC50 values [pg/ml] of BCMA/CD3 bispecific antibodies of the epitope cluster E3 analyzed in a 51-chromium (.sup.51Cr) release cytotoxicity assay using CHO cells transfected with human BCMA as target cells, and stimulated enriched human CD8 T cells as effector cells. BCMA/CD3 bispecific antibody EC50 [pg/ml] R square value BCMA-83 0.38 0.79 BCMA-98 0.27 0.85 BCMA-71 3.2 0.85 BCMA-34 3.4 0.81 BCMA-74 0.73 0.80 BCMA-20 0.83 0.82

[0492] 8.3 FACS-Based Cytotoxicity Assay with Unstimulated Human PBMC Isolation of effector Cells

[0493] Human peripheral blood mononuclear cells (PBMC) were prepared by Ficoll density gradient centrifugation from enriched lymphocyte preparations (buffy coats), a side product of blood banks collecting blood for transfusions. Buffy coats were supplied by a local blood bank and PBMC were prepared on the same day of blood collection. After Ficoll density centrifugation and extensive washes with Dulbecco's PBS (Gibco), remaining erythrocytes were removed from PBMC via incubation with erythrocyte lysis buffer (155 mM NH.sub.4Cl, 10 mM KHCO.sub.3, 100 μM EDTA). Platelets were removed via the supernatant upon centrifugation of PBMC at 100×g. Remaining lymphocytes mainly encompass B and T lymphocytes, NK cells and monocytes. PBMC were kept in culture at 37° C./5% CO.sub.2 in RPMI medium (Gibco) with 10% FCS (Gibco).

[0494] Depletion of CD14+ and CD56+ Cells

[0495] For depletion of CD14.sup.+ cells, human CD14 MicroBeads (Milteny Biotec, MACS, #130-050-201) were used, for depletion of NK cells human CD56 MicroBeads (MACS, #130-050-401). PBMC were counted and centrifuged for 10 min at room temperature with 300×g. The supernatant was discarded and the cell pellet resuspended in MACS isolation buffer [80 μL/10.sup.7 cells; PBS (Invitrogen, #20012-043), 0.5% (v/v) FBS (Gibco, #10270-106), 2 mM EDTA (Sigma-Aldrich, #E-6511)]. CD14 MicroBeads and CD56 MicroBeads (20 μL/10.sup.7 cells) were added and incubated for 15 min at 4-8° C. The cells were washed with MACS isolation buffer (1-2 mL/10.sup.7 cells). After centrifugation (see above), supernatant was discarded and cells resuspended in MACS isolation buffer (500 μL/10.sup.8 cells). CD14/CD56 negative cells were then isolated using LS Columns (Miltenyi Biotec, #130-042-401). PBMC w/o CD14+/CD56+ cells were cultured in RPMI complete medium i.e. RPM11640 (Biochrom AG, #FG1215) supplemented with 10% FBS (Biochrom AG, #S0115), 1× non-essential amino acids (Biochrom AG, #K0293), 10 mM Hepes buffer (Biochrom AG, #L1613), 1 mM sodium pyruvate (Biochrom AG, #L0473) and 100 U/mL penicillin/streptomycin (Biochrom AG, #A2213) at 37° C. in an incubator until needed.

[0496] Target Cell Labeling

[0497] For the analysis of cell lysis in flow cytometry assays, the fluorescent membrane dye DiOC.sub.18 (DiO) (Molecular Probes, #V22886) was used to label human BCMA- or macaque BCMA-transfected CHO cells as target cells and distinguish them from effector cells. Briefly, cells were harvested, washed once with PBS and adjusted to 10.sup.6 cell/mL in PBS containing 2% (v/v) FBS and the membrane dye DiO (5 μL/10.sup.6 cells). After incubation for 3 min at 37° C., cells were washed twice in complete RPMI medium and the cell number adjusted to 1.25×10.sup.5 cells/mL. The vitality of cells was determined using 0.5% (v/v) isotonic EosinG solution (Roth, #45380).

[0498] Flow Cytometry Based Analysis

[0499] This assay was designed to quantify the lysis of macaque or human BCMA-transfected CHO cells in the presence of serial dilutions of BCMA bispecific antibodies.

[0500] Equal volumes of DiO-labeled target cells and effector cells (i.e., PBMC w/o CD14.sup.+ cells) were mixed, resulting in an E:T cell ratio of 10:1. 160 μL of this suspension were transferred to each well of a 96-well plate. 40 μL of serial dilutions of the BCMA bispecific antibodies and a negative control bispecific (an CD3-based bispecific antibody recognizing an irrelevant target antigen) or RPMI complete medium as an additional negative control were added. The bispecific antibody-mediated cytotoxic reaction proceeded for 48 hours in a 7% CO.sub.2 humidified incubator. Then cells were transferred to a new 96-well plate and loss of target cell membrane integrity was monitored by adding propidium iodide (PI) at a final concentration of 1 μg/mL. PI is a membrane impermeable dye that normally is excluded from viable cells, whereas dead cells take it up and become identifiable by fluorescent emission.

[0501] Samples were measured by flow cytometry on a FACSCanto II instrument and analyzed by FACSDiva software (both from Becton Dickinson).

[0502] Target cells were identified as DiO-positive cells. PI-negative target cells were classified as living target cells. Percentage of cytotoxicity was calculated according to the following formula:

[00002]$\mathrm{Cytotoxicity}\left[\%\right]=\frac{n_{\mathrm{dead}\mathrm{target}\mathrm{cells}}}{n_{\mathrm{target}\mathrm{cells}}}\times 100$$n=\mathrm{number}\mathrm{of}\mathrm{events}$

[0503] Using GraphPad Prism 5 software (Graph Pad Software, San Diego), the percentage of cytotoxicity was plotted against the corresponding bispecific antibody concentrations. Dose response curves were analyzed with the four parametric logistic regression models for evaluation of sigmoid dose response curves with fixed hill slope and EC50 values were calculated.

[0504] 8.4 Unstimulated Human PBMC Against Human BCMA-Transfected Target Cells

[0505] The cytotoxic activity of BCMA/CD3 bispecific antibodies was analyzed in a FACS-based cytotoxicity assay using CHO cells transfected with human BCMA as target cells, and unstimulated human PBMC as effector cells. The assay was carried out as described above (Example 8.3).

[0506] The results of the FACS-based cytotoxicity assays with unstimulated human PBMC as effector cells and human BCMA-transfected CHO cells as targets are shown in FIG. 10 and Table 6.

TABLE-US-00006 TABLE 6 EC50 values [pg/ml] of BCMA/CD3 bispecific antibodies of epitope cluster E3 as measured in a 48-hour FACS-based cytotoxicity assay with unstimulated human PBMC as effector cells and CHO cells transfected with human BCMA as target cells. BCMA/CD3 bispecific antibody EC50 [pg/ml] R square value BCMA-83 212 0.97 BCMA-7  102 0.97 BCMA-5  58.4 0.94 BCMA-98 53.4 0.95 BCMA-71 208 0.94 BCMA-34 149 0.94 BCMA-74 125 0.97 BCMA-20 176 0.98

Example 9

[0507] 9.1 Exclusion of Cross-Reactivity with BAFF-Receptor

[0508] For flow cytometry, 200,000 cells of the respective cell lines were incubated for 30 min on ice with 50 μl of purified bispecific molecules at a concentration of 5 μg/ml. The cells were washed twice in PBS with 2% FCS and binding of the constructs was detected with a murine PentaHis antibody (Qiagen; diluted 1:20 in 50 μl PBS with 2% FCS). After washing, bound PentaHis antibodies were detected with an Fc gamma-specific antibody (Dianova) conjugated to phycoerythrin, diluted 1:100 in PBS with 2% FCS. Samples were measured by flow cytometry on a FACSCanto II instrument and analyzed by FACSDiva software (both from Becton Dickinson). The bispecific binders were shown to not be cross-reactive with BAFF receptor.

[0509] 9.2 Exclusion of BCMA/CD3 Bispecific Antibody Cross-Reactivity with Human BAFF-Receptor (BAFF-R) and TACI

[0510] For exclusion of binding to human BAFF-R and TACI, BCMA/CD3 bispecific antibodies were tested by flow cytometry using CHO cells transfected with human BAFF-R and TACI, respectively. Moreover, L363 multiple myeloma cells were used as positive control for binding to human BCMA. Expression of BAFF-R and TACI antigen on CHO cells was confirmed by two positive control antibodies. Flow cytometry was performed as described in the previous example.

[0511] Flow cytometric analysis confirmed that none of the BCMA/CD3 bispecific antibodies of the epitope cluster E3 cross-reacts with human BAFF-R or human TACI (see FIGS. 11A-H).

Example 10

[0512] Cytotoxic Activity

[0513] The potency of human-like BCMA bispecific antibodies in redirecting effector T cells against BCMA-expressing target cells is analyzed in five additional in vitro cytotoxicity assays:

[0514] 1. The potency of BCMA bispecific antibodies in redirecting stimulated human effector T cells against a BCMA-positive (human) tumor cell line is measured in a 51-chromium release assay.

[0515] 2. The potency of BCMA bispecific antibodies in redirecting the T cells in unstimulated human PBMC against human BCMA-transfected CHO cells is measured in a FACS-based cytotoxicity assay.

[0516] 3. The potency of BCMA bispecific antibodies in redirecting the T cells in unstimulated human PBMC against a BCMA-positive (human) tumor cell line is measured in a FACS-based cytotoxicity assay.

[0517] 4. For confirmation that the cross-reactive BCMA bispecific antibodies are capable of redirecting macaque T cells against macaque BCMA-transfected CHO cells, a FACS-based cytotoxicity assay is performed with a macaque T cell line as effector T cells.

[0518] 5. The potency gap between monomeric and dimeric forms of BCMA bispecific antibodies is determined in a 51-chromium release assay using human BCMA-transfected CHO cells as target cells and stimulated human T cells as effector cells.

Example 11

[0519] Stimulated Human T cells Against the BCMA-Positive Human Multiple Myeloma Cell Line L363

[0520] The cytotoxic activity of BCMA/CD3 bispecific antibodies was analyzed in a 51-chromium (.sup.51Cr) release cytotoxicity assay using the BCMA-positive human multiple myeloma cell line L363 (DSMZ No. ACC49) as source of target cells, and stimulated enriched human CD8 T cells as effector cells. The assay was carried out as described in Example 8.1.

[0521] In accordance with the results of the 51-chromium release assays with stimulated enriched human CD8 T lymphocytes as effector cells and human BCMA-transfected CHO cells as targets, BCMA/CD3 bispecific antibodies of epitope cluster E3 are very potent in cytotoxic activity (FIG. 12 and Table 7).

[0522] Another group of antibodies was identified during epitope clustering (see Examples 1 and 3), which is capable of binding to epitope clusters 1 and 4 of BCMA (“E1/E4”). Unexpectedly, BCMA/CD3 bispecific antibodies of epitope cluster E1/E4—although potent in cytotoxic activity against CHO cell transfected with human BCMA—proved to be rather weakly cytotoxic against the human multiple myeloma cell line L363 expressing native BCMA at low density on the cell surface (FIG. 12 and Table 7). Without wishing to be bound by theory, the inventors believe that the E1/E4 epitope of human BCMA might be less well accessible on natural BCMA expressers than on BCMA-transfected cells.

TABLE-US-00007 TABLE 7 EC50 values [pg/ml] of BCMA/CD3 bispecific antibodies of epitope clusters E1/E4 (rows 1 and 2) and E3 (rows 3 to 8) analyzed in an 18- hour 51-chromium (.sup.51Cr) release cytotoxicity assay with the BCMA- positive human multiple myeloma cell line L363 as source of target cells, and stimulated enriched human CD8 T cells as effector cells. BCMA/CD3 bispecific antibody EC50 [pg/ml] R square value 1 BCMA-54 685 0.84 2 BCMA-53 1107 0.82 3 BCMA-83 28 0.83 4 BCMA-98 10 0.81 5 BCMA-71 125 0.86 6 BCMA-34 42 0.81 7 BCMA-74 73 0.79 8 BCMA-20 21 0.85

Example 12

[0523] Unstimulated Human PBMC Against the BCMA-Positive Human Multiple Myeloma Cell Line L363

[0524] The cytotoxic activity of BCMA/CD3 bispecific antibodies was furthermore analyzed in a FACS-based cytotoxicity assay using the BCMA-positive human multiple myeloma cell line L363 (DSMZ, ACC49)—showing the weakest surface expression of native BCMA of all tested target T cell lines—as source of target cells and unstimulated human PBMC as effector cells. The assay was carried out as described above (Example 8.3).

[0525] As observed in the 51-chromium release assay with stimulated enriched human CD8 T lymphocytes against the human multiple myeloma cell line L363, the BCMA/CD3 bispecific antibodies of epitope cluster E1/E4—in contrast to their potent cytotoxic activity against CHO cell transfected with human BCMA—proved to be again less potent in redirecting the cytotoxic activity of unstimulated PBMC against the human multiple myeloma cell line L363 expressing native BCMA at low density on the cell surface. This is in line with the theory provided hereinabove, i.e., the E1/E4 epitope of human BCMA may be less well accessible on natural BCMA expressers than on BCMA-transfected cells. BCMA/CD3 bispecific antibodies of the epitope cluster E3 presented with 3-digit pg/ml EC50-values in this assay (see FIG. 13 and Table 8).

TABLE-US-00008 TABLE 8 EC50 values [pg/ml] of BCMA/CD3 bispecific antibodies of epitope clusters E1/E4 (rows 1 and 2) and E3 (rows 3 to 8) as measured in a 48- hour FACS-based cytotoxicity assay with unstimulated human PBMC as effector cells and the human multiple myeloma cell line L363 as source of target cells. BCMA/CD3 bispecific antibody EC50 [pg/ml] R square value 1 BCMA-54 3162 0.99 2 BCMA-53 2284 0.98 3 BCMA-83 241 0.99 4 BCMA-98 311 0.99 5 BCMA-71 284 0.99 6 BCMA-34 194 0.99 7 BCMA-74 185 0.99 8 BCMA-20 191 0.99

[0526] Expectedly, EC50-values were higher in cytotoxicity assays with unstimulated PBMC as effector cells than in cytotoxicity assays using enriched stimulated human CD8 T cells.

Example 13

[0527] Unstimulated Human PBMC Against the BCMA-Positive Human Multiple Myeloma Cell Line NCI-H929

[0528] The cytotoxic activity of BCMA/CD3 bispecific antibodies was analyzed in a FACS-based cytotoxicity assay using the BCMA-positive human multiple myeloma cell line NCI-H929 (ATCC CRL-9068) as source of target cells and unstimulated human PBMC as effector cells. The assay was carried out as described above (Example 8.3).

[0529] The results of this assay with another human multiple myeloma cell line (i.e. NCI-H929) expressing native BCMA on the cell surface confirm those obtained with human multiple myeloma cell line L363. Again, BCMA/CD3 bispecific antibodies of epitope cluster E1/E4—in contrast to their potent cytotoxic activity against CHO cell transfected with human BCMA—proved to be less potent in redirecting the cytotoxic activity of unstimulated PBMC against human multiple myeloma cells confirming the theory that the E1/E4 epitope of human BCMA may be less well accessible on natural BCMA expressers than on BCMA-transfected cells. Such an activity gap between BCMA-transfected target cells and natural expressers as seen for the E1/E4 binders was not found for the E3. BCMA/CD3 bispecific antibodies of the epitope cluster E3 presented with 2- to 3-digit pg/ml EC50-values and hence redirected unstimulated PBMC against NCI-H929 target cells with very good EC50-values (see FIG. 14 and Table 9).

TABLE-US-00009 TABLE 9 EC50 values [pg/ml] of BCMA/CD3 bispecific antibodies of epitope clusters E1/E4 (rows 1 and 2) and E3 (rows 3 to 8) as measured in a 48- hour FACS-based cytotoxicity assay with unstimulated human PBMC as effector cells and the human multiple myeloma cell line NCI-H929 as source of target cells. BCMA/CD3 bispecific antibody EC50 [pg/ml] R square value 1 BCMA-54 2604 0.99 2 BCMA-53 2474 0.99 3 BCMA-83 154 0.93 4 BCMA-98 67.6 0.87 5 BCMA-71 50.7 0.96 6 BCMA-34 227 0.99 7 BCMA-74 103 0.97 8 BCMA-20 123 0.97

[0530] As expected, EC50-values were lower with the human multiple myeloma cell line NCI-H929, which expresses higher levels of BCMA on the cell surface compared to L363.

Example 14

[0531] Macaque T Cells Against Macaque BCMA-Expressing Target Cells

[0532] Finally, the cytotoxic activity of BCMA/CD3 bispecific antibodies was analyzed in a FACS-based cytotoxicity assay using CHO cells transfected with macaque BCMA as target cells, and a macaque T cell line as source of effector cells.

[0533] The macaque T cell line 4119LnPx (Knappe et al. Blood 95:3256-61 (2000)) was used as source of effector cells. Target cell labeling of macaque BCMA-transfected CHO cells and flow cytometry based analysis of cytotoxic activity was performed as described above.

[0534] Macaque T cells from cell line 4119LnPx were induced to efficiently kill macaque BCMA-transfected CHO cells by BCMA/CD3 bispecific antibodies of the E3 epitope cluster. The antibodies presented very potently with 1-digit to low 2-digit pg/ml EC50-values in this assay, confirming that these antibodies are very active in the macaque system. On the other hand, BCMA/CD3 bispecific antibodies of the epitope cluster E1/E4 showed a significantly weaker potency with EC50-values in the 2-digit to 3-digit pg/ml range (see FIG. 15 and Table 10). The E3 specific antibodies are hence about 3 to almost 100 times more potent in the macaque system.

TABLE-US-00010 TABLE 10 EC50 values [pg/ml] of BCMA/CD3 bispecific antibodies of epitope clusters E1/E4 (rows 1 and 2) and E3 (rows 3 to 8) as measured in a 48- hour FACS-based cytotoxicity assay with macaque T cell line 4119LnPx as effector cells and CHO cells transfected with macaque BCMA as target cells. BCMA/CD3 bispecific antibody EC50 [pg/ml] R square value 1 BCMA-54 78.5 0.98 2 BCMA-53 183 0.96 3 BCMA-83 10.9 0.97 4 BCMA-98 2.5 0.89 5 BCMA-71 3.2 0.97 6 BCMA-34 2.1 0.95 7 BCMA-74 2.0 0.95 8 BCMA-20 26 0.98

Example 15

[0535] Potency Gap Between BCMA/CD3 Bispecific Antibody Monomer and Dimer

[0536] In order to determine the difference in cytotoxic activity between the monomeric and the dimeric isoform of individual BCMA/CD3 bispecific antibodies (referred to as potency gap), a 51-chromium release cytotoxicity assay as described hereinabove (Example 8.1) was carried out with purified BCMA/CD3 bispecific antibody monomer and dimer. The potency gap was calculated as ratio between EC50 values of the bispecific antibody's monomer and dimer. Potency gaps of the tested BCMA/CD3 bispecific antibodies of the epitope cluster E3 were between 0.03 and 1.2. There is hence no substantially more active dimer compared to its respective monomer.

Example 16

[0537] Monomer to Dimer Conversion After Three Freeze/Thaw Cycles

[0538] Bispecific BCMA/CD3 antibody monomer were subjected to three freeze/thaw cycles followed by high performance SEC to determine the percentage of initially monomeric antibody, which had been converted into antibody dimer.

[0539] 15 μg of monomeric antibody were adjusted to a concentration of 250 μg/ml with generic buffer and then frozen at −80° C. for 30 min followed by thawing for 30 min at room temperature. After three freeze/thaw cycles the dimer content was determined by HP-SEC. To this end, 15 μg aliquots of the monomeric isoforms of the antibodies were thawed and equalized to a concentration of 250 μg/ml in the original SEC buffer (10 mM citric acid—75 mM lysine HCl—4% trehalose—pH 7.2) followed by incubation at 37° C. for 7 days. A high resolution SEC Column TSK Gel G3000 SWXL (Tosoh, Tokyo-Japan) was connected to an Akta Purifier 10 FPLC (GE Lifesciences) equipped with an A905 Autosampler. Column equilibration and running buffer consisted of 100 mM KH2PO4—200 mM Na2SO4 adjusted to pH 6.6. After 7 days of incubation, the antibody solution (15 μg protein) was applied to the equilibrated column and elution was carried out at a flow rate of 0.75 ml/min at a maximum pressure of 7 MPa. The whole run was monitored at 280, 254 and 210 nm optical absorbance. Analysis was done by peak integration of the 210 nm signal recorded in the Akta Unicorn software run evaluation sheet. Dimer content was calculated by dividing the area of the dimer peak by the total area of monomer plus dimer peak.

[0540] The BCMA/CD3 bispecific antibodies of the epitope cluster E3 presented with dimer percentages of 0.7 to 1.1% after three freeze/thaw cycles, which is considered good. However, the dimer conversion rates of BCMA/CD3 bispecific antibodies of the epitope cluster E1/E4 reached unfavorably high values, exceeding the threshold to disadvantageous dimer values of —2.5% (4.7% and 3.8%, respectively), see Table 11.

TABLE-US-00011 TABLE 11 Percentage of monomeric versus dimeric BCMA/CD3 bispecific antibodies of epitope clusters E1/E4 (rows 1 and 2) and E3 (rows 3 to 8) after three freeze/thaw cycles as determined by High Performance Size Exclusion Chromatography (HP-SEC). BCMA/CD3 bispecific antibody Monomer [%] Dimer [%] 1 BCMA-54 95.3 4.7 2 BCMA-53 96.2 3.8 3 BCMA-83 99.1 0.9 4 BCMA-98 99.1 0.9 5 BCMA-71 99.1 0.9 6 BCMA-34 98.9 1.1 7 BCMA-74 99.3 0.7 8 BCMA-20 99.2 0.8

Example 17

[0541] Thermostability

[0542] Temperature melting curves were determined by Differential Scanning calorimetry (DSC) to determine intrinsic biophysical protein stabilities of the BCMA/CD3 bispecific antibodies. These experiments were performed using a MicroCal LLC (Northampton, Mass., U.S.A) VP-DSC device. The energy uptake of a sample containing BCMA/CD3 bispecific antibody was recorded from 20 to 90° C. compared to a sample which just contained the antibody's formulation buffer.

[0543] In detail, BCMA/CD3 bispecific antibodies were adjusted to a final concentration of 250 μg/ml in storage buffer. 300 μl of the prepared protein solutions were transferred into a deep well plate and placed into the cooled autosampler rack position of the DSC device. Additional wells were filled with the SEC running buffer as reference material for the measurement. For the measurement process the protein solution was transferred by the autosampler into a capillary. An additional capillary was filled with the SEC running buffer as reference. Heating and recording of required heating energy to heat up both capillaries at equal temperature ranging from 20 to 90° C. was done for all samples.

[0544] For recording of the respective melting curve, the overall sample temperature was increased stepwise. At each temperature T energy uptake of the sample and the formulation buffer reference was recorded. The difference in energy uptake Cp (kcal/mole/° C.) of the sample minus the reference was plotted against the respective temperature. The melting temperature is defined as the temperature at the first maximum of energy uptake.

[0545] All tested BCMA/CD3 bispecific antibodies of the epitope cluster E3 showed favorable thermostability with melting temperatures above 60° C., more precisely between 61.62° C. and 63.05° C.

Example 18

[0546] Exclusion of Plasma Interference by Flow Cytometry

[0547] To determine potential interaction of BCMA/CD3 bispecific antibodies with human plasma proteins, a plasma interference test was established. To this end, 10 μg/ml of the respective BCMA/CD3 bispecific antibodies were incubated for one hour at 37° C. in 90% human plasma. Subsequently, the binding to human BCMA expressing CHO cells was determined by flow cytometry.

[0548] For flow cytometry, 200,000 cells of the respective cell lines were incubated for 30 min on ice with 50 μl of purified antibody at a concentration of 5 μg/ml. The cells were washed twice in PBS/2% FCS and binding of the constructs was detected with a murine PentaHis antibody (Qiagen; diluted 1:20 in 50 μl PBS/2% FCS). After washing, bound PentaHis antibodies were detected with an Fc gamma-specific antibody (Dianova) conjugated to phycoerythrin, diluted 1:100 in PBS/2% FCS. Samples were measured by flow cytometry on a FACSCanto II instrument and analyzed by FACSDiva software (both from Becton Dickinson).

[0549] The obtained data were compared with a control assay using PBS instead of human plasma. Relative binding was calculated as follows:

[0550] (signal PBS sample/signal w/o detection agent)/(signal plasma sample/signal w/o detection agent).

[0551] In this experiment it became obvious that there was no significant reduction of target binding of the respective BCMA/CD3 bispecific antibodies of the epitope cluster E3 mediated by plasma proteins. The relative plasma interference value was below a value of 2 in all cases, more precisely between 1.29±0.25 and 1.70±0.26 (with a value of “2” being considered as lower threshold for interference signals).

Example 19

[0552] Therapeutic Efficacy of BCMA/CD3 Bispecific Antibodies in Human Tumor Xenograft Models

[0553] On day 1 of the study, 5×10.sup.6 cells of the human cancer cell line NCI-H929 were subcutaneously injected in the right dorsal flank of female NOD/SCID mice.

[0554] On day 9, when the mean tumor volume had reached about 100 mm.sup.3, in vitro expanded human CD3.sup.+ T cells were transplanted into the mice by injection of about 2×10.sup.7 cells into the peritoneal cavity of the animals. Mice of vehicle control group 1 (n=5) did not receive effector cells and were used as an untransplanted control for comparison with vehicle control group 2 (n=10, receiving effector cells) to monitor the impact of T cells alone on tumor growth.

[0555] The antibody treatment started on day 13, when the mean tumor volume had reached about 200 mm.sup.3. The mean tumor size of each treatment group on the day of treatment start was not statistically different from any other group (analysis of variance). Mice were treated with 0.5 mg/kg/day of the BCMA/CD3 bispecific antibodies BCMA-98×CD3 (group 3, n=7) or BCMA-34×CD3 (group 4, n=6) by intravenous bolus injection for 17 days.

[0556] Tumors were measured by caliper during the study and progress evaluated by intergroup comparison of tumor volumes (TV). The tumor growth inhibition T/C [%] was determined by calculating TV as T/C %=100× (median TV of analyzed group)/(median TV of control group 2). The results are shown in Table 12 and FIG. 16.

TABLE-US-00012 TABLE 12 Median tumor volume (TV) and tumor growth inhibition (T/C) at days 13 to 30. Dose group Data d 13 d 14 d 15 d 16 d 18 d 19 d 21 d 23 d 26 d 28 d 30 1 Vehi. med. TV 238 288 395 425 543 632 863 1067 1116 1396 2023 control [mm.sup.3] w/o T/C [%] 120 123 127 118 104 114 122 113 87 85 110 T cells 2 med. TV 198 235 310 361 525 553 706 942 1290 1636 1839 Vehicle [mm.sup.3] control T/C [%] 100 100 100 100 100 100 100 100 100 100 100 3 med. TV 207 243 248 235 164 137 93.5 46.2 21.2 0.0 0.0 BCMA- [mm.sup.3] 98 T/C [%] 105 104 79.7 65.0 31.2 24.7 13.2 4.9 1.6 0.0 0.0 4 med. TV 206 233 212 189 154 119 56.5 17.4 0.0 0.0 0.0 BCMA- [mm.sup.3] 34 T/C [%] 104 99.2 68.2 52.3 29.4 21.5 8.0 1.8 0.0 0.0 0.0

Example 20

[0557] Exclusion of Lysis of Target Negative Cells

[0558] An in vitro lysis assay was carried out using the BCMA-positive human multiple myeloma cell line NCI-H929 and purified T cells at an effector to target cell ratio of 5:1 and with an incubation time of 24 hours. BCMA/CD3 bispecific antibodies of epitope cluster E3 (BCMA-34 and BCMA-98) showed high potency and efficacy in the lysis of NCI-H929. However, no lysis was detected in the BCMA negative cell lines HL60 (AML/myeloblast morphology), MES-SA (uterus sarcoma, fibroblast morphology), and SNU-16 (stomach carcinoma, epithelial morphology) for up to 500 nM of the respective antibody.

Example 21

[0559] Induction of T Cell Activation of Different PBMC Subsets

[0560] A FACS-based cytotoxicity assay (48 h; E:T=10:1) was carried out using human multiple myeloma cell lines NCI-H929, L-363 and OPM-2 as target cells and different subsets of human PBMC (CD4.sup.+/CD8.sup.+/CD25.sup.+/CD69.sup.+) as effector cells. The results (see Table 13) show that the degree of activation, as measured by the EC.sub.50 value, is essentially in the same range for the different analyzed PBMC subsets.

TABLE-US-00013 TABLE 13 EC50 values [ng/ml] of BCMA/CD3 bispecific antibodies of epitope cluster E3 as measured in a 48-hour FACS-based cytotoxicity assay with different subsets of human PBMC as effector cells and different human multiple myeloma cell lines as target cells. EC.sub.50 [ng/ml] Cell line PBMC BCMA-98 × CD3 BCMA-34 × CD3 NCI-H929 CD4.sup.+/CD25.sup.+ 1.46 1.20 CD8.sup.+/CD25.sup.+ 0.53 0.49 CD4.sup.+/CD69.sup.+ 0.59 0.47 CD8.sup.+/CD69.sup.+ 0.21 0.21 OPM-2 CD4.sup.+/CD25.sup.+ 2.52 4.88 CD8.sup.+/CD25.sup.+ 1.00 1.20 CD4.sup.+/CD69.sup.+ 1.65 2.27 CD8.sup.+/CD69.sup.+ 0.48 0.42 L-363 CD4.sup.+/CD25.sup.+ 0.54 0.62 CD8.sup.+/CD25.sup.+ 0.24 0.28 CD4.sup.+/CD69.sup.+ 0.35 0.34 CD8.sup.+/CD69.sup.+ 0.12 0.11

Example 22

[0561] Induction of Cytokine Release

[0562] A FACS-based cytotoxicity assay (48 h; E:T=10:1) was carried out using human multiple myeloma cell lines NCI-H929, L-363 and OPM-2 as target cells and human PBMC as effector cells. The levels of cytokine release [pg/ml] were determined at increasing concentrations of BCMA/CD3 bispecific antibodies of epitope cluster E3. The following cytokines were analyzed: 11-2, IL-6, IL-10, TNF and IFN-gamma. The results are shown in Table 14 and FIGS. 17A-F.

TABLE-US-00014 TABLE 14 Release of IL-2, IL-6, IL-10, TNF and IFN-gamma [pg/ml] induced by 2.5 μg/ml of BCMA/CD3 bispecific antibodies of epitope cluster E3 (BCMA-98 and BCMA-34) in a 48-hour FACS-based cytotoxicity assay with human PBMC as effector cells and different human multiple myeloma cell lines as target cells (E:T = 10:1). Cytokine levels [pg/ml] IL-2 IL-6 IL-10 TNF IFN-gamma NCI-H929 BCMA-98 1357 699 2798 10828 73910 BCMA-34 1327 631 3439 6675 77042 OPM-2 BCMA-98 41 118 990 5793 33302 BCMA-34 28 109 801 4913 23214 L-363 BCMA-98 97 314 2433 5397 64981 BCMA-34 168 347 2080 5930 75681

TABLE-US-00015 SEQ ID NO Designation Designation Format/source Type Sequence    1 BCMA-1 BC G59 91-C7-B10 VH CDR1 aa NYDMA    2 BCMA-1 BC G59 91- VH CDR2 aa SIITSGDATYYRDSVKG C7-B10    3 BCMA-1 BC G59 91- VH CDR3 aa HDYYDGSYGFAY C7-B10    4 BCMA-1 BC G59 91- VL CDR1 aa KASQSVGINVD C7-B10    5 BCMA-1 BC G59 91- VL CDR2 aa GASNRHT C7-B10    6 BCMA-1 BC G59 91- VL CDR3 aa LQYGSIPFT C7-B10    7 BCMA-1 BC 5G9 91 VH aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDATYYRDSVKGR C7-B10 FTISRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSS    8 BCMA-1 BC 5G9 91 VL aa EIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGSGS C7-B10 GREFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK    9 BCMA-1 BC 5G9 91- scFv aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDATYYRDSVKGR C7-B10 FTISRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGREFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK   10 BCMA-1 HL x CD3 HL BC 5G9 91- bispecific molecule  aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDATYYRDSVKGR C7-B10 HL x CD3 HL FTISRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGREFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL   11 BCMA-2 BC 5G9 91-C7-D8 VH CDR1 aa NYDMA   12 BCMA-2 BC 5G9 91-C7-D8 VH CDR2 aa SIITSGDMTYYRDSVKG   13 BCMA-2 BC 5G9 91-C7-D8 VH CDR3 aa HDYYDGSYGFAY   14 BCMA-2 BC 5G9 91-C7-D8 VL CDR1 aa KASQSVGINVD   15 BCMA-2 BC 5G9 91-C7-D8 VL CDR2 aa GASNRHT   16 BCMA-2 BC 5G9 91-C7-D8 VL CDR3 aa LQYGSIPFT   17 BCMA-2 BC 5G9 91-C7-D8 VH aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDMTYYRDSVKGR FTISRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSS   18 BCMA-2 BC 5G9 91-C7-D8 VL aa EIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGSGS GREFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK   19 BCMA-2 BC 5G9 91-C7-D8 scFv aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDMTYYRDSVKGR FTISRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGREFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK   20 BCMA-2 HL x CD3 HL BC 5G9 91-C7-D8 HL x bispecific molecule aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDMTYYRDSVKGR CD3 HL FTISRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGREFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL   21 BCMA-3 BC 5G9 91-E4-B10 VH CDR1 aa NYDMA   22 BCMA-3 BC 5G9 91-E4-B10 VH CDR2 aa SIITSGDATYYRDSVKG   23 BCMA-3 BC 5G9 91-E4-B10 VH CDR3 aa HDYYDGSYGFAY   24 BCMA-3 BC 5G9 91-E4-B10 VL CDR1 aa KASQSVGINVD   25 BCMA-3 BC 5G9 91-E4-B10 VL CDR2 aa GASNRHT   26 BCMA-3 BC 5G9 91-E4-B10 VL CDR3 aa LQYGSIPFT   27 BCMA-3 BC 5G9 91-E4-B10 VH aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDATYYRDSVKGR FTISRDNSKNTLYLQMNSLRSEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSS   28 BCMA-3 BC 5G9 91-E4-B10 VL aa EIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGSGS GTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK   29 BCMA-3 BC 5G9 91-E4-B10 scFv aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDATYYRDSVKGR FTISRDNSKNTLYLQMNSLRSEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK   30 BCMA-3 HL x CD3 HL BC 5G9 91-E4-B10 HL x bispecific molecule aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDATYYRDSVKGR CD3 HL FTISRDNSKNTLYLQMNSLRSEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL   31 BCMA-4 BC 5G9 91-E4-D8 VH CDR1 aa NYDMA   32 BCMA-4 BC 5G9 91-E4-D8 VH CDR2 aa SIITSGDMTYYRDSVKG   33 BCMA-4 BC 5G9 91-E4-D8 VH CDR3 aa HDYYDGSYGFAY   34 BCMA-4 BC 5G9 91-E4-D8 VL CDR1 aa KASQSVGINVD   35 BCMA-4 BC 5G9 91-E4-D8 VL CDR2 aa GASNRHT   36 BCMA-4 BC 5G9 91-E4-D8 VL CDR3 aa LQYGSIPFT   37 BCMA-4 BC 5G9 91-E4-D8 VH aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDMTYYRDSVKGR FTISRDNSKNTLYLQMNSLRSEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSS   38 BCMA-4 BC 5G9 91-E4-D8 VL aa EIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGSGS GTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK   39 BCMA-4 BC 5G9 91-E4-D8 scFv aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDMTYYRDSVKGR FTISRDNSKNTLYLQMNSLRSEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK   40 BCMA-4 HL x BC 5G9 91-E4-D8 HL x bispecific molecule aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDMTYYRDSVKGR CD3 HL CD3 HL FTISRDNSKNTLYLQMNSLRSEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL   41 BCMA-5 BC 5G9 91-D2-B10 VH CDR1 aa NYDMA   42 BCMA-5 BC 5G9 91-D2-B10 VH CDR2 aa SIITSGDATYYRDSVKG   43 BCMA-5 BC 5G9 91-D2-B10 VH CDR3 aa HDYYDGSYGFAY   44 BCMA-5 BC 5G9 91-D2-B10 VL CDR1 aa KASQSVGINVD   45 BCMA-5 BC 5G9 91-D2-B10 VL CDR2 aa GASNRHT   46 BCMA-5 BC 5G9 91-D2-B10 VL CDR3 aa LQYGSIPFT   47 BCMA-5 BC 5G9 91-D2-B10 VH aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDATYYRDSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSS   48 BCMA-5 BC 5G9 91-D2-B10 VL aa EIVMTQSPASMSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGSGS GTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK   49 BCMA-5 BC 5G9 91-D2-B10 scFv aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDATYYRDSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPASMSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK   50 BCMA-5 HL x BC 5G9 91- bispecific molecule aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDATYYRDSVKGR CD3 HL D2-B10 HL FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG x CD3 HL GSEIVMTQSPASMSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL   51 BCMA-6 BC 5G9 91-D2-D8 VH CDR1 aa NYDMA   52 BCMA-6 BC 5G9 91-D2-D8 VH CDR2 aa SIITSGDMTYYRDSVKG   53 BCMA-6 BC 5G9 91-D2-D8 VH CDR3 aa HDYYDGSYGFAY   54 BCMA-6 BC 5G9 91-D2-D8 VL CDR1 aa KASQSVGINVD   55 BCMA-6 BC 5G9 91-D2-D8 VL CDR2 aa GASNRHT   56 BCMA-6 BC 5G9 91-D2-D8 VL CDR3 aa LQYGSIPFT   57 BCMA-6 BC 5G9 91-D2-D8 VH aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDMTYYRDSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSS   58 BCMA-6 BC 5G9 91-D2-D8 VL aa EIVMTQSPASMSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGSGS GTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK   59 BCMA-6 BC 5G9 91-D2-D8 scFv aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDMTYYRDSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPASMSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK   60 BCMA-6 HL x BC 5G9 91-D2-D8 HL x bispecific molecule aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDMTYYRDSVKGR CD3 HL FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPASMSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL   61 BCMA-7 BC 5G9 92-E10-B10 VH CDR1 aa NYDMA   62 BCMA-7 BC 5G9 92-E10-B10 VH CDR2 aa SIITSGDATYYRDSVKG   63 BCMA-7 BC 5G9 92-E10-B10 VH CDR3 aa HDYYDGSYGFAY   64 BCMA-7 BC 5G9 92-E10-B10 VL CDR1 aa KASQSVGINVD   65 BCMA-7 BC 5G9 92-E10-B10 VL CDR2 aa GASNRHT   66 BCMA-7 BC 5G9 92-E10-B10 VL CDR3 aa LQYGSIPFT   67 BCMA-7 BC 5G9 92-E10-B10 VH aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDATYYRDSVKGR FTVSRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSS   68 BCMA-7 BC 59G 92-E10-B10 VL aa EIVMTQSPATLSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGSGS GTEFTLTISSLQAEDFAVYYCLQYGSIPFTFGPGTKVDIK   69 BCMA-7 BC 5G9 92-E10-B10 scFv aa FTVSRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQAEDFAVYYCLQYGSIPFTFGPGTKVDIK   70 BCMA-7 HL x BC 5G9 92-E10-B10 x bispecific molecule aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDATYYRDSVKGR CD3 HL CD3 HL FTVSRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQAEDFAVYYCLQYGSIPFTFGPGTKVDIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL   71 BCMA-8 BC 5G9 92-E10-D8 VH CDR1 aa NYDMA   72 BCMA-8 BC 5G9 92-E10-D8 VH CDR2 aa SIITSGDMTYYRDSVKG   73 BCMA-8 BC 5G9 92-E10-D8 VH CDR3 aa HDYYDGSYGFAY   74 BCMA-8 BC 5G9 92-E10-D8 VL CDR1 aa KASQSVGINVD   75 BCMA-8 BC 5G9 92-E10-D8 VL CDR2 aa GASNRHT   76 BCMA-8 BC 5G9 92-E10-D8 VL CDR3 aa LQYGSIPFT   77 BCMA-8 BC 5G9 92-E10-D8 VH aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDMTYYRDSVKGR FTVSRDNSKNTLYLQMNSLRAEDTAVYYCNRHDYYDGSYGFAYWGQGTLVTVSS   78 BCMA-8 BC 5G9 92-E10-D8 VL aa EIVMTQSPATLSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGSGS GTEFTLTISSLQAEDFAVYYCLQYGSIPFTFGPGTKVDIK   79 BCMA-8 BC 5G9 92-E10-D8 scFv aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDMTYYRDSVKGR FTVSRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQAEDFAVYYCLQYGSIPFTFGPGTKVDIK   80 BCMA-8 HL x BC 5G9 92-E10-D8 HL x bispecific molecule aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGDMTYYRDSVKGR CD3 HL CD3 HL FTVSRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQAEDFAVYYCLQYGSIPFTFGPGTKVDIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL   81 BCMA-9 BC H1 38-D2-A4 VH CDR1 aa NYWIH   82 BCMA-9 BC H1 38-D2-A4 VH CDR2 aa AIYPGNSDTHYNQKFQG   83 BCMA-9 BC H1 38-D2-A4 VH CDR3 aa SSYYYDGSLFAS   84 BCMA-9 BC H1 38-D2-A4 VL CDR1 aa RSSQSIVHSNGNTYLY   85 BCMA-9 BC H1 38-D2-A4 VL CDR2 aa RVSNRFS   86 BCMA-9 BC H1 38-D2-A4 VL CDR3 aa FQGSTLPFT   87 BCMA-9 BC H1 38-D2-A4 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGK VTITRDTSASTAYMELSSLTSEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSS   88 BCMA-9 BC H1 38-D2-A4 VL aa DIVMTQTPLSLSVSPGQPASISCRSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCFQGSTLPFTFGQGTKLEIK   89 BCMA-9 BC H1 38-D2-A4 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGK VTITRDTSASTAYMELSSLTSEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSSGGGGSGGGGSGGG GSDIVMTQTPLSLSVSPGQPASISCRSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSTLPFTFGQGTKLEIK   90 BCMA-9 HL x BC H1 38- bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGK CD3 HL D2-A4 HL VTITRDTSASTAYMELSSLTSEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSSGGGGSGGGGSGGG x CD3 HL GSDIVMTQTPLSLSVSPGQPASISCRSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSTLPFTFGQGTKLEIKSGGGGSEVQLVESGGGLVQP GGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAAL TLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL   91 BCMA-10 BC H1 38-D2-F12 VH CDR1 aa NYWIH   92 BCMA-10 BC H1-38-D2-F12 VH CDR2 aa AIYPGNSDTHYNQKFQG   93 BCMA-10 BC H1 38-D2-F12 VH CDR3 aa SSYYYDGSLFAS   94 BCMA-10 BC H1-38-D2-F12 VL CDR1 aa RSSQSIVHSNGNTYLY   95 BCMA-10 BC H1-38-D2-F12 VL CDR2 aa RVSNRFS   96 BCMA-10 BC H1 38-D2-F12 VL CDR3 aa FQGSHLPFT   97 BCMA-10 BC H1 38-D2-F12 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGK VTITRDTSASTAYMELSSLTSEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSS   98 BCMA-10 BC H1 38-D2-F12 VL aa DIVMTQTPLSLSVSPGQPASISCRSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCFQGSHLPFTFGQGTKLEIK   99 BCMA-10 BC H1-38-D2-F12 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGK VTITRDTSASTAYMELSSLTSEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSSGGGGSGGGGSGGG GSDIVMTQTPLSLSVSPGQPASISCRSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHLPFTFGQGTKLEIK  100 BCMA-10 HL x BC H1 38- bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGK CD3 HL D2-F12 HL VTITRDTSASTAYMELSSLTSEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSSGGGGSGGGGSGGG x CD3 HL GSDIVMTQTPLSLSVSPGQPASISCRSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHLPFTFGQGTKLEIKSGGGGSEVQLVESGGGLVQP GGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAAL TLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  101 BCMA-11 BC H1 38-C1-A4 VH CDR1 aa NYWIH  102 BCMA-11 BC H1 38-C1-A4 VH CDR2 aa AIYPGNSDTHYNQKFQG  103 BCMA-11 BC H1 38-C1-A4 VH CDR3 aa SSYYYDGSLFAS  104 BCMA-11 BC H1 38-C1-A4 VL CDR1 aa KSSQSIVHSNGNTYLY  105 BCMA-11 BC H1 38-C1-A4 VL CDR2 aa RVSNRFS  106 BCMA-11 BC H1 38-C1-A4 VL CDR3 aa FQGSTLPFT  107 BCMA-11 BC H1 38-C1-A4 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGK VTITRDTSASTAYMELSSLTSEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSS  108 BCMA-11 BC H1 38-C1-A4 VL aa DIVMTQTPLSLSVTPGQQASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCFQGSTLPFTFGQGTKLEIK  109 BCMA-11 BC H1 38-C1-A4 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGK   VTITRDTSASTAYMELSSLTSEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSSGGGGSGGGGSGGG GSDIVMTQTPLSLSVTPGQQASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSTLPFTFGQGTKLEIK  110 BCMA-11 HL x BC H1 38- bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGK CD3 HL C1-A4 HL VTITRDTSASTAYMELSSLTSEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSSGGGGSGGGGSGGG x CD3 HL GSDIVMTQTPLSLSVTPGQQASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSTLPFTFGQGTKLEIKSGGGGSEVQLVESGGGLVQP GGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAAL TLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  111 BCMA-12 BC H1 38-C1-F12 VH CDR1 aa NYWIH  112 BCMA-12 BC H1 38-C1-F12 VH CDR2 aa AIYPGNSDTHYNQKFQG  113 BCMA-12 BC H1 38-C1-F12 VH CDR3 aa SSYYYDGSLFAS  114 BCMA-12 BC H1 38-C1-F12 VL CDR1 aa KSSQSIVHSNGNTYLY  115 BCMA-12 BC H1 38-C1-F12 VL CDR2 aa RVSNRFS  116 BCMA-12 BC H1 38-C1-F12 VL CDR3 aa FQGSHLPFT  117 BCMA-12 BC H1 38-C1-F12 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGK VTITRDTSASTAYMELSSLTSEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSS  118 BCMA-12 BC H1 38-C1-F12 VL aa DIVMTQTPLSLSVTPGQQASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCFQGSHLPFTFGQGTKLEIK  119 BCMA-12 BC H1 38-C1-F12 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGK VTITRDTSASTAYMELSSLTSEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSSGGGGSGGGGSGGG GSDIVMTQTPLSLSVTPGQQASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHLPFTFGQGTKLEIK  120 BCMA-12 HL x BC H1 38-C1-F12 HL x bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGK CD3 HL CD3 HL VTITRDTSASTAYMELSSLTSEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSSGGGGSGGGGSGGG GSDIVMTQTPLSLSVTPGQQASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHLPFTFGQGTKLEIKSGGGGSEVQLVESGGGLVQP GGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAAL TLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  121 BCMA-13 BC H1 39-B2-A4 VH CDR1 aa NYWIH  122 BCMA-13 BC H1 39-B2-A4 VH CDR2 aa AIYPGNSDTHYNQKFQG  123 BCMA-13 BC H1 39-B2-A4 VH CDR3 aa SSYYYDGSLFAS  124 BCMA-13 BC H1 39-B2-A4 VL CDR1 aa KSSQSIVHSNGNTYLY  125 BCMA-13 BC H1 39-B2-A4 VL CDR2 aa RVSNRFS  126 BCMA-13 BC H1 39-B2-A4 VL CDR3 aa FQGSTLPFT  127 BCMA-13 BC H1 39-B2-A4 VH aa QVQLVQSGAVVAKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWMGAIYPGNSDTHYNQKFQGR VTLITDTSASTAYMELSSLRNEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSS  128 BCMA-13 BC H1 39-B2-A4 VL aa DIVMTQTPLSLSVTPGQQASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCFQGSTLPFTFGQGTKLEIK  129 BCMA-13 BC H1 39-B2-A4 scFv aa QVQLVQSGAVVAKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWMGAIYPGNSDTHYNQKFQGR VTLITDTSASTAYMELSSLRNEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSSGGGGSGGGGSGGG GSDIVMTQTPLSLSVTPGQQASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSTLPFTFGQGTKLEIK  130 BCMA-13 HL x BC H1 39-CD3 HL x bispecific molecule aa QVQLVQSGAVVAKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWMGAIYPGNSDTHYNQKFQGR CD3 HL B2-A4 HL VTLITDTSASTAYMELSSLRNEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSSGGGGSGGGGSGGG GSDIVMTQTPLSLSVTPGQQASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSTLPFTFGQGTKLEIKSGGGGSEVQLVESGGGLVQP GGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAAL TLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  131 BCMA-14 BC H1 39-B2-F12 VH CDR1 aa NYWIH  132 BCMA-14 BC H1 39-B2-F12 VH CDR2 aa AIYPGNSDTHYNQKFQG  133 BCMA-14 BC H1 39-B2-F12 VH CDR3 aa SSYYYDGSLFAS  134 BCMA-14 BC H1 39-B2-F12 VL CDR1 aa KSSQSIVHSNGNTYLY  135 BCMA-14 BC H1 39-B2-F12 VL CDR2 aa RVSNRFS  136 BCMA-14 BC H1 39-B2-F12 VL CDR3 aa FQGSHLPFT  137 BCMA-14 BC H1 39-B2-F12 VH aa QVQLVQSGAVVAKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWMGAIYPGNSDTHYNQKFQGR VTLITDTSASTAYMELSSLRNEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSS  138 BCMA-14 BC H1 39-B2-F12 VL aa DIVMTQTPLSLSVTPGQQASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCFQGSHLPFTFGQGTKLEIK  139 BCMA-14 BC H1 39-B2-F12 scFv aa QVQLVQSGAVVAKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWMGAIYPGNSDTHYNQKFQGR VTLITDTSASTAYMELSSLRNEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSSGGGGSGGGGSGGG GSDIVMTQTPLSLSVTPGQQASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHLPFTFGQGTKLEIK  140 BCMA-14 HL x BC H1 39-B2-F12 HL x bispecific molecule aa QVQLVQSGAVVAKPGASVKVSCKASGYTFTNYWIHWVKQAPGQRLEWMGAIYPGNSDTHYNQKFQGR CD3 HL CD3 HL VTLITDTSASTAYMELSSLRNEDTAVYYCTRSSYYYDGSLFASWGQGTLVTVSSGGGGSGGGGSGGG GSDIVMTQTPLSLSVTPGQQASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHLPFTFGQGTKLEIKSGGGGSEVQLVESGGGLVQP GGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAAL TLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  141 BCMA-15 BC H1 39-C9-A4 VH CDR1 aa SYWIH  142 BCMA-15 BC H1 39-C9-A4 VH CDR2 aa AIYPGNSDTHYNQKFQG  143 BCMA-15 BC H1 39-C9-A4 VH CDR3 aa SSYYYDGSLFAD  144 BCMA-15 BD H1 39-C9-A4 VL CDR1 aa KSSQSIVHSNGNTYLY  145 BCMA-15 BC H1 39-C9-A4 VL CDR2 aa RVSNRFS  146 BCMA-15 BC H1 39-C9-A4 VL CDR3 aa FQGSTLPFT  147 BCMA-15 BC H1-39-C9-A4 VH aa QVQLVQSGAEVKKPGTSVKVSCKASGYTFTSYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGR VTLTRDTSASTAYMELSSLRSEDSAVYYCTRSSYYYDGSLFADWGQGTLVTVSS  148 BCMA-15 BC H1-39-C9-A4 VL aa DIVMTQTPLSLSVTPGQPASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCFQGSTLPFTFGQGTKLEIK  149 BCMA-15 BC H1 39-C9-A4 scFv aa QVQLVQSGAEVKKPGTSVKVSCKASGYTFTSYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGR VTLTRDTSASTAYMELSSLRSEDSAVYYCTRSSYYYDGSLFADWGQGTLVTVSSGGGGSGGGGSGGG GSDIVMTQTPLSLSVTPGQPASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSTLPFTFGQGTKLEIK  150 BCMA-15 HL x BC H1 39- bispecific molecule aa QVQLVQSGAEVKKPGTSVKVSCKASGYTFTSYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGR CD3 HL C9-A4 HL VTLTRDTSASTAYMELSSLRSEDSAVYYCTRSSYYYDGSLFADWGQGTLVTVSSGGGGSGGGGSGGG x CD3 HL GSDIVMTQTPLSLSVTPGQPASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSTLPFTFGQGTKLEIKSGGGGSEVQLVESGGGLVQP GGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAAL TLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  151 BCMA-16 BC H1 39-C9-F12 VH CDR1 aa SYWIH  152 BCMA-16 BC H1 39-C9-F12 VH CDR2 aa AIYPGNSDTHYNQKFQG  153 BCMA-16 BC H1 39-C9-F12 VH CDR3 aa SSYYYDGSLFAD  154 BCMA-16 BC H1 39-C9-F12 VL CDR1 aa KSSQSIVHSNGNTYLY  155 BCMA-16 BC H1 39-C9-F12 VL CDR2 aa RVSNRFS  156 BCMA-16 BC H1 39-C9-F12 VL CDR3 aa FQGSHLPFT  157 BCMA-16 BC H1 39-C9-F12 VH aa QVQLVQSGAEVKKPGTSVKVSCKASGYTFTSYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGR VTLTRDTSASTAYMELSSLRSEDSAVYYCTRSSYYYDGSLFADWGQGTLVTVSS  158 BCMA-16 BC H1 39-C9-F12 VL aa DIVMTQTPLSLSVTPGQPASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCFQGSHLPFTFGQGTKLEIK  159 BCMA-16 BC H1 39-C9-F12 scFv aa QVQLVQSGAEVKKPGTSVKVSCKASGYTFTSYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGR VTLTRDTSASTAYMELSSLRSEDSAVYYCTRSSYYYDGSLFADWGQGTLVTVSSGGGGSGGGGSGGG GSDIVMTQTPLSLSVTPGQPASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHLPFTFGQGTKLEIK  160 BCMA-16 HL x BC H1 39-C9-F12 HL x bispecific molecule aa QVQLVQSGAEVKKPGTSVKVSCKASGYTFTSYWIHWVKQAPGQRLEWIGAIYPGNSDTHYNQKFQGR CD3 HL CD3 HL VTLTRDTSASTAYMELSSLRSEDSAVYYCTRSSYYYDGSLFADWGQGTLVTVSSGGGGSGGGGSGGG GSDIVMTQTPLSLSVTPGQPASISCKSSQSIVHSNGNTYLYWYLQKPGQPPQLLIYRVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHLPFTFGQGTKLEIKSGGGGSEVQLVESGGGLVQP GGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTA YLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAAL TLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  161 BCMA-17 BC C3 33-D7-E6 VH CDR1 aa NFDMA  162 BCMA-17 BC C3 33-D7-E6 VH CDR2 aa SITTGADHAIYADSVKG  163 BCMA-17 BC C3 33-D7-E6 VH CDR3 aa HGYYDGYHLFDY  164 BCMA-17 BC C3 33-D7-E6 VL CDR1 aa RASQGISNYLN  165 BCMA-17 BC C3 33-D7-E6 VL CDR2 aa YTSNLQS  166 BCMA-17 BC C3 33-D7-E6 VL CDR3 aa QQYDISSYT  167 BCMA-17 BC C3 33-D7-E6 VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS  168 BCMA-17 BC C3 33-D7-E6 VL aa DIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS GTDYTLTISSLQPEDFATYYCQQYDISSYTFGQGTKLEIK  169 BCMA-17 BC C3 33-D7-E6 scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQYDISSYTFGQGTKLEIK  170 BCMA-17 HL x BC C3 33-D7-E6 HL x bispecific molecule aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR CD3 HL CD3 HL FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQYDISSYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  171 BCMA-18 BC C3 33-D7-E6B1 VH CDR1 aa NFDMA  172 BCMA-18 BC C3 33-D7-E6B1 VH CDR2 aa SITTGADHAIYADSVKG  173 BCMA-18 BC C3 33-D7-E6B1 VH CDR3 aa GHYYDGYHLFDY  174 BCMA-18 BC C3 33-D7-E6B1 VL CDR1 aa RASQGISNYLN  175 BCMA-18 BC C3 33-D7-E6B1 VL CDR2 aa YTSNLQS  176 BCMA-18 BC C3 33-D7-E6B1 VL CDR3 aa MGQTISSYT  177 BCMA-18 BC C3 33-D7-E6B1 VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS  178 BCMA-18 BC C3 33-D7-E6B1 VL aa DIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS GTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK  179 BCMA-18 BC C3 33-D7-E6B1 scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK  180 BCM1-18 HL x BC C3 33-D7-E6B1 HL x bispecific molecule aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR CD3 HL CD3 HL FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  181 BCMA-19 BC C3 33-F8-E6 VH CDR1 aa NFDMA  182 BCMA-19 BC C3 33-F8-E6 VH CDR2 aa SITTGADHAIYADSVKG  183 BCMA-19 BC C3 33-F8-E6 VH CDR3 aa HGYYDGYHLFDY  184 BCMA-19 BC C3 33-F8-E6 VL CDR1 aa RASQGISNYLN  185 BCMA-19 BC C3 33-F8-E6 VL CDR2 aa YTSNLQS  186 BCMA-19 BC C3 33-F8-E6 VL CDR3 aa QQYDISSYT  187 BCMA-19 BC C3 33-F8-E6 VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS  188 BCMA-19 BC C3 33-F8-E6 VL aa DIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS GTDYTLTISSLQPEDFATYYCQQYDISSYTFGQGTKLEIK  189 BCMA-19 BC C3 33-F8-E6 scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQYDISSYTFGQGTKLEIK  190 BCMA-19 HL x BC C3 33-F8-E6 HL x bispecific molecule aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR CD3 HL CD3 HL FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQYDISSYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  191 BCMA-20 BC C3 33-F8-E6B1 VH CDR1 aa NFDMA  192 BCMA-20 BC C3 33-F8-E6B1 VH CDR2 aa SITTGADHAIYADSVKG  193 BCMA-20 BC C3 33-F8-E6B1 VH CDR3 aa HGYYDGYHLFDY  194 BCMA-20 BC C3 33-F8-E6B1 VL CDR1 aa RASQGISNYLN  195 BCMA-20 BC C3 33-F8-E6B1 VL CDR2 aa YTSNLQS  196 BCMA-20 BC C3 33-F8-E6B1 VL CDR3 aa MGQTISSYT  197 BCMA-20 BC C3 33-F8-E6B1 VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS  198 BCMA-20 BC C3 33-F8-E6B1 VL aa DIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS GTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK  199 BCMA-20 BC C3 33-F8-E6B1 scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK  200 BCMA-20 HL x BC C3 33-F8-E6B1 HL x bispecific molecule aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR CD3 HL CD3 HL FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  201 BCMA-21 BC C3 33-F9-E6 VH CDR1 aa NFDMA  202 BCMA-21 BC C3 33-F9-E6 VH CDR2 aa SITTGADHAIYADSVKG  203 BCMA-21 BC C3 33-F9-E6 VH CDR3 aa HGYYDGYHLFDY  204 BCMA-21 BC C3 33-F9-E6 VL CDR1 aa RASQGISNYLN  205 BCMA-21 BC C3 33-F9-E6 VL CDR2 aa YTSNLQS  206 BCMA-21 BC C3 33-F9-E6 VL CDR3 aa QQYDISSYT  207 BCMA-21 BC C3 33-F9-E6 VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS  208 BCMA-21 BC C3 33-F9-E6 VL aa DIQMTQSPSSLSASVGDRVTISCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS GTDYTLTISSLQPEDFATYYCQQYDISSYTFGQGTKLEIK  209 BCMA-21 BC C3 33-F9-E6 scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQYDISSYTFGQGTKLEIK  210 BCMA-21 HL x BC C33-F9-E6 HL x bispecific molecule aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYADSVKGR CD3 HL CD3 HL FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQYDISSYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  211 BCMA-22 BC C3 33-F9-E6B1-E VH CDR1 aa NFDMA  212 BCMA-22 BC C3 33-F9-E6B1-E VH CDR2 aa SITTGADHAIYAESVKG  213 BCMA-22 BC C3 33-F9-E6B1-E VH CDR3 aa HGYYDGYHLFDY  214 BCMA-22 BC C3 33-F9-E6B1-E VL CDR1 aa RASQGISNYLN  215 BCMA-22 BC C3 33-F9-E6B1-E VL CDR2 aa YTSNLQS  216 BCMA-22 BC C3 33-F9-E6B1-E VL CDR3 aa MGQTISSYT  217 BCMA-22 BC C3 33-F9-E6B1-E VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYAESVKGR FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS  218 BCMA-22 BC C3 33-F9-E6B1-E VL aa DIQMTQSPSSLSASVGDRVTISCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS GTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK  219 BCMA-22 BC C3 33-F9-E6B1-E scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYAESVKGR FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK  220 BCMA=22 HL x BC C3 33-F9-E6B1-E bispecific molecule aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGADHAIYAESVKGR CD3 HL HL x CD3  HL FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  221 BCMA-23 BC C3 33-F10-E6B1 VH CDR1 aa NFDMA   222 BCMA-23 BC C3 33-F10-E6B1 VH CDR2 aa SITTGADHAIYADSVKG  223 BCMA-23 BC C3 33-F10-E6B1 VH CDR3 aa HGYYDGYHLFDY  224 BCMA-23 BC C3 33-F10-E6B1 VL CDR1 aa RASQGISNYLN  225 BCMA-23 BC C3 33-F10-E6B1 VL CDR2 aa YTSNLQS  226 BCMA-23 BC C3 33-F10-E6B1 VL CDR3 aa MGQTISSYT  227 BCMA-23 BC C3 33-F10-E6B1 VH aa EVQLVESGGGLVQPGRSLRLSCAASGFTFSNFDMAWVRQAPAKGLEWVSSITTGADHAIYADSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS  228 BCMA-23 BC C3 33-F10-E6B1 VL aa DIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS GTDFTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK  229 BCMA-23 BC C3 33-F10-E6B1 scFv aa EVQLVESGGGLVQPGRSLRLSCAASGFTFSNFDMAWVRQAPAKGLEWVSSITTGADHAIYADSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK  230 BCMA-23 HL x BC C3 33-F10-E6B1 bispecific molecule aa EVQLVESGGGLVQPGRSLRLSCAASGFTFSNFDMAWVRQAPAKGLEWVSSITTGADHAIYADSVKGR CD3 HL HL x CD3 HL FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  231 BCMA-24 BC B6 64-H5-A4 VH CDR1 aa DYYIN  232 BCMA-24 BC B6 64-H5-A4 VH CDR2 aa WIYFASGNSEYNQKFTG  233 BCMA-24 BC B6 64-H5-A4 VH CDR3 aa LYDYDWYFDV  234 BCMA-24 BC B6 64-H5-A4 VL CDR1 aa KSSQSLVHSNGNTYLH  235 BCMA-24 BC B6 64-H5-A4 VL CDR2 aa KVSNRFS  236 BCMA-24 BC B6 64-H5-A4 VL CDR3 aa AETSHVPWT  237 BCMA-24 BC B6 64-H5-A4 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS  238 BCMA-24 BC B6 64-H5-A4 VL DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKINRVEAEDVGVYYCAETSHVPWTFGQGTKLEIK  239 BCMA-24 BC B6 64-H5-A4 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKINRVEAEDVGVYYCAETSHVPWTFGQGTKLEIK  240 BCMA-24 HL x BC B6 64-H5-A4 HL x bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL CD3 HL VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKINRVEAEDVGVYYCAETSHVPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  241 BCMA-25 BC B6 64-H5-H9 VH CDR1 aa DYYIN  242 BCMA-25 BC B6 64-H5-H9 VH CDR2 aa WIYFASGNSEYNQKFTG  243 BCMA-25 BC B6 64-H5-H9 VH CDR3 aa LYDYDWYFDV  244 BCMA-25 BC B6 64-H5-H9 VL CDR1 aa KSSQSLVHSNGNTYLH  245 BCMA-25 BC B6 64-H5-H9 VL CDR2 aa KVSNRFS  246 BCMA-25 BC B6 64-H5-H9 VL CDR3 aa LTTSHVPWT  247 BCMA-25 BC B6 64-H5-H9 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS  248 BCMA-25 BC B6 64-H5-H9 VL aa DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKINRVEAEDVGVYYCLITSHVPWTFGQGTKLEIK  249 BCMA-25 BC B6 64-H5-H9 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKINRVEAEDVGVYYCLITSHVPWTFGQGTKLEIK  250 BCMA-25 HL x BC B6 64-H5-H9 HL x bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL CD3 HL VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKINRVEAEDVGVYYCLITSHVPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  251 BCMA-26 BC B6 65-B5-A4 VH CDR1 aa DYYIN  252 BCMA-26 BC B6 65-B5-A4 VH CDR2 aa WIYFASGNSEYNQKFTG  253 BCMA-26 BC B6 65-B5-A4 VH CDR3 aa LYDYDWYFDV  254 BCMA-26 BC B6 65-B5-A4 VL CDR1 aa KSSQSLVHSNGNTYLH  255 BCMA-26 BC B6 65-B5-A4 VL CDR2 aa KVSNRFS  256 BCMA-26 BC B6 65-B5-A4 VL CDR3 aa AETSHVPWT  257 BCMA-26 BC B6 65-B5-A4 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS  258 BCMA-26 BC B6 65-B5-A4 VL aa DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCAETSHVPWTFGQGTKLEIK  259 BCMA-26 BC B6 65-B5-A4 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCAETSHVPWTFGQGTKLEIK  260 BCMA-26 HL x BC B6 65-B4-A4 HL x bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3  HL CD3 HL VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCAETSHVPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  261 BCMA-27 BC B6 65-B5-H9 VH CDR1 aa DYYIN  262 BCMA-27 BC B6 65-B5-H9 VH CDR2 aa WIYFASGNSEYNQKFTG  263 BCMA-27 BC B6 65-B5-H9 VH CDR3 aa LYDYDWYFDV  264 BCMA-27 BC B6 65-B5-H9 VL CDR1 aa KSSQSLVHSNGNTYLH  265 BCMA-27 BC B6 65-B5-H9 VL CDR2 aa KVSNRFS  266 BCMA-27 BC B6 65-B5-H9 VL CDR3 aa LTTSHVPWT  267 BCMA-27 BC B6 65-B5-H9 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS  268 BCMA-27 BC B6 65-B5-H9 VL aa DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCLTTSHVPWTFGQGTKLEIK  269 BCMA-27 BC B6 65-B5-H9 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCLTTSHVPWTFGQGTKLEIK  270 BCMA-27 HL x BC B6 65-B5-H9 HL x bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL CD3 HL VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCLTTSHVPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL   QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  271 BCMA-28 BC B6 65-H7-A4 VH CDR1 aa DYYIN  272 BCMA-28 BC B6 65-H7-A4 VH CDR2 aa WIYFASGNSEYNQKFTG  273 BCMA-28 BC B6 65-H7-A4 VH CDR3 aa LYDYDWYFDV  274 BCMA-28 BC B6 65-H7-A4 VL CDR1 aa KSSQSLVHSNGNTYLH  275 BCMA-28 BC B6 65-H7-A4 VL CDR2 aa KVSNRFS  276 BCMA-28 BC B6 65-H7-A4 VL CDR3 aa AETSHVPWT  277 BCMA-28 BC B6 65-H7-A4 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS  278 BCMA-28 BC B6 65-H7-A4 VL aa DIVMTQTPLSLSVSPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCAETSHVPWTFGQGTKLEIK  279 BCMA-28 BC B6 65-H7-A4 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVSPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCAETSHVPWTFGQGTKLEIK  280 BCMA-28 HL x BC B6 65-H7-A4 HL x bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL CD3  HL VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVSPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCAETSHVPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  281 BCMA-29 BC B6 65-H7-H9 VH CDR1 aa DYYIN  282 BCMA-29 BC B6 65-H7-H9 VH CDR2 aa WIYFASGNSEYNQKFTG  283 BCMA-29 BC B6 65-H7-H9 VH CDR3 aa LYDYDWYFDV  284 BCMA-29 BC B6 65-H7-H9 VL CDR1 aa KSSQSLVHSNGNTYLH  285 BCMA-29 BC B6 65-H7-H9 VL CDR2 aa KVSNRFS  286 BCMA-29 BC B6 65-H7-H9 VL CDR3 aa LTTSHVPWT  287 BCMA-29 BC B6 65-H7-H9 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS  288 BCMA-29 BC B6 65-H7-H9 VL aa DIVMTQTPLSLSVSPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCLTTSHVPWTFGQGTKLEIK  289 BCMA-29 BC B6 65-H7-H9 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVSPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCLTTSHVPWTFGQGTKLEIK  290 BCMA-29 HL x BC B6 65-H7 H9 HL x bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL CD3 HL VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVSPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCLTTSHVPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  291 BCMA-30 BC B6 65-H8-A4 VH CDR1 aa DYYIN  292 BCMA-30 BC B6 65-H8-A4 VH CDR2 aa WIYFASGNSEYNQKFTG  293 BCMA-30 BC B6 65-H8-A4 VH CDR3 aa LYDYDWYFDV  294 BCMA-30 BC B6 65-H8-A4 VL CDR1 aa KSSQSLVHSNGNTYLH  295 BCMA-30 BC B6 65-H8-A4 VL CDR2 aa KVSNRFS  296 BCMA-30 BC B6 65-H8-A4 VL CDR3 aa AETSHVPWT  297 BCMA-30 BC B6 65-H8-A4 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS  298 BCMA-30 BC B6 65-H8-A4 VL aa DIVMTQTPLSLSVTPGEPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGADFTLKISRVEAEDVGVYYCAETSHVPWTFGQGTKLEIK  299 BCMA-30 BC B6 65-H8-A4 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGEPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGADFTLKISRVEAEDVGVYYCAETSHVPWTFGQGTKLEIK  300 BCMA-30 HL x BC B6 65-H8-A4 HL x bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL CD3 HL VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGEPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGADFTLKISRVEAEDVGVYYCAETSHVPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  301 BCMA-31 BC B6 65-H8-H9 VH CDR1 aa DYYIN  302 BCMA-31 BC B6 65-H8-H9 VH CDR2 aa WIYFASGNSEYNQKFTG  303 BCMA-31 BC B6 65-H8-H9 VH CDR3 aa LYDYDWYFDV  304 BCMA-31 BC B6 65-H8-H9 VL CDR1 aa KSSQSLVHSNGNTYLH  305 BCMA-31 BC B6 65-H8-H9 VL CDR2 aa KVSNRFS  306 BCMA-31 BC B6 65-H8-H9 VL CDR3 aa LTTSHVPWT  307 BCMA-31 BC B6 65-H8-H9 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS  308 BCMA-31 BC B6 65-H8-H9 VL aa DIVMTQTPLSLSVTPGEPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGADFTLKISRVEAEDVGVYYCLTTSHVPWTFGQGTKLEIK  309 BCMA-31 BC B6 65-H8-H9 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGEPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGADFTLKISRVEAEDVGVYYCLTTSHVPWTFGQGTKLEIK  310 BCMA-31 HL x BC B6 65-H8-H9 HL x bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL CD3 HL VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGEPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGADFTLKISRVEAEDVGVYYCLTTSHVPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYMANWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  311 BCMA-32 BC A7 27-A6-G7 VH CDR1 aa NHIIH  312 BCMA-32 BC A7 27-A6-G7 VH CDR2 aa YINPYPGYHAYNEKFQG  313 BCMA-32 BC A7 27-A6-G7 VH CDR3 aa DGYYRDTDVLDY  314 BCMA-32 BC A7 27-A6-G7 VL CDR1 aa QASQDISNYLN  315 BCMA-32 BC A7 27-A6-G7 VL CDR2 aa YTSRLHT  316 BCMA-32 BC A7 27-A6-G7 VL CDR3 aa QQGNTLPWT  317 BCMA-32 BC A7 27-A6-G7 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYPGYHAYNEKFQGR ATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSS  318 BCMA-32 BC A7 27-A6-G7 VL aa DIQMTQSPSSLSASLGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGSGS GTDFTFTISSLQQEDIATYYCQQGNTLPWTFGQGTKVEIK  319 BCMA-32 BC A7 27-A6-G7 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYPGYHAYNEKFQGR ATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASLGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGS GSGTDFTFTISSLQQEDIATYYCQQGNTLPWTFGQGTKVEIK  320 BCMA-32 HL x BC A7 27-A6-G7 HL x bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYPGYHAYNEKFQGR CD3 HL CD3 HL ATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASLGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGS GSGTDFTFTISSLQQEDIATYYCQQGNTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  321 BCMA-33 BC A7 27-A6-H11 VH CDR1 aa NHIIH  322 BCMA-33 BC A7 27-A6-H11 VH CDR2 aa YINPYDGWGDYNEKFQG  323 BCMA-33 BC A7 27-A6-H11 VH CDR3 aa DGYYRDADVLDY  324 BCMA-33 BC A7 27-A6-H11 VL CDR1 aa QASQDISNYLN  325 BCMA-33 BC A7 27-A6-H11 VL CDR2 aa YTSRLHT  326 BCMA-33 BC A7 27-A6-H11 VL CDR3 aa QQGNTLPWT  327 BCMA-33 BC A7 27-A6-H11 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYDGWGDYNEKFQGR ATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDADVLDYWGQGTLVTVSS  328 BCMA-33 BC A7 27-A6-H11 VL aa DIQMTQSPSSLSASLGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGSGS GTDFTFTISSLQQEDIATYYCQQGNTLPWTFGQGTKVEIK  329 BCMA-33 BC A7 27-A6-H11 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYDGWGDYNEKFQGR ATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDADVLDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASLGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGS GSGTDFTFTISSLQQEDIATYYCQQGNTLPWTFGQGTKVEIK  330 BCMA-33 HL x BC A7 27-A6-H11 HL x bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYDGWGDYNEKFQGR CD3 HL CD3 HL ATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDADVLDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASLGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGS GSGTDFTFTISSLQQEDIATYYCQQGNTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  331 BCMA-34 BC A7 27-C4-G7 VH CDR1 aa NHIIH  332 BCMA-34 BC A7 27-C4-G7 VH CDR2 aa YINPYPGYHAYNEKFQG  333 BCMA-34 BC A7 27-C4-G7 VH CDR3 aa DGYYRDTDVLDY  334 BCMA-34 BC A7 27-C4-G7 VL CDR1 aa QASQDISNYLN  335 BCMA-34 BC A7 27-C4-G7 VL CDR2 aa YTSRLHT  336 BCMA-34 BC A7 27-C4-G7 VL CDR3 aa QQGNTLPWT  337 BCMA-34 BC A7 27-C4-G7 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYPGYHAYNEKFQGR ATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSS  338 BCMA-34 BC A7 27-C4-G7 VL aa DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGSGS GTDFTFTISSLEPEDIATYYCQQGNTLPWTFGQGTKVEIK  339 BCMA-34 BC A7 27-C4-G7 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYPGYHAYNEKFQGR ATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGS GSGTDFTFTISSLEPEDIATYYCQQGNTLPWTFGQGTKVEIK  340 BCMA-34 HL x BC A7 27-C4-G7 HL x bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYPGYHAYNEKFQGR CD3 HL CD3 HL ATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGS GSGTDFTFTISSLEPEDIATYYCQQGNTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  341 BCMA-35 BC A7 27-C4-H11 VH CDR1 aa NHIIH  342 BCMA-35 BC A7 27-C4-H11 VH CDR2 aa YINPYDGWGDYNEKFQG  343 BCMA-35 BC A7 27-C4-H11 VH CDR3 aa DGYYRDADVLDY  344 BCMA-35 BC A7 27-C4-H11 VL CDR1 aa QASQDISNYLN  345 BCMA-35 BC A7 27-C4-H11 VL CDR2 aa YTSRLHT  346 BCMA-35 BC A7 27-C4-H11 VL CDR3 aa QQGNTLPWT  347 BCMA-35 BC A7 27-C4-H11 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYDGWGDYNEKFQGR ATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDADVLDYWGQGTLVTVSS  348 BCMA-35 BC A7 27-C4-H11 VL aa DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGSGS GTDFTFTISSLEPEDIATYYCQQGNTLPWTFGQGTKVEIK  349 BCMA-35 BC A7 27-C4-H11 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYDGWGDYNEKFQGR ATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDADVLDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGS GSGTDFTFTISSLEPEDIATYYCQQGNTLPWTFGQGTKVEIK  350 BCMA-35 HL x BC A7 27-C4-H11 HL x bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYDGWGDYNEKFQGR CD3 HL CD3 HL ATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDADVLDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGS GSGTDFTFTISSLEPEDIATYYCQQGNTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  351 BCMA-36 BC A7 15-H2-G7 VH CDR1 aa NHIIH  352 BCMA-36 BC A7 15-H2-G7 VH CDR2 aa YINPYPGYHAYNQKFQG  353 BCMA-36 BC A7 15-H2-G7 VH CDR3 aa DGYYRDTDVLDY  354 BCMA-36 BC A7 15-H2-G7 VL CDR1 aa QASQDISNYLN  355 BCMA-36 BC A7 15-H2-G7 VL CDR2 aa YTSRLHT  356 BCMA-36 BC A7 15-H2-G7 VL CDR3 aa QQGNTLPWT  357 BCMA-36 BC A7 15-H2-G7 VH aa QVQLVQSGAKVIKPGASVKVSCKASGYTFTNIHWVRQKPGQGLEWMGYINPYPGYHAYNQKFQGR BTMTRDKSTSTVYMELSSLTSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSS  358 BCMA-36 BC A7 15-H2-G7 VL aa DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGRAPKLLIYYTSRLHTGVPSRFSGSGS GTDYSFTISSLQPEDIATYYCQQGNTLPWTFGQGTKVEIK  359 BCMA-36 BC A7 15-H2-G7 scFv aa QVQLVQSGAKVIKPGASVKVSCKASGYTFTNHIIHWVRQKPGQGLEWMGYINPYPGYHAYNQKFQGR VTMTRDKSTSTVYMELSSLTSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGRAPKLLIYYTSRLHTGVPSRFSGS GSGTDYSFTISSLQPEDIATYYCQQGNTLPWTFGQGTKVEIK  360 BCMA-36 HL x BC A7 15-H2-G7 HL x bispecific molecule aa QVQLVQSGAKVIKPGASVKVSCKASGYTFTNHIIHWVRQKPGQGLEWMGYINPYPGYHAYNQKFQGR CD3 HL CD3 HL VTMTRDKSTSTVYMELSSLTSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGRAPKLLIYYTSRLHTGVPSRFSGS GSGTDYSFTISSLQPEDIATYYCQQGNTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  361 BCMA-37 BC A7 15-H2-H11 VH CDR1 aa NHIIH  362 BCMA-37 BC A7 15-H2-H11 VH CDR2 aa YINPYDGWGDYNQKFQG  363 BCMA-37 BC A7 15-H2-H11 VH CDR3 aa DGYYRDADVLDY  364 BCMA-37 BC A7 15-H2-H11 VL CDR1 aa QASQDISNYLN  365 BCMA-37 BC A7 15-H2-H11 VL CDR2 aa YTSRLHT  366 BCMA-37 BC A7 15-H2-H11 VL CDR3 aa QQGNTLPWT  367 BCMA-37 BC A7 15-H2-H11 VH aa QVQLVQSGAKVIKPGASVKVSCKASGYTFTNHIIHWVRQKPGQGLEWMGYINPYDGWGDYNQKFQGR VTMTRDKSTSTVYMELSSLTSEDTAVYYCARDGYYRDADVLDYWGQGTLVTVSS  368 BCMA-37 BC A7 15-H2-H11 VL aa DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGRAPKLLIYYTSRLHTGVPSRFSGSGS GTDYSFTISSLQPEDIATYYCQQGNTLPWTFGQGTKVEIK  369 BCMA-37 BC A7 15-H2-H11 scFv aa QVQLVQSGAKVIKPGASVKVSCKASGYTFTNHIIHWVRQKPGQGLEWMGYINPYDGWGDYNQKFQGR VTMTRDKSTSTVYMELSSLTSEDTAVYYCARDGYYRDADVLDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGRAPKLLIYYTSRLHTGVPSRFSGS GSGTDYSFTISSLQPEDIATYYCQQGNTLPWTFGQGTKVEIK  370 BCMA-37 HL x BC A7 15-H2-H11 HL c bispecific molecule aa QVQLVQSGAKVIKPGASVKVSCKASGYTFTNHIIHWVRQKPGQGLEWMGYINPYDGWGDYNQKFQGR CD3 HL CD3 HL VTMTRDKSTSTVYMELSSLTSEDTAVYYCARDGYYRDADVLDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGRAPKLLIYYTSRLHTGVPSRFSGS GSGTDYSFTISSLQPEDIATYYCQQGNTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  371 BCMA-38 BC A7 15-H8-G7 VH CDR1 aa NHIIH  372 BCMA-38 BC A7 15-H8-G7 VH CDR2 aa YINPYPGYHAYNQKFQG  373 BCMA-38 BC A7 15-H8-G7 VH CDR3 aa DGYYRDTDVLDY  374 BCMA-38 BC A7 15-H8-G7 VL CDR1 aa QASQDISNYLN  375 BCMA-38 BC A7 15-H8-G7 VL CDR2 aa YTSRLHT  376 BCMA-38 BC A7 15-H8-G7 VL CDR3 aa QQGNTLPWT  377 BCMA-38 BC A7 15-H8-G7 VH aa QVQLVQSGAEVIKPGASVKVSCKASGYTFTNHIIHWVRQKPGQGLEWIGYINPYPGYHAYNQKFQGK VTMTRDTSTSTVYMELSSLTSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSS  378 BCMA-38 BC A7 15-H8-G7 VL aa DIQMTQSPSSLSASLGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGSGS GTDFTFTISSLQQEDIATYYCQQGNTLPWTFGQGTKVEIK  379 BCMA-38 BC A7 15-H8-G7 scFv aa QVQLVQSGAEVIKPGASVKVSCKASGYTFTNHIIHWVRQKPGQGLEWIGYINPYPGYHAYNQKFQGK VTMTRDTSTSTVYMELSSLTSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASLGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGS GSGTDFTFTISSLQQEDIATYYCQQGNTLPWTFGQGTKVEIK  380 BCMA-38 HL x BC A7 15-H8-G7 HL x bispecific molecule aa QVQLVQSGAEVIKPGASVKVSCKASGYTFTNHIIHWVRQKPGQGLEWIGYINPYPGYHAYNQKFQGK CD3 HL CD3 HL VTMTRDTSTSTVYMELSSLTSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASLGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGS GSGTDFTFTISSLQQEDIATYYCQQGNTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  381 BCMA-39 BC A7 15-H8-H11 VH CDR1 aa NHIIH  382 BCMA-39 BC A7 15-H8-H11 VH CDR2 aa YINPYDGWGDYNQKFQG  383 BCMA-39 BC A7 15-H8-H11 VH CDR3 aa DGYYRDADVLDY  384 BCMA-39 BC A7 15-H8-H11 VL CDR1 aa QASQDISNYLN  385 BCMA-39 BC A7 15-H8-H11 VL CDR2 aa YTSRLHT  386 BCMA-39 BC A7 15-H8-H11 VL CDR3 aa QQGNTLPWT  387 BCMA-39 BC A7 15-H8-H11 VH aa QVQLVQSGAEVIKPGASVKVSCKASGYTFTNHIIHWVRQKPGQGLEWIGYINPYDGWGDYNQKFQGK VTMTRDTSTSTVYMELSSLTSEDTAVYYCARDGYYRDADVLDYWGQGTLVTVSS  388 BCMA-39 BC A7 15-H8-H11 VL aa DIQMTQSPSSLSASLGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGSGS GTDFTFTISSLQQEDIATYYCQQGNTLPWTFGQGTKVEIK  389 BCMA-39 BC A7 15-H8-H11 scFv aa QVQLVQSGAEVIKPGASVKVSCKASGYTFTNHIIHWVRQKPGQGLEWIGYINPYDGWGDYNQKFQGK VTMTRDTSTSTVYMELSSLTSEDTAVYYCARDGYYRDADVLDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASLGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGS GSGTDFTFTISSLQQEDIATYYCQQGNTLPWTFGQGTKVEIK  390 BCMA-39 HL x BC A7 15-H8-H11 HL x bispecific molecule aa QVQLVQSGAEVIKPGASVKVSCKASGYTFTNHIIHWVRQKPGQGLEWIGYINPYDGWGDYNQKFQGK CD3 HL CD3 HL VTMTRDTSTSTVYMELSSLTSEDTAVYYCARDGYYRDADVLDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASLGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGS GSGTDFTFTISSLQQEDIATYYCQQGNTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  391 BCMA-40 BC 7A4 96-D4-A12 VH CDR1 aa DYYIN  392 BCMA-40 BC 7A4 96-D4-A12 VH CDR2 aa WIYFASGNSEYNQKFTG  393 BCMA-40 BC 7A4 96-D4-A12 VH CDR3 aa LYDYDWYFDV  394 BCMA-40 BC 7A4 96-D4-A12 VL CDR1 aa KSSQSLVHSNGNTYLH  395 BCMA-40 BC 7A4 96-D4-A12 VL CDR2 aa KVSNRFS  396 BCMA-40 BC 7A4 96-D4-A12 VL CDR3 aa SQSSTAPWT  397 BCMA-40 BC 7A4 96-D4-A12 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS  398 BCMA-40 BC 7A4 96-D4-A12 VL aa DIVMTQTPLSLPVTLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSTAPWTFGQGTKLEIK  399 BCMA-40 BC 7A4 96-D4-A12 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLPVTLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSTAPWTFGQGTKLEIK  400 BCMA-40 HL x BC 7A4 96-D4-A12 HL x bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL CD3 HL VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLPVTLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSTAPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  401 BCMA-41 BC 7A4 96-D4-D7 VH CDR1 aa DYYIN  402 BCMA-41 BC 7A4 96-D4-D7 VH CDR2 aa WIYFASGNSEYNQKFTG  403 BCMA-41 BC 7A4 96-D4-D7 VH CDR3 aa LYDYDWYFDV  404 BCMA-41 BC 7A4 96-D4-D7 VL CDR1 aa KSSQSLVHSNGNTYLH  405 BCMA-41 BC 7A4 96-D4-D7 VL CDR2 aa KVSNRFS  406 BCMA-41 BC 7A4 96-D4-D7 VL CDR3 aa SQSSIYPWT  407 BCMA-41 BC 7A4 96-D4-D7 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS  408 BCMA-41 BC 7A4 96-D4-D7 VL aa DIVMTQTPLSLPVTLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSIYPWTFGQGTKLEIK  409 BCMA-41 BC 7A4 96-D4-D7 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLPVTLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVDPRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSIYPWTFGQGTKLEIK  410 BCMA-41 HL x BC 7A4 96-D4-D7 HL x bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL CD3 HL VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLPVTLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSIYPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  411 BCMA-42 BC 7A4 96-D4-E7 VH CDR1 aa DYYIN  412 BCMA-42 BC 7A4 96-D4-E7 VH CDR2 aa WIYFASGNSEYNQKFTG  413 BCMA-42 BC 7A4 96-D4-E7 VH CDR3 aa LYDYDWYFDV  414 BCMA-42 BC 7A4 96-D4-E7 VL CDR1 aa KSSQSLVHSNGNTYLH  415 BCMA-42 BC 7A4 96-D4-E7 VL CDR2 aa KVSNRFS  416 BCMA-42 BC 7A4 96-D4-E7 VL CDR3 aa SQSTYPEFT  417 BCMA-42 BC 7A4 96-D4-E7 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS  418 BCMA-42 BC 7A4 96-D4-E7 VL aa DIVMTQTPLSLPVTLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSTYPEFTFGQGTKLEIK  419 BCMA-42 BC 7A4 96-D4-E7 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLPVTLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSTYPEFTFGQGTKLEIK  420 BCMA-42 HL x BC 7A496-D4-E7 HL x bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL CD3 HL VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLPVTLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSTYPEFTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  421 BCMA-43 BC 7A4 96-F4-A12 VH CDR1 aa DYYIN  422 BCMA-43 F4-A12 VH CDR2 aa WIYFASGNSEYNQKFTG  423 BCMA-43 F4-A12 VH CDR3 aa LYDYDWYFDV  424 BCMA-43 F4-A12 VL CDR1 aa KSSQSLVHSNGNTYLH  425 BCMA-43 F4-A12 VL CDR2 aa KVSNRFS  426 BCMA-43 F4-A12 VL CDR3 aa SQSSTAPWT  427 BCMA-43 F4-A12 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS  428 BCMA-43 F4-A12 VL aa DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSTAPWTFGQGTKLEIK  429 BCMA-43 F4-A12 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSTAPWTFGQGTKLEIK  430 BCMA-43 HL x BC 7A4 96-F4-A12 HL x bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL CD3 HL VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSTAPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  431 BCMA-44 BC 7A4 96-F4-D7 VH CDR1 aa DYYIN  432 BCMA-44 BC 7A4 96-F4-D7 VH CDR2 aa WIYFASGNSEYNQKFTG  433 BCMA-44 BC 7A4 96-F4-D7 VH CDR3 aa LYDYDWYFDV  434 BCMA-44 BC 7A4 96-F4-D7 VL CDR1 aa KSSQSLVHSNGNTYLH  435 BCMA-44 BC 7A4 96-F4-D7 VL CDR2 aa KVSNRFS  436 BCMA-44 BC 7A4 96-F4-D7 VL CDR3 aa SQSSIYPWT  437 GCMA-44 BC 7A4 96-F4-D7 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS  438 BCMA-44 BC 7A4 96-F4-D7 VL aa DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSIYPWTFGQGTKLEIK  439 BCMA-44 BC 7A4 96-F4-D7 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSIYPWTFGQGTKLEIK  440 BCMA-44 HL x BC 7A4 96-F4-D7 HL x bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL CD3  HL VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSIYPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYMANWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  441 BCMA-45 BC 7A4 96-F4-E7 VH CDR1 aa DYYIN  442 BCMA-45 BC 7A4 96-F4-E7 VH CDR2 aa WIYFASGNSEYNQKFTG  443 BCMA-45 BC 7A4 96-F4-E7 VH CDR3 aa LYDYDWYFDV  444 BCMA-45 BC 7A4 96-F4-E7 VL CDR1 aa KSSQSLVHSNGNTYLH  445 BCMA-45 BC 7A4 96-F4-E7 VL CDR2 aa KVSNRFS  446 BCMA-45 BC 7A4 96-F4-E7 VL CDR3 aa SQSTYPEFT  447 BCMA-45 BC 7A4 96-F4-E7 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS  448 BCMA-45 BC 7A4 96-F4-E7 VL aa DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSTYPEFTFGQGTKLEIK  449 BCMA-45 BC 7A4 96-F4-E7 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSTYPEFTFGQGTKLEIK  450 BCMA-45 HL x BC 7A4 96-F4-E7 HL x bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL CD3 HL VTMTRDTSISTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSTYPEFTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  451 BCMA-46 BC 7A4 96-G2-A12 VH CDR1 aa DYYIN  452 BCMA-46 BC 7A4 96-G2-A12 VH CDR2 aa WIYFASGNSEYNEKFTG  453 BCMA-46 BC 7A4 96-G2-A12 VH CDR3 aa LYDYDWYFDV  454 BCMA-46 BC 7A4 96-G2-A12 VL CDR1 aa KSSQSLVHSNGNTYLH  455 BCMA-46 BC 7A4 96-G2-A12 VL CDR2 aa KVSNRFS  456 BCMA-46 BC 7A4 96-G2-A12 VL CDR3 aa SQSSTAPWT  457 BCMA-46 BC 7A4 96-G2-A12 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNEKFTGR VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS  458 BCMA-46 BC 7A4 96-G2-A12 VL aa DIVMTQTPLSLSVSLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSTAPWTFGQGTKLEIK  459 BCMA-46 BC 7A4 96-G2-A12 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNEKFTGR VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVSLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSTAPWTFGQGTKLEIK  460 BCMA-46 HL x BC 7A4 96-G2-A12 HL x bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNEKFTGR CD3 HL CD3 HL DIVMTQTPLSLSVSLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSTAPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  461 BCMA-47 BC 7A4 96-G2-D7 VH CDR1 aa DYYIN  462 BCMA-47 BC 7A4 96-G2-D7 VH CDR2 aa WIYFASGNSEYNEKFTG  463 BCMA-47 BC 7A4 96-G2-D7 VH CDR3 aa LYDYDWYFDV  464 BCMA-47 BC 7A4 96-G2-D7 VL CDR1 aa KSSQSLVHSNGNTYLH  465 BCMA-47 BC 7A4 96-G2-D7 VL CDR2 aa KVSNRFS  466 BCMA-47 BC 7A4 96-G2-D7 VL CDR3 aa SQSSIYPWT  467 BCMA-47 BC 7A4 96-G2-D7 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNEKFTGR VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS  468 BCMA-47 BC 7A4 96-G2-D7 VL aa DIVMTQTPLSLSVSLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSIYPWTFGQGTKLEIK  469 BCMA-47 BC 7A4 96-G2-D7 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNEKFTGR VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVSLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSIYPWTFGQGTKLEIK  470 BCMA-47 HL x BC 7A4 96-G2-D7 HL x bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNEKFTGR CD3 HL CD3 HL VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVSLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSSIYPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  471 BCMA-48 BC 7A4 96-G2-E7 VH CDR1 aa DYYIN  472 BCMA-48 BC 7A4 96-G2-E7 VH CDR2 aa WIYFASGNSEYNEKFTG  473 BCMA-48 BC 7A4 96-G2-E7 VH CDR3 aa LYDYDWYFDV  474 BCMA-48 BC 7A4 96-G2-E7 VL CDR1 aa KSSQSLVHSNGNTYLH  475 BCMA-48 BC 7A4 96-G2-E7 VL CDR2 aa KVSNRFS  476 BCMA-48 BC 7A4 96-G2-E7 VL CDR3 aa SQSTYPEFT  477 BCMA-48 BC 7A4 96-G2-E7 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNEKFTGR VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS  478 BCMA-48 BC 7A4 96-G2-E7 VL aa DIVMTQTPLSLSVSLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSTYPEFTFGQGTKLEIK  479 BCMA-48 BC 7A4 96-G2-E7 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNEKFTGR VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVSLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSTYPEFTFGQGTKLEIK  480 BCMA-48 HL x BC 7A4 96-G2-E7 HL x bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNEKFTGR CD3 HL CD3 HL VTMTRDTSSSTAYMELSSLRSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVSLGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCSQSTYPEFTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  481 BCMA-49 BC 7A4 97-A3-A12 VH CDR1 aa DYYIN  482 BCMA-49 BC 7A4 97-A3-A12 VH CDR2 aa WIYFASGNSEYNQKFTG  483 BCMA-49 BC 7A4 97-A3-A12 VH CDR3 aa LYDYDWYFDV  484 BCMA-49 BC 7A4 97-A3-A12 VL CDR1 aa KSSQSLVHSNGNTYLH  485 BCMA-49 BC 7A4 97-A3-A12 VL CDR2 aa KVSNRFS  486 BCMA-49 BC 7A4 97-A3-A12 VL CDR3 aa SQSSTAPWT  487 BCMA-49 BC 7A4 97-A3-A12 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSINTAYMELSSLTSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS  488 BCMA-49 BC 7A4 97-A3-A12 VL aa DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGIYYCSQSSTAPWTFGQGTKLEIK  489 BCMA-49 BC 7A4 97-A3-A12 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSINTAYMELSSLTSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGIYYCSQSSTAPWTFGQGTKLEIK  490 BCMA-49 HL x BC 7A4 97-A3-A12 HL x bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL CD3 HL VTMTRDTSINTAYMELSSLTSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGIYYCSQSSTAPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  491 BCMA-50 BC 7A4 97-A3-D7 VH CDR1 aa DYYIN  492 BCMA-50 BC 7A4 97-A3-D7 VH CDR2 aa WIYFASGNSEYNQKFTG  493 BCMA-50 BC 7A4 97-A3-D7 VH CDR3 aa LYDYDWYFDV  494 BCMA-50 BC 7A4 97-A3-D7 VL CDR1 aa KSSQSLVHSNGNTYLH  495 BCMA-50 BC 7A4 97-A3-D7 VL CDR2 aa KVSNRFS  496 BCMA-50 BC 7A4 97-A3-D7 VL CDR3 aa SQSSIYPWT  497 BCMA-50 BC 7A4 97-A3-D7 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSINTAYMELSSLTSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS  498 BCMA-50 BC 7A4 97-A3-D7 VL aa DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGIYYCSQSSIYPWTFGQGTKLEIK  499 BCMA-50 BC 7A4 97-A3-D7 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSINTAYMELSSLTSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGIYYCSQSSIYPWTFGQGTKLEIK  500 BCMA-50 HL x BC 7A4 97-A3-D7 HL x bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL CD3 HL VTMTRDTSINTAYMELSSLTSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGIYYCSQSSIYPWTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYMANWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  501 BCMA-51 BC 7A4 97-A3-E7 VH CDR1 aa DYYIN  502 BCMA-51 BC 7A4 97-A3-E7 VH CDR2 aa WIYFASGNSEYNQKFTG  503 BCMA-51 BC 7A4 97-A3-E7 VH CDR3 aa LYDYDWYFDV  504 BCMA-51 BC 7A4 97-A3-E7 VL CDR1 aa KSSQSLVHSNGNTYLH  505 BCMA-51 BC 7A4 97-A3-E7 VL CDR2 aa KVSNRFS  506 BCMA-51 BC 7A4 97-A3-E7 VL CDR3 aa SQSTYPEFT  507 BCMA-51 BC 7A4 97-A3-E7 VH aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSINTAYMELSSLTSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSS  508 BCMA-51 BC 7A4 97-A3-E7 VL aa DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGIYYCSQSTYPEFTFGQGTKLEIK  509 BCMA-51 BC 7A4 97-A3-E7 scFv aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR VTMTRDTSINTAYMELSSLTSEDTAVYFCASLYDYDWYFDVWGQGTMVTVSSGGGGSGGGGSGGGGS DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGIYYCSQSTYPEFTFGQGTKLEIK  510 BCMA-51 HL x BC 7A4 97-A3-E7 HL x bispecific molecule aa QVQLVQSGAEVKKPGASVKVSCKASGYSFPDYYINWVRQAPGQGLEWMGWIYFASGNSEYNQKFTGR CD3 HL CD3 HL DIVMTQTPLSLSVTPGQPASISCKSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDVGIYYCSQSTYPEFTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGG SLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYL QMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTL SGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL  511 BCMA-52 BC E11 19-F11-F8 VH CDR1 aa NAWMD  512 BCMA-52 BC E11 19-F11-F8 VH CDR2 aa QITAKSNNYATYYAEPVKG  513 BCMA-52 BC E11 19-F11-F8 VH CDR3 aa DGYH  514 BCMA-52 BC E11 19-F11-F8 VL CDR1 aa RASEDIRNGLA  515 BCMA-52 BC E11 19-F11-F8 VL CDR2 aa NANSLHT  516 BCMA-52 BC E11 19-F11-F8 VL CDR3 aa EDTSKYPYT  517 BCMA-52 BC E11 19-F11-F8 VH aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWVAQITAKSNNYATYYAEPVK GRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTDDGYHWGQGTLVTVSS  518 BCMA-52 BC E11 19-F11-F8 VL aa AIQMTQSPSSLSASVGETVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGS GTEFTLKISSLQPEDEATYYCEDTSKYPYTFGQGTKLEIK  519 BCMA-52 BC E11 19-F11-F8 scFv aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWVAQITAKSNNYATYYAEPVK GRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM TQSPSSLSASVGETVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGSGTEF TLKISSLQPEDEATYYCEDTSKYPYTFGQGTKLEIK  520 BCMA-52 HL x BC E11 19-F11-F8 HL x bispecific molecule aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWVAQITAKSNNYATYYAEPVK CD3 HL CD3 HL GRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM TQSPSSLSASVGETVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGSGTEF TLKISSLQPEDEATYYCEDTSKYPYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAAS GFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTED TAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVT LTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCVLWYSNRWVFGGGTKLTVL  521 BCMA-53 BC E11 19-G3-F8 VH CDR1 aa NAWMD  522 BCMA-53 BC E11 19-G3-F8 VH CDR2 aa QITAKSNNYATYYAAPVKG  523 BCMA-53 BC E11 19-G3-F8 VH CDR3 aa DGYH  524 BCMA-53 BC E11 19-G3-F8 VL CDR1 aa RASEDIRNGLA  525 BCMA-53 BC E11 19-G3-F8 VL CDR2 aa NANSLHS  526 BCMA-53 BC E11 19-G3-F8 VL CDR3 aa EDTSKYPYT  527 BCMA-53 BC E11 19-G3-F8 VH aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWIAQITAKSNNYATYYAAPVK GRFTISRDDSKNTLYLQMNSLKKEDTAVYYCTDDGYHWGQGTLVTVSS  528 BCMA-53 BC E11 19-G3-F8 VL aa AIQMTQSPSSLSASVGDRVTIKCRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHSGVPSRFSGSGS GTDFTLTISSMQPEDEGTYYCEDTSKYPYTFGQGTKLEIK  529 BCMA-53 BC E11 19-G3-F8 scFv aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWIAQITAKSNNYATYYAAPVK GRFTISRDDSKNTLYLQMNSLKKEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM TQSPSSLSASVGDRVTIKCRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHSGVPSRFSGSGSGTDF TLTISSMQPEDEGTYYCEDTSKYPYTFGQGTKLEIK  530 BCMA-53 HL x BC E11 19-G3-F8 HL x bispecific molecule aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWIAQITAKSNNYATYYAAPVK CD3 HL CD3 HL GRFTISRDDSKNTLYLQMNSLKKEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM TQSPSSLSASVGDRVTIKCRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHSGVPSRFSGSGSGTDF TLTISSMQPEDEGTYYCEDTSKYPYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAAS GFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTED TAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVT LTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCVLWYSNRWVFGGGTKLTVL  531 BCMA-54 BC E11 19-B2-F8 VH CDR1 aa NAWMD  532 BCMA-54 BC E11 19-B2-F8 VH CDR2 aa QITAKSNNYATYYAAPVKG  533 BCMA-54 BC E11 19-B2-F8 VH CDR3 aa DGYH  534 BCMA-54 BC E11 19-B2-F8 VL CDR1 aa RASEDIRNGLA  535 BCMA-54 BC E11 19-B2-F8 VL CDR2 aa NANSLHT  536 BCMA-54 BC E11 19-B2-F8 VL CDR3 aa EDTSKYPYT  537 BCMA-54 BC E11 19-B2-F8 VH aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWIAQITAKSNNYATYYAAPVK GRFTISRDDSKNTLYLQMNSLKKEDTAVYYCTDDGYHWGQGTLVTVSS  538 BCMA-54 BC E11 19-B2-F8 VL aa AIQMTQSPSSLSASVGDRVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGS GTDFTLTISSLQPEDEAIYYCEDTSKYPYTFGQGTKLEIK  539 BCMA-54 BC E11 19-B2-F8 scFv aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWIAQITAKSNNYATYYAAPVK GRFTISRDDSKNTLYLQMNSLKKEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM TQSPSSLSASVGDRVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGSGTDF TLTISSLQPEDEAIYYCEDTSKYPYTFGQGTKLEIK  540 BCMA-54 HL x BC E11 19-B2-F8 HL x bispecific molecule aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWIAQITAKSNNYATYYAAPVK CD3 HL CD3 HL GRFTISRDDSKNTLYLQMNSLKKEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM TQSPSSLSASVGDRVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGSGTDF TLTISSLQPEDEAIYYCEDTSKYPYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAAS GFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTED TAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVT LTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCVLWYSNRWVFGGGTKLTVL  541 BCMA-55 BC E11-20-H9-E9 VH CDR1 aa NAWMD  542 BCMA-55 BC E11-20-H9-E9 VH CDR2 aa QITAKSNNYATYYAAPVKG  543 BCMA-55 BC E11-20-H9-E9 VH CDR3 aa DGYH  544 BCMA-55 BC E11-20-H9-E9 VL CDR1 aa RASEDIRNGLA  545 BCMA-55 BC E11-20-H9-E9 VL CDR2 aa NANSLHT  546 BCMA-55 BC E11-20-H9-E9 VL CDR3 aa EETLKYPYT  547 BCMA-55 BC E11-20-H9-E9 VH aa EVQLVESGGSLVKPGGSLRLSCAASGFTFSNAWMDWVRQAPGKRLEWVAQITAKSNNYATYYAAPVK GRFTISRDDSKNTLYLQMNSLKEEDTAVYYCTDDGYHWGQGTLVTVSS  548 BCMA-55 BC E11-20-H9-E9 VL aa AIQMTQSPSSLSASVGDRVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGS GTDFTLTISNLQPEDEATYYCEETLKYPYTFGQGTKLEIK  549 BCMA-55 BC E11-20-H9-E9 scFv aa EVQLVESGGSLVKPGGSLRLSCAASGFTFSNAWMDWVRQAPGKRLEWVAQITAKSNNYATYYAAPVK GRFTISRDDSKNTLYLQMNSLKEEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM TQSPSSLSASVGDRVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGSGTDF TLTISNLQPEDEATYYCEETLKYPYTFGQGTKLEIK  550 BCMA-55 HL x BC E11-20-H9-E9 HL x bispecific molecule aa EVQLVESGGSLVKPGGSLRLSCAASGFTFSNAWMDWVRQAPGKRLEWVAQITAKSNNYATYYAAPVK CD3 HL CD3 HL GRFTISRDDSKNTLYLQMNSLKEEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM TQSPSSLSASVGDRVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGSGTDF TLTISNLQPEDEATYYCEETLKYPYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAAS GFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTED TAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVT LTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCVLWYSNRWVFGGGTKLTVL  551 BCMA-56 BC E11-19-F11-E9 VH CDR1 aa NAWMD  552 BCMA-56 BC E11-19-F11-E9 VH CDR2 aa QITAKSNNYATYYAEPVKG  553 BCMA-56 BC E11-19-F11-E9 VH CDR3 aa DGYH  554 BCMA-56 BC E11-19-F11-E9 VL CDR1 aa RASEDIRNGLA  555 BCMA-56 BC E11-19-F11-E9 VL CDR2 aa NANSLHT  556 BCMA-56 BC E11-19-F11-E9 VL CDR3 aa EETLKYPYT  557 BCMA-56 BC E11-19-F11-E9 VH aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWVAQITAKSNNYATYYAEPVK GRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTDDGYHWGQGTLVTVSS  558 BCMA-56 BC E11-19-F11-E9 VL aa AIQMTQSPSSLSASVGETVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGS GTEFTLKISSLQPEDEATYYCEETLKYPYTFGQGTKLEIK  559 BCMA-56 BC E11-19-F11-E9 scFv aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWVAQITAKSNNYATYYAEPVK GRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM TQSPSSLSASVGETVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGSGTEF TLKISSLQPEDEATYYCEETLKYPYTFGQGTKLEIK  560 BCMA-56 HL x BC E11-19-F11-E9 HL x bispecific molecule aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWVAQITAKSNNYATYYAEPVK CD3 HL CD3 HL GRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM TQSPSSLSASVGETVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGSGTEF TLKISSLQPEDEATYYCEETLKYPYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAAS GFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTED TAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVT LTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCVLWYSNRWVFGGGTKLTVL  561 BCMA-57 BC E11-19-B2-E9 VH CDR1 aa NAWMD  562 BCMA-57 BC E11-19-B2-E9 VH CDR2 aa QITAKSNNYATYYAAPVKG  563 BCMA-57 BC E11-19-B2-E9 VH CDR3 aa DGYH  564 BCMA-57 BC E11-19-B2-E9 VL CDR1 aa RASEDIRNGLA  565 BCMA-57 BC E11-19-B2-E9 VL CDR2 aa NANSLHT  566 BCMA-57 BC E11-19-B2-E9 VL CDR3 aa EETLKYPYT  567 BCMA-57 BC E11-19-B2-E9 VH aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWIAQITAKSNNYATYYAAPVK GRFTISRDDSKNTLYLQMNSLKKEDTAVYYCTDDGYHWGQGTLVTVSS  568 BCMA-57 BC E11-19-B2-E9 VL aa AIQMTQSPSSLSASVGDRVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGS GTDFTLTISSLQPEDEAIYYCEETLKYPYTFGQGTKLEIK  569 BCMA-57 BC E11-19-B2-E9 scFv aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWIAQITAKSNNYATYYAAPVK GRFTISRDDSKNTLYLQMNSLKKEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM TQSPSSLSASVGDRVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGSGTDF TLTISSLQPEDEAIYYCEETLKYPYTFGQGTKLEIK  570 BCMA-57 HL x BC E11-19-B2-E9 HL x bispecific molecule aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWIAQITAKSNNYATYYAAPVK CD3 HL CD3 HL GRFTISRDDSKNTLYLQMNSLKKEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM TQSPSSLSASVGDRVTIACRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHTGVPSRFSGSGSGTDF TLTISSLQPEDEAIYYCEETLKYPYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAAS GFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTED TAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVT LTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCVLWYSNRWVFGGGTKLTVL  571 BCMA-58 BC E11-19-G3-E9 VH CDR1 aa NAWMD  572 BCMA-58 BC E11-19-G3-E9 VH CDR2 aa QITAKSNNYATYYAAPVKG  573 BCMA-58 BC E11-19-G3-E9 VH CDR3 aa DGYH  574 BCMA-58 BC E11-19-G3-E9 VL CDR1 aa RASEDIRNGLA  575 BCMA-58 BC E11-19-G3-E9 VL CDR2 aa NANSLHS  576 BCMA-58 BC E11-19-G3-E9 VL CDR3 aa EETLKYPYT  577 BCMA-58 BC E11-19-G3-E9 VH aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWIAQITAKSNNYATYYAAPVK GRFTISRDDSKNTLYLQMNSLKKEDTAVYYCTDDGYHWGQGTLVTVSS  578 BCMA-58 BC E11-19-G3-E9 VL aa AIQMTQSPSSLSASVGDRVTIKCRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHSGVPSRFSGSGS GTDFTLTISSMQPEDEGTYYCEETLKYPYTFGQGTKLEIK  579 BCMA-58 BC E11-19-G3-E9 scFv aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWIAQITAKSNNYATYYAAPVK GRFTISRDDSKNTLYLQMNSLKKEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM TQSPSSLSASVGDRVTIKCRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHSGVPSRFSGSGSGTDF TLTISSMQPEDEGTYYCEETLKYPYTFGQGTKLEIK  580 BCMA-58 HL x BC E11-19-G3-E9 HL x bispecific molecule aa EVQLVESGGGLVKPGESLRLSCAASGFTFSNAWMDWVRQAPGKRLEWIAQITAKSNNYATYYAAPVK CD3 HL CD3 HL GRFTISRDDSKNTLYLQMNSLKKEDTAVYYCTDDGYHWGQGTLVTVSSGGGGSGGGGSGGGGSAIQM TQSPSSLSASVGDRVTIKCRASEDIRNGLAWYQQKPGKAPKLLIYNANSLHSGVPSRFSGSGSGTDF TLTISSMQPEDEGTYYCEETLKYPYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAAS GFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTED TAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVT LTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCVLWYSNRWVFGGGTKLTVL  581 BCMA-59 BC 5G9-91-D2 VH CDR1 aa NYDMA  582 BCMA-59 BC 5G9-91-D2 VH CDR2 aa SIITSGGDNYYRDSVKG  583 BCMA-59 BC 5G9-91-D2 VH CDR3 aa HDYYDGSYGFAY  584 BCMA-59 BC 5G9-91-D2 VL CDR1 aa KASQSVGINVD  585 BCMA-59 BC 5G9-91-D2 VL CDR2 aa GASNRHT  586 BCMA-59 BC 5G9-91-D2 VL CDR3 aa LQYGSIPFT  587 BCMA-59 BC 5G9-91-D2 VH aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGGDNYYRDSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSS  588 BCMA-59 BC 5G9-91-D2 VL aa EIVMTQSPASMSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGSGS GTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK  589 BCMA-59 BC 5G9-91-D2 scFv aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGGDNYYRDSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPASMSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK  590 BCMA-59 HL x BC 5G9- bispecific molecule aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGGDNYYRDSVKGR CD3 HL 91-D2 HL x CD3 HL FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPASMSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  591 BCMA-60 BC 5G9-91-C7 VH CDR1 aa NYDMA  592 BCMA-60 BC 5G9-91-C7 VH CDR2 aa SIITSGGDNYYRDSVKG  593 BCMA-60 BC 5G9-91-C7 VH CDR3 aa HDYYDGSYGFAY  594 BCMA-60 BC 5G9-91-C7 VL CDR1 aa KASQSVGINVD  595 BCMA-60 BC 5G9-91-C7 VL CDR2 aa GASNRHT  596 BCMA-60 BC 5G9-91-C7 VL CDR3 aa LQYGSIPFT  597 BCMA-60 BC 5G9-91-C7 VH aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGGDNYYRDSVKGR FTISRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSS  598 BCMA-60 BC 5G9-91-C7 VL aa EIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGSGS GREFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK  599 BCMA-60 BC 5G9-91-C7 scFv aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGGDNYYRDSVKGR FTISRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGREFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK  600 BCMA-60 HL x BC 5G9- bispecific molecule aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGGDNYYRDSVKGR CD3 HL 91-C7 HL x CD3 HL FTISRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGREFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  601 BCMA-61 BC 5G9-91-E4 VH CDR1 aa NYDMA  602 BCMA-61 BC 5G9-91-E4 VH CDR2 aa SIITSGGDNYYRDSVKG  603 BCMA-61 BC 5G9-91-E4 VH CDR3 aa HDYYDGSYGFAY  604 BCMA-61 BC 5G9-91-E4 VL CDR1 aa KASQSVGINVD  605 BCMA-61 BC 5G9-91-E4 VL CDR2 aa GASNRHT  606 BCMA-61 BC 5G9-91-E4 VL CDR3 aa LQYGSIPFT  607 BCMA-61 BC 5G9-91-E4 VH aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGGDNYYRDSVKGR FTISRDNSKNTLYLQMNSLRSEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSS  608 BCMA-61 BC 5G9-91-E4 VL aa EIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGSGS GTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK  609 BCMA-61 BC 5G9-91-E4 scFv aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGGDNYYRDSVKGR FTISRDNSKNTLYLQMNSLRSEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIK  610 BCMA-61 HL x BC 5G9-91-E4 HL x bispecific molecule aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGGDNYYRDSVKGR CD3 HL CD3 HL FTISRDNSKNTLYLQMNSLRSEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERVTLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCLQYGSIPFTFGPGTKVDIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  611 BCMA-62 BC 5G9-92-E10 VH CDR1 aa NYDMA  612 BCMA-62 BC 5G9-92-E10 VH CDR2 aa SIITSGGDNYYRDSVKG  613 BCMA-62 BC 5G9-92-E10 VH CDR3 aa HDYYDGSYGFAY  614 BCMA-62 BC 5G9-92-E10 VL CDR1 aa KASQSVGINVD  615 BCMA-62 BC 5G9-92-E10 VL CDR2 aa GASNRHT  616 BCMA-62 BC 5G9-92-E10 VL CDR3 aa LQYGSIPFT  617 BCMA-62 BC 5G9-92-E10 VH aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGGDNYYRDSVKGR FTVSRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSS  618 BCMA-62 BC 5G9-92-E10 VL aa EIVMTQSPATLSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGSGS GTEFTLTISSLQAEDFAVYYCLQYGSIPFTFGPGTKVDIK  619 BCMA-62 BC 5G9-92-E10 scFv aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGGDNYYRDSVKGR FTVSRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQAEDFAVYYCLQYGSIPFTFGPGTKVDIK  620 BCMA-62 HL x BC 5G9- bispecific molecule aa QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVASIITSGGDNYYRDSVKGR CD3 HL 92-E10 HL x CD3 HL FTVSRDNSKNTLYLQMNSLRAEDTAVYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSEIVMTQSPATLSVSPGERATLSCKASQSVGINVDWYQQKPGQAPRLLIYGASNRHTGIPARFSGS GSGTEFTLTISSLQAEDFAVYYCLQYGSIPFTFGPGTKVDIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  621 BCMA-63 BC 3A4-37-C8 VH CDR1 aa NYDMA  622 BCMA-63 BC 3A4-37-C8 VH CDR2 aa SISTRGDITSYRDSVKG  623 BCMA-63 BC 3A4-37-C8 VH CDR3 aa QDYYTDYMGFAY  624 BCMA-63 BC 3A4-37-C8 VL CDR1 aa RASEDIYNGLA  625 BCMA-63 BC 3A4-37-C8 VL CDR2 aa GASSLQD  626 BCMA-63 BC 3A4-37-C8 VL CDR3 aa QQSYKYPLT  627 BCMA-63 BC 3A4-37-C8 VH aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSS  628 BCMA-63 BC 3A4-37-C8 VL aa AIQMTQSPSSLSASVGDTVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGSGS GTDYTLTISSLQPEDEATYYCQQSYKYPLTFGGGTKVEIK  629 BCMA-63 BC 3A4-37-C8 scFv aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDTVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTDYTLTISSLQPEDEATYYCQQSYKYPLTFGGGTKVEIK  630 BCMA-63 HL x BC 3A4-37-C8 HL x bispecific molecule aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR CD3 HL CD3 HL FTISRDNAKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDTVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTDYTLTISSLQPEDEATYYCQQSYKYPLTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  631 BCMA-64 BC 3A4-37-C9 VH CDR1 aa NYDMA  632 BCMA-64 BC 3A4-37-C9 VH CDR2 aa SISTRGDITSYRDSVKG  633 BCMA-64 BC 3A4-37-C9 VH CDR3 aa QDYYTDYMGFAY  634 BCMA-64 BC 3A4-37-C9 VL CDR1 aa RASEDIYNGLA  635 BCMA-64 BC 3A4-37-C9 VL CDR2 aa GASSLQD  636 BCMA-64 BC 3A4-37-C9 VL CDR3 aa QQSYKYPLT  637 BCMA-64 BC 3A4-37-C9 VH aa EVQLLESGGGLVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSS  638 BCMA-64 BC 3A4-37-C9 VL aa AIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGSGS GTDFTLTISSMQPEDEATYYCQQSYKYPLTFGGGTKVEIK  639 BCMA-64 BC 3A4-37-C9 scFv aa EVQLLESGGGLVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTDFTLTISSMQPEDEATYYCQQSYKYPLTFGGGTKVEIK  640 BCMA-64 HL x BC 3A4-37-C9 HL x bispecific molecule aa EVQLLESGGGLVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR CD3 HL CD3 HL FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTDFTLTISSMQPEDEATYYCQQSYKYPLTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  641 BCMA-65 BC 3A4-37-E11 VH CDR1 aa NYDMA  642 BCMA-65 BC 3A4-37-E11 VH CDR2 aa SISTRGDITSYRDSVKG  643 BCMA-65 BC 3A4-37-E11 VH CDR3 aa QDYYTDYMGFAY  644 BCMA-65 BC 3A4-37-E11 VL CDR1 aa RASEDIYNGLA  645 BCMA-65 BC 3A4-37-E11 VL CDR2 aa GASSLQD  646 BCMA-65 BC 3A4-37-E11 VL CDR3 aa QQSYKYPLT  647 BCMA-65 BC 3A4-37-E11 VH aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSS  648 BCMA-65 BC 3A4-37-E11 VL aa AIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGSGS GTHYTLTISSLQPEDEATYYCQQSYKYPLTFGGGTKVEIK  649 BCMA-65 BC 3A4-37-E11 scFv aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTHYTLTISSLQPEDEATYYCQQSYKYPLTFGGGTKVEIK  650 BCMA-65  HL x BC 3A4-37-E11 HL x bispecific molecule aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR CD3 HL CD3 HL FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTHYTLTISSLQPEDEATYYCQQSYKYPLTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  651 BCMA-66 BC 3A4-37-C8-G1 VH CDR1 aa NYDMA  652 BCMA-66 BC 3A4-37-C8-G1 VH CDR2 aa SISTRGDITSYRDSVKG  653 BCMA-66 BC 3A4-37-C8-G1 VH CDR3 aa QDYYTDYMGFAY  654 BCMA-66 BC 3A4-37-C8-G1 VL CDR1 aa RASEDIYNGLA  655 BCMA-66 BC 3A4-37-C8-G1 VL CDR2 aa GASSLQD  656 BCMA-66 BC 3A4-37-C8-G1 VL CDR3 aa AGPHKYPLT  657 BCMA-66 BC 3A4-37-C8-G1 VH aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSS  658 BCMA-66 BC 3A4-37-C8-G1 VL aa AIQMTQSPSSLSASVGDTVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGSGS GTDYTLTISSLQPEDEATYYCAGPHKYPLTFGGGTKVEIK  659 BCMA-66 BC 3A4-37-C8-G1 scFv aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDTVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTDYTLTISSLQPEDEATYYCAGPHKYPLTFGGGTKVEIK  660 BCMA-66 HL x BC 3A4-37-C8-G1 HL x bispecific molecule aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR CD3 HL CD3 HL FTISRDNAKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDTVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTDYTLTISSLQPEDEATYYCAGPHKYPLTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  661 BCMA-67 BC 3A4-37-E11-G1 VH CDR1 aa NYDMA  662 BCMA-67 BC 3A4-37-E11-G1 VH CDR2 aa SISTRGDITSYRDSVKG  663 BCMA-67 BC 3A4-37-E11-G1 VH CDR3 aa QDYYTDYMGFAY  664 BCMA-67 BC 3A4-37-E11-G1 VL CDR1 aa RASEDIYNGLA  665 BCMA-67 BC 3A4-37-E11-G1 VL CDR2 aa GASSLQD  666 BCMA-67 BC 3A4-37-E11-G1 VL CDR3 aa AGPHKYPLT  667 BCMA-67 BC 3A4-37-E11-G1 VH aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSS  668 BCMA-67 BC 3A4-37-E11-G1 VL aa AIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGSGS GTHYTLTISSLQPEDEATYYCAGPHKYPLTFGGGTKVEIK  669 BCMA-67 BC 3A4-37-E11-G1 scFv aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTHYTLTISSLQPEDEATYYCAGPHKYPLTFGGGTKVEIK  670 BCMA-67 HL x BC 3A4-37- bispecific molecule aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR CD3 HL E11-G1 HL x CD3 HL FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTHYTLTISSLQPEDEATYYCAGPHKYPLTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  671 BCMA-68 BC 3A4-37-C8-G8 VH CDR1 aa NYDMA  672 BCMA-68 BC 3A4-37-C8-G8 VH CDR2 aa SISTRGDITSYRDSVKG  673 BCMA-68 BC 3A4-37-C8-G8 VH CDR3 aa QDYYTDYMGFAY  674 BCMA-68 BC 3A4-37-C8-G8 VL CDR1 aa RASEDIYNGLA  675 BCMA-68 BC 3A4-37-C8-G8 VL CDR2 aa GASSLQD  676 BCMA-68 BC 3A4-37-C8-G8 VL CDR3 aa QQSRNYQQT  677 BCMA-68 BC 3A4-37-C8-G8 VH aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSS  678 BCMA-68 BC 3A4-37-C8-G8 VL aa AIQMTQSPSSLSASVGDTVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGSGS GTDYTLTISSLQPEDEATYYCQQSRNYQQTFGGGTKVEIK  679 BCMA-68 BC 3A4-37-C8-G8 scFv aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDTVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTDYTLTISSLQPEDEATYYCQQSRNYQQTFGGGTKVEIK  680 BCMA-68 HL x BC 3A4-37-C8-G8 HL x bispecific molecule aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR CD3 HL CD3 HL FTISRDNAKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDTVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTDYTLTISSLQPEDEATYYCQQSRNYQQTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  681 BCMA-69 BC 3A4-37-E11-G8 VH CDR1 aa NYDMA  682 BCMA-69 BC 3A4-37-E11-G8 VH CDR2 aa SISTRGDITSYRDSVKG  683 BCMA-69 BC 3A4-37-E11-G8 VH CDR3 aa QDYYTDYMGFAY  684 BCMA-69 BC 3A4-37-E11-G8 VL CDR1 aa RASEDIYNGLA  685 BCMA-69 BC 3A4-37-E11-G8 VL CDR2 aa GASSLQD  686 BCMA-69 BC 3A4-37-E11-G8 VL CDR3 aa QQSRNYQQT  687 BCMA-69 BC 3A4-37-E11-G8 VH aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR ISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSS  688 BCMA-69 BC 3A4-37-E11-G8 VL aa AIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGSGS GTHYTLTISSLQPEDEATYYCQQSRNYQQTFGGGTKVEIK  689 BCMA-69 BC 3A4-37-E11-G8 scFv aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTHYTLTISSLQPEDEATYYCQQSRNYQQTFGGGTKVEIK  690 BCMA-69 HL x BC 3A4-37- bispecific molecule aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR CD3 HL E11-G8 HL x CD3 HL FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTHYTLTISSLQPEDEATYYCQQSRNYQQTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  691 BCMA-70 BC 3A4-37-A11-G8 VH CDR1 aa NYDMA  692 BCMA-70 BC 3A4-37-A11-G8 VH CDR2 aa SISTRGDITSYRDSVKG  693 BCMA-70 BC 3A4-37-A11-G8 VH CDR3 aa QDYYTDYMGFAY  694 BCMA-70 BC 3A4-37-A11-G8 VL CDR1 aa RASEDIYNGLA  695 BCMA-70 BC 3A4-37-A11-G8 VL CDR2 aa GASSLQD  696 BCMA-70 BC 3A4-37-A11-G8 VL CDR3 aa QQSRNYQQT  697 BCMA-70 BC 3A4-37-A11-G8 VH aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSKVKR FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSS  698 BCMA-70 BC 3A4-37-A11-G8 VL aa AIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGSGS GTEFTLTISSLQPEDEATYYCQQSRNYQQTFGGGTKVEIK  699 BCMA-70 BC 3A4-37-A11-G8 scFv aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTEFTLTISSLQPEDEATYYCQQSRNYQQTFGGGTKVEIK  700 BCMA-70 HL x BC 3A4-37- bispecific molecule aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR CD3 HL A11-G8 HL x CD3 HL FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTEFTLTISSLQPEDEATYYCQQSRNYQQTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  701 BCMA-71 BC 3A4-37-A11-G1 VH CDR1 aa NYDMA  702 BCMA-71 BC 3A4-37-A11-G1 VH CDR2 aa SISTRGDITSYRDSVKG  703 BCMA-71 BC 3A4-37-A11-G1 VH CDR3 aa QDYYTDYMGFAY  704 BCMA-71 BC 3A4-37-A11-G1 VL CDR1 aa RASEDIYNGLA  705 BCMA-71 BC 3A4-37-A11-G1 VL CDR2 aa GASSLQD  706 BCMA-71 BC 3A4-37-A11-G1 VL CDR3 aa AGPHKYPLT  707 BCMA-71 BC 3A4-37-A11-G1 VH aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSS  708 BCMA-71 BC 3A4-37-A11-G1 VL aa AIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGSGS GTEFTLTISSLQPEDEATYYCAGPHKYPLTFGGGTKVEIK  709 BCMA-71 BC 3A4-37-A11-G1 scFv aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTEFTLTISSLQPEDEATYYCAGPHKYPLTFGGGTKVEIK  710 BCMA-71 HL x BC 3A4-37- bispecific molecule aa EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR CD3 HL A11-G1 HL x CD3 HL FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTEFTLTISSLQPEDEATYYCAGPHKYPLTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  711 BCMA-72 BC 3A4-37-C9-G1 VH CDR1 aa NYDMA  712 BCMA-72 BC 3A4-37-C9-G1 VH CDR2 aa SISTRGDITSYRDSVKG  713 BCMA-72 BC 3A4-37-C9-G1 VH CDR3 aa QDYYTDYMGFAY  714 BCMA-72 BC 3A4-37-C9-G1 VL CDR1 aa RASEDIYNGLA  715 BCMA-72 BC 3A4-37-C9-G1 VL CDR2 aa GASSLQD  716 BCMA-72 BC 3A4-37-C9-G1 VL CDR3 aa AGPHKYPLT  717 BCMA-72 BC 3A4-37-C9-G1 VH aa EVQLLESGGGLVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSS  718 BCMA-72 BC 3A4-37-C9-G1 VL aa AIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGSGS GTDFTLTISSMQPEDEATYYCAGPHKYPLTFGGGTKVEIK  719 BCMA-72 BC 3A4-37-C9-G1 scFv aa EVQLLESGGGLVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTDFTLTISSMQPEDEATYYCAGPHKYPLTFGGGTKVEIK  720 BCMA-72 HL x BC 3A4-37-C9-G1 HL x bispecific molecule aa EVQLLESGGGLVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR CD3 HL CD3 HL FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTDFTLTISSMQPEDEATYYCAGPHKYPLTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  721 BCMA-73 BC 3A4-37-C9-G8 VH CDR1 aa NYDMA  722 BCMA-73 BC 3A4-37-C9-G8 VH CDR2 aa SISTRGDITSYRDSVKG  723 BCMA-73 BC 3A4-37-C9-G8 VH CDR3 aa QDYYTDYMGFAY  724 BCMA-73 BC 3A4-37-C9-G8 VL CDR1 aa RASEDIYNGLA  725 BCMA-73 BC 3A4-37-C9-G8 VL CDR2 aa GASSLQD  726 BCMA-73 BC 3A4-37-C9-G8 VL CDR3 aa QQSRNYQQT  727 BCMA-73 BC 3A4-37-C9-G8 VH aa EVQLLESGGGLVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSS  728 BCMA-73 BC 3A4-37-C9-G8 VL aa AIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGSGS GTDFTLTISSMQPEDEATYYCQQSRNYQQTFGGGTKVEIK  729 BCMA-73 BC 3A4-37-C9-G8 scFv aa EVQLLESGGGLVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTDFTLTISSMQPEDEATYYCQQSRNYQQTFGGGTKVEIK  730 BCMA-73 HL x BC 3A4-37-C9-G8 HL x bispecific molecule aa EVQLLESGGGLVQPGRSLRLSCAASGFTFSNYDMAWVRQAPGKGLEWVSSISTRGDITSYRDSVKGR CD3 HL CD3 HL FTISRDNSKNTLYLQMNSLRAEDTAVYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGGG GSAIQMTQSPSSLSASVGDRVTITCRASEDIYNGLAWYQQKPGKAPKLLIYGASSLQDGVPSRFSGS GSGTDFTLTISSMQPEDEATYYCQQSRNYQQTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  731 BCMA-74 BC C3-33-D7-B1 VH CDR1 aa NFDMA  732 BCMA-74 BC C3-33-D7-B1 VH CDR2 aa SITTGGGDTYYADSVKG  733 BCMA-74 BC C3-33-D7-B1 VH CDR3 aa HGYYDGYHLFDY  734 BCMA-74 BC C3-33-D7-B1 VL CDR1 aa RASQGISNYLN  735 BCMA-74 BC C3-33-D7-B1 VL CDR2 aa YTSNLQS  736 BCMA-74 BC C3-33-D7-B1 VL CDR3 aa MGQTISSYT  737 BCMA-74 BC C3-33-D7-B1 VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS  738 BCMA-74 BC C3-33-D7-B1 VL aa DIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS GTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK  739 BCMA-74 BC C3-33-D7-B1 scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK  740 BCMA-74 HL x BC C3-33-D7-B1 HL x bispecific molecule aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR CD3 HL CD3 HL FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  741 BCMA-75 BC C3-33-F8-B1 VH CDR1 aa NFDMA  742 BCMA-75 BC C3-33-F8-B1 VH CDR2 aa SITTGGGDTYYADSVKG  743 BCMA-75 BC C3-33-F8-B1 VH CDR3 aa HGYYDGYHLFDY  744 BCMA-75 BC C3-33-F8-B1 VL CDR1 aa RASQGISNYLN  745 BCMA-75 BC C3-33-F8-B1 VL CDR2 aa YTSNLQS  746 BCMA-75 BC C3-33-F8-B1 VL CDR3 aa MGQTISSYT  747 BCMA-75 BC C3-33-F8-B1 VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS  748 BCMA-75 BC C3-33-F8-B1 VL aa DIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS GTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK  749 BCMA-75 BC C3-33-F8-B1 scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK  750 BCMA-75 HL x BC C3-33-F8-B1 HL x bispecific molecule aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR CD3 HL CD3 HL FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  751 BCMA-76 BC C3-33-F9-B1 VH CDR1 aa NFDMA  752 BCMA-76 BC C3-33-F9-B1 VH CDR2 aa SITTGGGDTYYADSVKG  753 BCMA-76 BC C3-33-F9-B1 VH CDR3 aa HGYYDGYHLFDY  754 BCMA-76 BC C3-33-F9-B1 VL CDR1 aa RASQGISNYLN  755 BCMA-76 BC C3-33-F9-B1 VL CDR2 aa YTSNLQS  756 BCMA-76 BC C3-33-F9-B1 VL CDR3 aa MGQTISSYT  757 BCMA-76 BC C3-33-F9-B1 VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS  758 BCMA-76 BC C3-33-F9-B1 VL aa DIQMTQSPSSLSASVGDRVTISCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS GTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK  759 BCMA-76 BC C3-33-F9-B1 scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK  760 BCMA-76 HL x BC C3-33-F9-B1 HL x bispecific molecule aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR CD3 HL CD3 HL FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  761 BCMA-77 BC C3-33-F10B1 VH CDR1 aa NFDMA  762 BCMA-77 BC C3-33-F10B1 VH CDR2 aa SITTGGGDTYYADSVKG  763 BCMA-77 BC C3-33-F10B1 VH CDR3 aa HGYYDGYHLFDY  764 BCMA-77 BC C3-33-F10B1 VL CDR1 aa RASQGISNYLN  765 BCMA-77 BC C3-33-F10B1 VL CDR2 aa YTSNLQS  766 BCMA-77 BC C3-33-F10B1 VL CDR3 aa MGQTISSYT  767 BCMA-77 BC C3-33-F10B1 VH aa EVQLVESGGGLVQPGRSLRLSCAASGFTFSNFDMAWVRQAPAKGLEWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS  768 BCMA-77 BC C3-33-F10B1 VL aa DIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS GTDFTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK  769 BCMA-77 BC C3-33-F10B1 scFv aa EVQLVESGGGLVQPGRSLRLSCAASGFTFSNFDMAWVRQAPAKGLEWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIK  770 BCMA-77 HL x BC C3-33-F10B1 HL x bispecific molecule aa EVQLVESGGGLVQPGRSLRLSCAASGFTFSNFDMAWVRQAPAKGLEWVSSITTGGGDTYYADSVKGR CD3 HL CD3 HL FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCMGQTISSYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  771 BCMA-78 BC E5-33-A11-A10 VH CDR1 aa NFDMA  772 BCMA-78 BC E5-33-A11-A10 VH CDR2 aa SITTGGGDTYYADSVKG  773 BCMA-78 BC E5-33-A11-A10 VH CDR3 aa HGYYDGYHLFDY  774 BCMA-78 BC E5-33-A11-A10 VL CDR1 aa RASQGISNHLN  775 BCMA-78 BC E5-33-A11-A10 VL CDR2 aa YTSNLQS  776 BCMA-78 BC E5-33-A11-A10 VL CDR3 aa QQYFDRPYT  777 BCMA-78 BC E5-33-A11-A10 VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGLVTVSS  778 BCMA-78 BC E5-33-A11-A10 VL aa DIQMTQSPSSLSASVGDRVTISCRASQGISNHLNWFQQKPGRAPKPLIYYTSNLQSGVPSRFSGSGS GTDFTLTISSLQPEDFATYYCQQYFDRPYTFGGGTKVEIK  779 BCMA-78 BC E5-33-A11-A10 scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQGISNHLNWFQQKPGRAPKPLIYYTSNLQSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQYFDRPYTFGGGTKVEIK  780 BCMA-78 HL x BC E5-33-A11-A10 HL x bispecific molecule aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR CD3 HL CD3 HL FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQGISNHLNWFQQKPGRAPKPLIYYTSNLQSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQYFDRPYTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  781 BCMA-79 BC E5-33-B11-A10 VH CDR1 aa NFDMA  782 BCMA-79 BC E5-33-B11-A10 VH CDR2 aa SITTGGGDTYYADSVKG  783 BCMA-79 BC E5-33-B11-A10 VH CDR3 aa HGYYDGYHLFDY  784 BCMA-79 BC E5-33-B11-A10 VL CDR1 aa RASQGISNHLN  785 BCMA-79 BC E5-33-B11-A10 VL CDR2 aa YTSNLQS  786 BCMA-79 BC E5-33-B11-A10 VL CDR3 aa QQYFDRPYT  787 BCMA-79 BC E5-33-B11-A10 VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS  788 BCMA-79 BC E5-33-B11-A10 VL aa DIQMTQSPSSLSASVGDRVTISCRASQGISNHLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS GTDYTLTISSLQPEDFATYYCQQYFDRPYTFGGGTKVEIK  789 BCMA-79 BC E5-33-B11-A10 scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQGISNHLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQYFDRPYTFGGGTKVEIK  790 BCMA-79 HL x BC E5-33-B11-A10 bispecific molecule aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR CD3 HL HL x CD3 HL FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQGISNHLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQYFDRPYTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  791 BCMA-80 BC E5-33-G11-A10 VH CDR1 aa NFDMA  792 BCMA-80 BC E5-33-G11-A10 VH CDR2 aa SITTGGGDTYYADSVKG  793 BCMA-80 BC E5-33-G11-A10 VH CDR3 aa HGYYDGYHLFDY  794 BCMA-80 BC E5-33-G11-A10 VL CDR1 aa RASQGISNHLN  795 BCMA-80 BC E5-33-G11-A10 VL CDR2 aa YTSNLQS  796 BCMA-80 BC E5-33-G11-A10 VL CDR3 aa QQYFDRPYT  797 BCMA-80 BC E5-33-G11-A10 VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS  798 BCMA-80 BC E5-33-G11-A10 VL aa DIQMTQSPSSLSASVGDRVTITCRASQGISNHLNWFQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS GTDFTLTISSLQPEDFATYYCQQYFDRPYTFGGGTKVEIK  799 BCMA-80 BC E5-33-G11-A10 scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQGISNHLNWFQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQYFDRPYTFGGGTKVEIK  800 BCMA-80 HL x BC E5-33- bispecific molecule aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR CD3 HL G11-A10 FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG HL x CD3 GSDIQMTQSPSSLSASVGDRVTITCRASQGISNHLNWFQQKPGKAPKPLIYYTSNLQSGVPSRFSGS HL GSGTDFTLTISSLQPEDFATYYCQQYFDRPYTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  801 BCMA-81 BC E5-33-G12-A10 VH CDR1 aa NFDMA  802 BCMA-81 BC E5-33-G12-A10 VH CDR2 aa SITTGGGDTYYADSVKG  803 BCMA-81 BC E5-33-G12-A10 VH CDR3 aa HGYYDGYHLFDY  804 BCMA-81 BC E5-33-G12-A10 VL CDR1 aa RASQGISNHLN  805 BCMA-81 BC E5-33-G12-A10 VL CDR2 aa YTSNLQS  806 BCMA-81 BC E5-33-G12-A10 VL CDR3 aa QQYFDRPYT  807 BCMA-81 BC E5-33-G12-A10 VH aa EVQLVESGGGLVQPGRSLRLSCAASGFTFSNFDMAWVRQAPAKGLEWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS  808 BCMA-81 BC E5-33-G12-A10 VL aa DIQMTQSPSSLSASVGERVTITCRASQGISNHLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGSGS GTDFTLTISSLQPEDFATYYCQQYFDRPYTFGGGTKVEIKR  809 BCMA-81 BC E5-33-G12-A10 scFv aa EVQLVESGGGLVQPGRSLRLSCAASGFTFSNFDMAWVRQAPAKGLEWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGERVTITCRASQGISNHLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQYFDRPYTFGGGTKVEIK  810 BCMA-81 HL x BC E5-33-G12-A10 bispecific molecule aa EVQLVESGGGLVQPGRSLRLSCAASGFTFSNFDMAWVRQAPAKGLEWVSSITTGGGDTYYADSVKGR CD3 HL HL x CD3  HL FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGERVTITCRASQGISNHLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQYFDRPYTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  811 BCMA-82 BC E5-33-A11-B8 VH CDR1 aa NFDMA  812 BCMA-82 BC E5-33-A11-B8 VH CDR2 aa SITTGGGDTYYADSVKG  813 BCMA-82 BC E5-33-A11-B8 VH CDR3 aa HGYYDGYHLFDY  814 BCMA-82 BC E5-33-A11-B8 VL CDR1 aa RASQGISNHLN  815 BCMA-82 BC E5-33-A11-B8 VL CDR2 aa YTSNLQS  816 BCMA-82 BC E5-33-A11-B8 VL CDR3 aa QQYSNLPYT  817 BCMA-82 BC E5-33-A11-B8 VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS  818 BCMA-82 BC E5-33-A11-B8 VL aa DIQMTQSPSSLSASVGDRVTISCRASQGISNHLNWFQQKPGRAPKPLIYYTSNLQSGVPSRFSGSGS GTDFTLTISSLQPEDFATYYCQQYSNLPYTFGGGTKVEIK  819 BCMA-82 BC E5-33-A11-B8 scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQGISNHLNWFQQKPGRAPKPLIYYTSNLQSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQYSNLPYTFGGGTKVEIK  820 BCMA-82 HL x BC E5-33-A11-B8 bispecific molecule aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR CD3 HL HL x CD3 HL FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQGISNHLNWFQQKPGRAPKPLIYYTSNLQSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQYSNLPYTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  821 BCMA-83 B11-E5-33-B11-B8 VH CDR1 aa NFDMA  822 BCMA-83 B11-E5-33-B11-B8 VH CDR2 aa SITTGGGDTYYADSVKG  823 BCMA-83 B11-E5-33-B11-B8 VH CDR3 aa HGYYDGYHLFDY  824 BCMA-83 B11-E5-33-B11-B8 VL CDR1 aa RASQGISNHLN  825 BCMA-83 B11-E5-33-B11-B8 VL CDR2 aa YTSNLQS  826 BCMA-83 B11-E5-33-B11-B8 VL CDR3 aa QQYSNLPYT  827 BCMA-83 B11-E5-33-B11-B8 VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS  828 BCMA-83 B11-E5-33-B11-B8 VL aa DIQMTQSPSSLSASVGDRVTISCRASQGISNHLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS GTDYTLTISSLQPEDFATYYCQQYSNLPYTFGGGTKVEIK  829 BCMA-83 B11-E5-33-B11-B8 scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQGISNHLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQYSNLPYTFGGGTKVEIK  830 BCMA-83 HL x BC E5B11-B8-33- bispecific molecule aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR CD3 HL B11-B8 HL x CD3 HL FTISRDNAKNTLYLQMDSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQGISNHLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQYSNLPYTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  831 BCMA-84 BC E5-33-G12-B8 VH CDR1 aa NFDMA  832 BCMA-84 BC E5-33-G12-B8 VH CDR2 aa SITTGGGDTYYADSVKG  833 BCMA-84 BC E5-33-G12-B8 VH CDR3 aa HGYYDGYHLFDY  834 BCMA-84 BC E5-33-G12-B8 VL CDR1 aa RASQGISNHLN  835 BCMA-84 BC E5-33-G12-B8 VL CDR2 aa YTSNLQS  836 BCMA-84 BC E5-33-G12-B8 VL CDR3 aa QQYSNLPYT  837 BCMA-84 BC E5-33-G12-B8 VH aa EVQLVESGGGLVQPGRSLRLSCAASGFTFSNFDMAWVRQAPAKGLEWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS  838 BCMA-84 BC E5-33-G12-B8 VL aa DIQMTQSPSSLSASVGERVTITCRASQGISNHLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGSGS GTDFTLTISSLQPEDFATYYCQQYSNLPYTFGGGTKVEIK  839 BCMA-84 BC E5-33-G12-B8 scFv aa EVQLVESGGGLVQPGRSLRLSCAASGFTFSNFDMAWVRQAPAKGLEWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGERVTITCRASQGISNHLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQYSNLPYTFGGGTKVEIK  840 BCMA-84 HL x BC E5-33- bispecific molecule aa EVQLVESGGGLVQPGRSLRLSCAASGFTFSNFDMAWVRQAPAKGLEWVSSITTGGGDTYYADSVKGR CD3 HL G12-B8 HL x CD3 HL FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGERVTITCRASQGISNHLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQYSNLPYTFGGGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  841 BCMA-85 BC C6-97-G5 VH CDR1 aa NFGMN  842 BCMA-85 BC C6-97-G5 VH CDR2 aa WINTYTGESIYADDFKG  843 BCMA-85 BC C6-97-G5 VH CDR3 aa GGVYGGYDAMDY  844 BCMA-85 BC C6-97-G5 VL CDR1 aa RASQDISNYLN  845 BCMA-85 BC C6-97-G5 VL CDR2 aa YTSRLHS  846 BCMA-85 BC C6-97-G5 VL CDR3 aa QQGNTLPWT  847 BCMA-85 BC C6-97-G5 VH aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSS  848 BCMA-85 BC C6-97-G5 VL aa DIQMTQSPSSLSASLGDRVTITCRASQDISNYLNWYQQKPDKAPKLLIYYTSRLHSGVPSRFSGSGS GTDYTLTISSLEPEDIATYYCQQGNTLPWTFGQGTKVEIK  849 BCMA-85 BC C6-97-G5 scFv aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASLGDRVTITCRASQDISNYLNWYQQKPDKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTLTISSLEPEDIATYYCQQGNTLPWTFGQGTKVEIK  850 BCMA-85 HL x BC C6-97-G5 HL x bispecific molecule aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR CD3 HL CD3 HL FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASLGDRVTITCRASQDISNYLNWYQQKPDKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTLTISSLEPEDIATYYCQQGNTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  851 BCMA-86 BC C6-98-C8 VH CDR1 aa NFGMN  852 BCMA-86 BC C6-98-C8 VH CDR2 aa WINTYTGESIYADDFKG  853 BCMA-86 BC C6-98-C8 VH CDR3 aa GGVYGGYDAMDY  854 BCMA-86 BC C6-98-C8 VL CDR1 aa RASQDISNYLN  855 BCMA-86 BC C6-98-C8 VL CDR2 aa YTSRLHS  856 BCMA-86 BC C6-98-C8 VL CDR3 aa QQGNTLPWT  857 BCMA-86 BC C6-98-C8 VH aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR FVFSSDTSVSTAYLQINSLKAEDTAVYFCARGGVYGGYDAMDYWGQGTLVTVSS  858 BCMA-86 BC C6-98-C8 VL aa DIQMTQTPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKALKLLIYYTSRLHSGVPSRFSGSGS GTDYSLTISNLQPEDIATYYCQQGNTLPWTFGQGTKVEIK  859 BCMA-86 BC C6-98-C8 scFv aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR FVFSSDTSVSTAYLQINSLKAEDTAVYFCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQTPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKALKLLIYYTSRLHSGVPSRFSGS GSGTDYSLTISNLQPEDIATYYCQQGNTLPWTFGQGTKVE1K  860 BCMA-86 HL x BC C6-98-C8 HL x bispecific molecule aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR CD3 HL CD3 HL FVFSSDTSVSTAYLQINSLKAEDTAVYFCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQTPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKALKLLIYYTSRLHSGVPSRFSGS GSGTDYSLTISNLQPEDIATYYCQQGNTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  861 BCMA-87 BC C6-97-A6 VH CDR1 aa NFGMN  862 BCMA-87 BC C6-97-A6 VH CDR2 aa WINTYTGESIYADDFKG  863 BCMA-87 BC C6-97-A6 VH CDR3 aa GGVYGGYDAMDY  864 BCMA-87 BC C6-97-A6 VL CDR1 aa RASQDISNYLN  865 BCMA-87 BC C6-97-A6 VL CDR2 aa YTSRLHS  866 BCMA-87 BC C6-97-A6 VL CDR3 aa QQGNTLPWT  867 BCMA-87 BC C6-97-A6 VH aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSS  868 BCMA-87 BC C6-97-A6 VL aa DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGS GTDYTLTISSLEQEDIATYFCQQGNTLPWTFGQGTKVEIK  869 BCMA-87 BC C6-97-A6 scFv aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTLTISSLEQEDIATYFCQQGNTLPWTFGQGTKVEIK  870 BCMA-87 HL x BC C6-97-A6 HL x bispecific molecule aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR CD3 HL CD3 HL FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTLTISSLEQEDIATYFCQQGNTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  871 BCMA-88 BC C6-98-C8-E3 VH CDR1 aa NFGMN  872 BCMA-88 BC C6-98-C8-E3 VH CDR2 aa WINTYTGESIYADDFKG  873 BCMA-88 BC C6-98-C8-E3 VH CDR3 aa GGVYGGYDAMDY  874 BCMA-88 BC C6-98-C8-E3 VL CDR1 aa RASQDISNYLN  875 BCMA-88 BC C6-98-C8-E3 VL CDR2 aa YTSRLHS  876 BCMA-88 BC C6-98-C8-E3 VL CDR3 aa QSFATLPWT  877 BCMA-88 BC C6-98-C8-E3 VH aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR FVFSSDTSVSTAYLQINSLKAEDTAVYFARGGVYGGYDAMDYWGQGTLVTVSS  878 BCMA-88 BC C6-98-C8-E3 VL aa DIQMTQTPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKALKLLIYYTSRLHSGVPSRFSGSGS GTDYSLTISNLQPEDIATYYCQSFATLPWTFGQGTKVEIK  879 BCMA-88 BC C6-98-C8-E3 scFv aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR FVFSSDTSVSTAYLQINSLKAEDTAVYFCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQTPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKALKLLIYYTSRLHSGVPSRFSGS GSGTDYSLTISNLQPEDIATYYCQSFATLPWTFGQGTKVEIK  880 BCMA-88 HL x BC C6-98-C8-E3 HL x bispecific molecule aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR CD3 HL CD3 HL FVFSSDTSVSTAYLQINSLKAEDTAVYFCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQTPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKALKLLIYYTSRLHSGVPSRFSGS GSGTDYSLTISNLQPEDIATYYCQSFATLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  881 BCMA-89 A1-E3C6-98-A1-E3 VH CDR1 aa NFGMN  882 BCMA-89 A1-E3C6-98-A1-E3 VH CDR2 aa WINTYTGESIYADDFKG  883 BCMA-89 A1-E3C6-98-A1-E3 VH CDR3 aa GGVYGGYDAMDY  884 BCMA-89 A1-E3C6-98-A1-E3 VL CDR1 aa RASQDISNYLN  885 BCMA-89 A1-E3C6-98-A1-E3 VL CDR2 aa YTSRLHS  886 BCMA-89 A1-E3C6-98-A1-E3 VL CDR3 aa QSFATLPWT  887 BCMA-89 A1-E3C6-98-A1-E3 VH aa QVQLVQSGSELKKPGASVKISCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR FVFSSDTSVSTAYLQINNLKAEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSS  888 BCMA-89 A1-E3C6-98-A1-E3 VL aa DIQMTQSPSSLSASVGDRVTISCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGS GTDYTFTISNLQPEDIATYYCQSFATLPWTFGQGTKVEIK  889 BCMA-89 A1-E3C6-98-A1-E3 scFv aa QVQLVQSGSELKKPGASVKISCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR FVFSSDTSVSTAYLQINNLKAEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTFTISNLQPEDIATYYCQSFATLPWTFGQGTKVEIK  890 BCMA-89 HL x BC C6-98-A1-E3 HL x bispecific molecule aa QVQLVQSGSELKKPGASVKISCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR CD3 HL CD3 HL FVFSSDTSVSTAYLQINNLKAEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTFTISNLQPEDIATYYCQSFATLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  891 BCMA-90 BC C6-97-G5-E3 VH CDR1 aa NFGMN  892 BCMA-90 BC C6-97-G5-E3 VH CDR2 aa WINTYTGESIYADDFKG  893 BCMA-90 BC C6-97-G5-E3 VH CDR3 aa GGVYGGYDAMDY  894 BCMA-90 BC C6-97-G5-E3 VL CDR1 aa RASQDISNYLN  895 BCMA-90 BC C6-97-G5-E3 VL CDR2 aa YTSRLHS  896 BCMA-90 BC C6-97-G5-E3 VL CDR3 aa QSFATLPWT  897 BCMA-90 BC C6-97-G5-E3 VH aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSS  898 BCMA-90 BC C6-97-G5-E3 VL aa DIQMTQSPSSLSASLGDRVTITCRASQDISNYLNWYQQKPDKAPKLLIYYTSRLHSGVPSRFSGSGS GTDYTLTISSLEPEDIATYYCQSFATLPWTFGQGTKVEIK  899 BCMA-90 BC C6-97-G5-E3 scFv aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASLGDRVTITCRASQDISNYLNWYQQKPDKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTLTISSLEPEDIATYYCQSFATLPWTFGQGTKVEIK  900 BCMA-90 HL x BC C6-97-G5-E3 bispecific molecule aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGKGLEWMGWINTYTGESIYADDFKGR CD3 HL HL x CD3 HL FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASLGDRVTITCRASQDISNYLNWYQQKPDKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTLTISSLEPEDIATYYCQSFATLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  901 BCMA-91 BC C6-97-A6-E3 VH CDR1 aa NFGMN  902 BCMA-91 BC C6-97-A6-E3 VH CDR2 aa WINTYTGESIYADDFKG  903 BCMA-91 BC C6-97-A6-E3 VH CDR3 aa GGVYGGYDAMDY  904 BCMA-91 BC C6-97-A6-E3 VL CDR1 aa RASQDISNYLN  905 BCMA-91 BC C6-97-A6-E3 VL CDR2 aa YTSRLHS  906 BCMA-91 BC C6-97-A6-E3 VL CDR3 aa QSFATLPWT  907 BCMA-91 BC C6-97-A6-E3 VH aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSS  908 BCMA-91 BC C6-97-A6-E3 VL aa DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGS GTDYTLTISSLEQEDIATYFCQSFATLPWTFGQGTKVEIK  909 BCMA-91 BC C6-97-A6-E3 scFv aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTLTISSLEQEDIATYFCQSFATLPWTFGQGTKVEIK  910 BCMA-91 HL x BC C6-97-A6-E3 HL x bispecific molecule aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR CD3 HL CD3 HL FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTLTISSLEQEDIATYFCQSFATLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  911 BCMA-92 BC C6-97-G5-G9 VH CDR1 aa NFGMN  912 BCMA-92 BC C6-97-G5-G9 VH CDR2 aa WINTYTGESIYADDFKG  913 BCMA-92 BC C6-97-G5-G9 VH CDR3 aa GGVYGGYDAMDY  914 BCMA-92 BC C6-97-G5-G9 VL CDR1 aa RASQDISNYLN  915 BCMA-92 BC C6-97-G5-G9 VL CDR2 aa YTSRLHS  916 BCMA-92 BC C6-97-G5-G9 VL CDR3 aa QHFRTLPWT  917 BCMA-92 BC C6-97-G5-G9 VH aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSS  918 BCMA-92 BC C6-97-G5-G9 VL aa DIQMTQSPSSLSASLGDRVTITCRASQDISNYLNWYQQKPDKAPKLLIYYTSRLHSGVPSRFSGSGS GTDYTLTISSLEPEDIATYYCQHFRTLPWTFGQGTKVEIK  919 BCMA-92 BC C6-97-G5-G9 scFv aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASLGDRVTITCRASQDISNYLNWYQQKPDKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTLTISSLEPEDIATYYCQHFRTLPWTFGQGTKVEIK  920 BCMA-92 HL x BC C6-97-G5-G9 HL x bispecific molecule aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR CD3 HL CD3 HL FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASLGDRVTITCRASQDISNYLNWYQQKPDKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTLTISSLEPEDIATYYCQHFRTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  921 BCMA-93 BC C6-98-C8-G9 VH CDR1 aa NFGMN  922 BCMA-93 BC C6-98-C8-G9 VH CDR2 aa WINTYTGESIYADDFKG  923 BCMA-93 BC C6-98-C8-G9 VH CDR3 aa GGVYGGYDAMDY  924 BCMA-93 BC C6-98-C8-G9 VL CDR1 aa RASQDISNYLN  925 BCMA-93 BC C6-98-C8-G9 VL CDR2 aa YTSRLHS  926 BCMA-93 BC C6-98-C8-G9 VL CDR3 aa QHFRTLPWT  927 BCMA-93 BC C6-98-C8-G9 VH aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR FVFSSDTSVSTAYLQINSLKAEDTAVYFCARGGVYGGYDAMDYWGQGTLVTVSS  928 BCMA-93 BC C6-98-C8-G9 VL aa DIQMTQTPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKALKLLIYYTSRLHSGVPSRFSGSGS GTDYSLTISNLQPEDIATYYCQHFRTLPWTFGQGTKVEIK  929 BCMA-93 BC C6-98-C8-G9 scFv aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR FVFSSDTSVSTAYLQINSLKAEDTAVYFCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQTPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKALKLLIYYTSRLHSGVPSRFSGS GSGTDYSLTISNLQPEDIATYYCQHFRTLPWTFGQGTKVEIK  930 BCMA-93 HL x BC C6-98-C8-G9 HL x bispecific molecule aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR CD3 HL CD3 HL FVFSSDTSVSTAYLQINSLKAEDTAVYFCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQTPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKALKLLIYYTSRLHSGVPSRFSGS GSGTDYSLTISNLQPEDIATYYCQHFRTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  931 BCMA-94 BC C6-97-A6-G9 VH CDR1 aa NFGMN  932 BCMA-94 BC C6-97-A6-G9 VH CDR2 aa WINTYTGESIYADDFKG  933 BCMA-94 BC C6-97-A6-G9 VH CDR3 aa GGVYGGYDAMDY  934 BCMA-94 BC C6-97-A6-G9 VL CDR1 aa RASQDISNYLN  935 BCMA-94 BC C6-97-A6-G9 VL CDR2 aa YTSRLHS  936 BCMA-94 BC C6-97-A6-G9 VL CDR3 aa QHFRTLPWT  937 BCMA-94 BC C6-97-A6-G9 VH aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSS  938 BCMA-94 BC C6-97-A6-G9 VL aa DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGS GTDYTLTISSLEQEDIATYFCQHFRTLPWTFGQGTKVEIK  939 BCMA-94 BC C6-97-A6-G9 scFv aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTLTISSLEQEDIATYFCQHFRTLPWTFGQGTKVEIK  940 BCMA-94 HL x BC C6-97-A6-G9 HL x bispecific molecule aa QVQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR CD3 HL CD3 HL FVFSLDTSVTTAYLQINSLKDEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTLTISSLEQEDIATYFCQHFRTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  941 BCMA-95 BC C6-98-A1-G9 VH CDR1 aa NFGMN  942 BCMA-95 BC C6-98-A1-G9 VH CDR2 aa WINTYTGESIYADDFKG  943 BCMA-95 BC C6-98-A1-G9 VH CDR3 aa GGVYGGYDAMDY  944 BCMA-95 BC C6-98-A1-G9 VL CDR1 aa RASQDISNYLN  945 BCMA-95 BC C6-98-A1-G9 VL CDR2 aa YTSRLHS  946 BCMA-95 BC C6-98-A1-G9 VL CDR3 aa QHFRTLPWT  947 BCMA-95 BC C6-98-A1-G9 VH aa QVQLVQSGSELKKPGASVKISCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR FVFSSDTSVSTAYLQINNLKAEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSS  948 BCMA-95 BC C6-98-A1-G9 VL aa DIQMTQSPSSLSASVGDRVTISCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGS GTDYTFTISNLQPEDIATYFCQHFRTLPWTFGQGTKVEIK  949 BCMA-95 BC C6-98-A1-G9 scFv aa QVQLVQSGSELKKPGASVKISCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR FVFSSDTSVSTAYLQINNLKAEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTFTISNLQPEDIATYFCQHFRTLPWTFGQGTKVEIK  950 BCMA-95 HL x BC C6-98-A1-G9 HL bispecific molecule aa QVQLVQSGSELKKPGASVKISCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR CD3 HL CD3 HL FVFSSDTSVSTAYLQINNLKAEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTFTISNLQPEDIATYFCQHFRTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  951 BCMA-96 BC C6 98-A1 VH CDR1 aa NFGMN  952 BCMA-96 BC C6 98-A1 VH CDR2 aa WINTYTGESIYADDFKG  953 BCMA-96 BC C6 98-A1 VH CDR3 aa GGVYGGYDAMDY  954 BCMA-96 BC C6 98-A1 VL CDR1 aa RASQDISNYLN  955 BCMA-96 BC C6 98-A1 VL CDR2 aa YTSRLHS  956 BCMA-96 BC C6 98-A1 VL CDR3 aa QQGNTLPWT  957 BCMA-96 BC C6 98-A1 VH aa QVQLVQSGSELKKPGASVKISCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR FVFSSDTSVSTAYLQINNLKAEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSS  958 BCMA-96 BC C6 98-A1 VL aa DIQMTQSPSSLSASVGDRVTISCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGS GTDYTFTISNLQPEDIATYYCQQGNTLPWTFGQGTKVEIK  959 BCMA-96 BC C6 98-A1 scFv aa QVQLVQSGSELKKPGASVKISCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR FVFSSDTSVSTAYLQINNLKAEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTFTISNLQPEDIATYYCQQGNTLPWTFGQGTKVE1K  960 BCMA-96 HL x BC C6 98-A1 HL x bispecific molecule aa QVQLVQSGSELKKPGASVKISCKASGYTFTNFGMNWVRQAPGQGLEWMGWINTYTGESIYADDFKGR CD3 HL CD3 HL FVFSSDTSVSTAYLQINNLKAEDTAVYYCARGGVYGGYDAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTISCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGS GSGTDYTFTISNLQPEDIATYYCQQGNTLPWTFGQGTKVEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  961 BCMA-97 BC B12-33-G2-B2 VH CDR1 aa NFDMA  962 BCMA-97 BC B12-33-G2-B2 VH CDR2 aa SITTGGGDTYYADSVKG  963 BCMA-97 BC B12-33-G2-B2 VH CDR3 aa HGYYDGYHLFDY  964 BCMA-97 BC B12-33-G2-B2 VL CDR1 aa RASQGISNNLN  965 BCMA-97 BC B12-33-G2-B2 VL CDR2 aa YTSNLQS  966 BCMA-97 BC B12-33-G2-B2 VL CDR3 aa QQFTSLPYT  967 BCMA-97 BC B12-33-G2-B2 VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS  968 BCMA-97 BC B12-33-G2-B2 VL aa DIQMTQSPSSMSASVGDRVTITCRASQGISNNLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGSGS GTDYTLTISSLQPEDFATYYCQQFTSLPYTFGQGTKLEIK  969 BCMA-97 BC B12-33-G2-B2 scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSMSASVGDRVTITCRASQGISNNLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQFTSLPYTFGQGTKLEIK  970 BCMA-97 HL x BC B12-33-G2-B2 HL x bispecific molecule aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR CD3 HL CD3 HL FTISRDNAKNTLYLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSMSASVGDRVTITCRASQGISNNLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQFTSLPYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  971 BCMA-98 BC B12-33-A4-B2 VH CDR1 aa NFDMA  972 BCMA-98 BC B12-33-A4-B2 VH CDR2 aa SITTGGGDTYYADSVKG  973 BCMA-98 BC B12-33-A4-B2 VH CDR3 aa HGYYDGYHLFDY  974 BCMA-98 BC B12-33-A4-B2 VL CDR1 aa RANQGISNNLN  975 BCMA-98 BC B12-33-A4-B2 VL CDR2 aa YTSNLQS  976 BCMA-98 BC B12-33-A4-B2 VL CDR3 aa QQFTSLPYT  977 BCMA-98 BC B12-33-A4-B2 VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR FTISRDNAKSTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS  978 BCMA-98 BC B12-33-A4-B2 VL aa DIQMTQSPSSLSASVGDRVTITCRANQGISNNLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGSGS GTDYTLTISSLQPEDFATYYCQQFTSLPYTFGQGTKLEIK  979 BCMA-98 BC B12-33-A4-B2 scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR FTISRDNAKSTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRANQGISNNLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQFTSLPYTFGQGTKLEIK  980 BCMA-98 HL x BC B12-33-A4-B2 HL x bispecific molecule aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR CD3 HL CD3 HL FTISRDNAKSTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRANQGISNNLNWYQQKPGKAPKPLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQFTSLPYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  981 BCMA-99 BC B12-33-A5-B2 VH CDR1 aa NFDMA  982 BCMA-99 BC B12-33-A5-B2 VH CDR2 aa SITTGGGDTYYADSVKG  983 BCMA-99 BC B12-33-A5-B2 VH CDR3 aa HGYYDGYHLFDY  984 BCMA-99 BC B12-33-A5-B2 VL CDR1 aa RASQGISNNLN  985 BCMA-99 BC B12-33-A5-B2 VL CDR2 aa YTSNLQS  986 BCMA-99 BC B12-33-A5-B2 VL CDR3 aa QQFTSLPYT  987 BCMA-99 BC B12-33-A5-B2 VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS  988 BCMA-99 BC B12-33-A5-B2 VL aa DIQMTQSPSSMSASVGDRVTITCRASQGISNNLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGSGS GTDYTLTISSLQPEDFATYYCQQFTSLPYTFGQGTKLEIK  989 BCMA-99 BC B12-33-A5-B2 scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSMSASVGDRVTITCRASQGISNNLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQFTSLPYTFGQGTKLEIK  990 BCMA-99 HL x BC B12-33-A5-B2 HL x bispecific molecule aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR CD3 HL CD3 HL FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSMSASVGDRVTITCRASQGISNNLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQFTSLPYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL  991 BCMA-100 BC B12-33-A5-C10 VH CDR1 aa NFDMA  992 BCMA-100 BC B12-33-A5-C10 VH CDR2 aa SITTGGGDTYYADSVKG  993 BCMA-100 BC B12-33-A5-C10 VH CDR3 aa HGYYDGYHLFDY  994 BCMA-100 BC B12-33-A5-C10 VL CDR1 aa RASQGISNNLN  995 BCMA-100 BC B12-33-A5-C10 VL CDR2 aa YTSNLQS  996 BCMA-100 BC B12-33-A5-C10 VL CDR3 aa QQFAHLPYT  997 BCMA-100 BC B12-33-A5-C10 VH aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSS  998 BCMA-100 BC B12-33-A5-C10 VL aa DIQMTQSPSSMSASVGDRVTITCRASQGISNNLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGSGS GTDYTLTISSLQPEDFATYYCQQFAHLPYTFGQGTKLEIK  999 BCMA-100 BC B12-33-A5-C10 scFv aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSMSASVGDRVTITCRASQGISNNLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQFAHLPYTFGQGTKLEIK 1000 BCMA-100 HL BC B12-33-A5- bispecific molecule aa EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQAPGKGLVWVSSITTGGGDTYYADSVKGR x CD3 HL C10 HL x CD3 HL FTISRDNAKNTLYLQMDSLRSEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSMSASVGDRVTITCRASQGISNNLNWYQQKPGKAPKSLIYYTSNLQSGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQFAHLPYTFGQGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLK LSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMN NLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCVLWYSNRWVFGGGTKLTVL 1001 human BCMA human na atgttgcagatggctgggcagtgctcccaaaatgaatattttgacagtttgttgcatgcttgcatac cttgtcaacttcgatgttcttctaatactcctcctctaacatgtcagcgttattgtaatgcaagtgt gaccaattcagtgaaaggaacgaatgcgattctctggacctgtttgggactgagcttaataatttct ttggcagttttcgtgctaatgtttttgctaaggaagataaactctgaaccattaaaggacgagttta aaaacacaggatcaggtctcctgggcatggctaacattgacctggaaaagagcaggactggtgatga aattattcttccgagaggcctcgagtacacggtggaagaatgcacctgtgaagactgcatcaagagc aaaccgaaggtcgactctgaccattgctttccactcccagctatggaggaaggcgcaaccattcttg tcaccacgaaaacgaatgactattgcaagagcctgccagctgctttgagtgctacggagatagagaa atcaatttctgctaggtaa 1002 human BCMA MLQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLICQRYCNASVINSVKGTNAILWICLGLSLIIS LAVFVLMFLLRKINSEPLKDEFKNTGSGLLGMANIDLEKSRTGDEIILPRGLEYTVEECTCEDCIKS KPKVDSDHCFPLPAMEEGATILVITKINDYCKSLPAALSATEIEKSISAR 1003 mouse BCMA murine na atggcgcaacagtgtttccacagtgaatattttgacagtctgctgcatgcttgcaaaccgtgtcact tgcgatgttccaaccctcctgcaacctgtcagccttactgtgatccaagcgtgaccagttcagtgaa agggacgtacacggtgctctggatcttcttggggctgaccttggtcctctctttggcacttttcaca atctcattcttgctgaggaagatgaaccccgaggccctgaaggacgagcctcaaagcccaggtcagc ttgacggatcggctcagctggacaaggccgacaccgagctgactaggatcagggctggtgacgacag gatctttccccgaagcctggagtatacagtggaagagtgcacctgtgaggactgtgtcaagagcaaa cccaagggggattctgaccatttcttcccgcttccagccatggaggagggggcaaccattcttgtca ccacaaaaacgggtgactacggcaagtcaagtgtgccaactgctttgcaaagtgtcatggggatgga gaagccaactcacactagataa 1004 mouse BCMA murine aa MAQQCFHSEYFDSLLHACKPCHLRCSNPPATCQPYCDPSVTSSVKGTYTVLWIFLGLTLVLSLALFT ISFLLRKMNPEALKDEPQSPGQLDGSAQLDKADTELTRIRAGDDRIFPRSLEYTVEECTCEDCVKSK PKGDSDHFFPLPAMEEGATILVTIKTGDYGKSSVPTALQSVMGMEKPTHIR 1005 macaque BCMA rhesus na atgttgcagatggctcggcagtgctcccaaaatgaatattttgacagtttgttgcatgattgcaaac cttgtcaacttcgatgttctagtactcctcctctaacatgtcagcgttattgcaatgcaagtatgac caattcagtgaaaggaatgaatgcgattctctggacctgtttgggactgagcttgataatttctttg acacaggatcaggtctcctgggcatggctaacattgacctggaaaagggcaggactggtgatgaaat tgttcttccaagaggcctggagtacacggtggaagaatgcacctgtgaagactgcatcaagaataaa ccaaaggttgattctgaccattgctttccactcccagccatggaggaaggcgcaaccattctcgtca ccacgaaaacgaatgactattgcaatagcctgtcagctgctttgagtgttacggagatagagaaatc aatttctgctaggtaa 1006 macaque BCMA rhssus aa MLQMARQCSQNEYFDSLLHDCKPCQLRCSSTPPLICQRYCNASMINSVKGMNAILWICLGLSLIISL AVFVLTFLLRKMSSEPLKDEFKNTGSGLLGMANIDLEKGRTGDEIVLPRGLEYTVEECTCEDCIKNK PKVDSDHCFPLPAMEEGATILVITKINDYCNSLSAALSVTEIEKSISAR 1007 hu BCMA ECD = positions 1-54 of human aa MLQMAGQCSQNEYFDSLLHACIPCQLRCSSNIPPLICQRYCNASVINSVKGTNA SEQ ID NO: 1002 1008 mu BCMA ECD = positions 1-49 of murine aa MAQQCFHSEYFDSLLHACKPCHLRCSNPPATCQPYCDPSVTSSVKGTYT SEQ ID NO: 1004 1009 hu BCMA ECD/E1 murine chimeric aa MAQQCSQNEYFDSLLHACIPCQLRCSSNIPPLICQRYCNASVINSVKGTNA hu/mu 1010 hu BCMA ECD/E2 murine chimeric aa MLQMAGQCFHSEYFDSLLHACIPCQLRCSSNIPPLICQRYCNASVINSVKGTNA hu/mu 1011 hu BCMA ECD/E3 murine chimeric aa MLQMAGQCSQNEYFDSLLHACIPCHLRCSNPPATCQPYCNASVINSVKGTNA hu/mu 1012 hu BCMA ECD/E4 murine chimeric aa MLQMAGQCSQNEYFDSLLHACIPCQLRCSSNIPPLTCQRYCDPSVTSSVKGTYT hu/mu 1013 hu BCMA  ECD/E5 murine chimeric aa MLQMAGQCSQNEYFDSLLHACKPCQLRCSSNTPPLTCQRYCNASVTNSVKGTNA hu/mu 1014 hu BCMA-ECD/E6 murine chimeric aa MLQMAGQCSQNEYFDSLLHACIPCHLRCSSNTPPLTCQRYCNASVTNSVKGTNA hu/mu 1015 hu BCMA-ECD/E7 murine chimeric aa MLQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQPYCNASVTNSVKGTNA hu/mu 1016 hu BCMA epitope cluster 3 human aa CQLRCSSNIPPLICQRYC 1017 mac BCMA epitope cluster 3 macaque aa CQLRCSSTPPLTCQRYC 1018 hu BCMA epitope cluster 1 human aa MLQMAGQ 1019 hu BCMA epitope cluster 4 human aa NASVTNSVKGTNA 1020 mac BCMA epitope cluster 1 macaque aa MLQMARQ 1021 mac BCMA epitope cluster 4 macaque aa NASMTNSVKGMNA 1022 BCMA-101 BC 5G9 VH CDR1 aa GFTFSNYDMA 1023 BCMA-101 BC 5G9 VH CDR2 aa SIITSGGDNYYRDSVKG 1024 BCMA-101 BC 5G9 VH CDR3 aa HDYYDGSYGFAY 1025 BCMA-101 BC 5G9 VL CDR1 aa KASQSVGINVD 1026 BCMA-101 BC 5G9 VL CDR2 aa GASNRHT 1027 BCMA-101 BC 5G9 VL CDR3 aa LQYGSIPFT 1028 BCMA-101 BC 5G9 VH aa EVQLVESGGGLVQPGRSLKLSCAASGFTFSNYDMAWVRQAPTKGLEWVASIITSGGDNYYRDSVKGR FTVSRDNAKSTLYLQMDSLRSEDTATYYCVRHDYYDGSYGFAYWGQGTLVTVSS 1029 BCMA-101 BC 5G9 VL aa ETVMTQSPTSMSTSIGERVTLNCKASQSVGINVDWYQQTPGQSPKLLIYGASNRHTGVPDRFTGSGF GRDFTLTISNVEAEDLAVYYCLQYGSIPFTFGSGTKLELK 1030 BCMA-101 BC 5G9 scFv aa EVQLVESGGGLVQPGRSLKLSCAASGFTFSNYDMAWVRQAPTKGLEWVASIITSGGDNYYRDSVKGR FTVSRDNAKSTLYLQMDSLRSEDTATYYCVRHDYYDGSYGFAYWGQGTLVTVSSGGGGSGGGGGSGG GGSETVMTQSPTSMSTSIGERVTLNCKASQSVGINVDWYQQTPGQSPKLLIYGASNRHTGVPDRFTG SGFGRDFTLTISNVEAEDLAVYYCLQYGSIPFTFGSGTKLELK 1031 BCMA-102 BC 244-A7 VH CDR1 aa GYTFTNHIIH 1032 BCMA-102 BC 244-A7 VH CDR2 aa YINPYNDDTEYNEKFKG 1033 BCMA-102 BC 244-A7 VH CDR3 aa DGYYRDMDVMDY 1034 BCMA-102 BC 244-A7 VL CDR1 aa RASQDISNYLN 1035 BCMA-102 BC 244-A7 VL CDR2 aa YTSRLHS 1036 BCMA-102 BC 244-A7 VL CDR3 aa QQGNTLPWT 1037 BCMA-102 BC 244-A7 VH aa EVQLVEQSGPELVKPGASVKMSCKASGYTFTNHIIHWVKQKPGQGLEWIGYINPYNDDTEYNEKFKG KATLTSDKSSTTAYMELSSLTSEDSAVYYCARDGYYRDMDVMDYWGQGTIVIVSS 1038 BCMA-102 BC 244-A7 VL aa ELVMTQTPSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGS GTDYSLTISNLEQEDIATYFCQQGNTLPWTFGGGTKLEIK 1039 BCMA-102 BC 244-A7 scFv aa EVQLVEQSGPELVKPGASVKMSCKASGYTFTNHIIHWVKQKPGQGLEWIGYINPYNDDTEYNEKFKG KATLTSDKSSTTAYMELSSLTSEDSAVYYCARDGYYRDMDVMDYWGQGTIVIVSSGGGGSGGGGSGG GGSELVMTQTPSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSG SGSGTDYSLTISNLEQEDIATYFCQQGNTLPWTFGGGTKLEIK 1040 BCMA-103 BC 263-A4 VH CDR1 aa GFTFSNYDMA 1041 BCMA-103 BC 263-A4 VH CDR2 aa SISTRGDITSYRDSVKG 1042 BCMA-103 BC 263-A4 VH CDR3 aa QDYYTDYMGFAY 1043 BCMA-103 BC 263-A4 VL CDR1 aa RASEDIYNGLA 1044 BCMA-103 BC 263-A4 VL CDR2 aa GASSLQD 1045 BCMA-103 BC 263-A4 VL CDR3 aa QQSYKYPLT 1046 BCMA-103 BC 263-A4 VH aa EVQLVEESGGGLLQPGRSLKLSCAASGFTFSNYDMAWVRQAPTKGLEWVASISTRGDITSYRDSVKG RFTISRDNAKSTLYLQMDSLRSEDTATYYCARQDYYTDYMGFAYWGQGTLVTVSS 1047 BCMA-103 BC 263-A4 VL aa ELVMTQSPASLSASLGETVTIECRASEDIYNGLAWYQQKPGKSPQLLIYGASSLQDGVPSRFSGSGS GTQYSLKISGMQPEDEANYFCQQSYKYPLTFGSGTKLELK 1048 BCMA-103 BC 263-A4 scFv aa EVQLVEESGGGLLQPGRSLKLSCAASGFTFSNYDMAWVRQAPTKGLEWVASISTRGDITSYRDSVKG RFTISRDNAKSTLYLQMDSLRSEDTATYYCARQDYYTDYMGFAYWGQGTLVTVSSGGGGSGGGGSGG GELVMTQSPASLSASLGETVTIECRASEDIYNGLAWYQQKPGKSPQLLIYGASSLQDGVPSRFSGSG SGTQYSLKISGMQPEDEANYFCQQSYKYPLTFGSGTKLELKGS 1049 BCMA-104 BC 271-C3 VH CDR1 aa GFTFSNFDMA 1050 BCMA-104 BC 271-C3 VH CDR2 aa SITTGGGDTYYRDSVKG 1051 BCMA-104 BC 271-C3 VH CDR3 aa HGYYDGYHLFDY 1052 BCMA-104 BC 271-C3 VL CDR1 aa RASQGISNYL 1053 BCMA-104 BC 271-C3 VL CDR2 aa YTSNLQS 1054 BCMA-104 BC 271-C3 VL CDR3 aa QQYDISSYT 1055 BCMA-104 BC 271-C3 VH aa EVQLVEESGGGLVQPGRSLKLSCAASGFTFSNFDMAWVRQAPTRGLEWVASITTGGGDTYYRDSVKG RFTISRDNAKSTLYLQMDSLRSEDTATYYCVRHGYYDGYHLFDYWGQGASVTVSS 1056 BCMA-104 BC 271-C3 VL aa ELVMTQTPSSMPASLGERVTISCRASQGISNYLNWYQQKPDGTIKPLIYYTSNLQSGVPSRFSGSGS GTDYSLTINSLEPEDFAVYYCQQYDISSYTFGAGTKLEIK 1057 BCMA-104 BC 271-C3 scFv aa EVQLVEESGGGLVQPGRSLKLSCAASGFTFSNFDMAWVRQAPTRGLEWVASITTGGGDTYYRDSVKG RFTISRDNAKSTLYLQMDSLRSEDTATYYCVRHGYYDGYHLFDYWGQGASVTVSSGGGGSGGGGSGG GGSELVMTQTPSSMPASLGERVTISCRASQGISNYLNWYQQKPDGTIKPLIYYTSNLQSGVPSRFSG SGSGTDYSLTINSLEPEDFAVYYCQQYDISSYTFGAGTKLEIK 1058 BCMA-105 BC 265-E5 VH CDR1 aa GFTFSNFDMA 1059 BCMA-105 BC 265-E5 VH CDR2 aa SITTGGGDTYYRDSVKG 1060 BCMA-105 BC 265-E5 VH CDR3 aa HGYYDGYHLFDY 1061 BCMA-105 BC 265-E5 VL CDR1 aa RASQGISNHLN 1062 BCMA-105 BC 265-E5 VL CDR2 aa YTSNLQS 1063 BCMA-105 BC 265-E5 VL CDR3 aa QQYDSFPLT 1064 BCMA-105 BC 265-E5 VH aa EVQLVEESGGGLVQPGRSLKLSCAASGFTFSNFDMAWVRQAPTRGLEWVASITTGGGDTYYRDSVKG RFTISRDNAKSTLYLQMDSLRSEDTATYYCVRHGYYDGYHLFDYWGQGTLVTVSS 1065 BCMA-105 BC 265-E5 VL aa ELVMTQTPSSMPASLGERVTISCRASQGISNHLNWYQQKPDGTIKPLIYYTSNLQSGVPSRFSGSGS GTDYSLTISSLEPEDFAMYYCQQYDSFPLTFGSGTKLEIK 1066 BCMA-105 BC 265-E5 scFv aa EVQLVEESGGGLVQPGRSLKLSCAASGFTFSNFDMAWVRQAPTRGLEWVASITTGGGDTYYRDSVKG RFTISRDNAKSTLYLQMDSLRSEDTATYYCVRHGYYDGYHLFDYWGQGTLVTVSSGGGGSGGGGSGG GGSELVMTQTPSSMPASLGERVTISCRASQGISNHLNWYQQKPDGTIKPLIYYTSNLQSGVPSRFSG SGSGTDYSLTISSLEPEDFAMYYCQQYDSFPLTFGSGTKLEIK 1067 BCMA-106 BC 271-B12 VH CDR1 aa GFTFSNFDMA 1068 BCMA-106 BC 271-B12 VH CDR2 aa SITTGGGDTYYRDSVKG 1069 BCMA-106 BC 271-B12 VH CDR3 aa HGYYDGYHLFDY 1070 BCMA-106 BC 271-B12 VL CDR1 aa RASQGISNNLN 1071 BCMA-106 BC 271-B12 VL CDR2 aa YTSNLQS 1072 BCMA-106 BC 271-B12 VL CDR3 aa QQFDTSPYT 1073 BCMA-106 BC 271-B12 VH aa EVQLVEESGGGLVQPGRSLKLSCAASGFTFSNFDMAWVRQAPTRGLEWVASITTGGGDTYYRDSVKG RFTISRDNAKSTLYLQMDSLRSEDTATYYCVRHGYYDGYHLFDYWGQGVMVIVSS 1074 BCMA-106 BC 271-B12 VL aa ELVMTQTPSSMPASLGERVTISCRASQGISNNLNWYQQKPDGTIKPLIYYTSNLQSGVPSRFSGSGS GTDYSLTISSLEPEDFAMYYCQQFDTSPYTFGAGTKLEIK 1075 BCMA-106 BC 271-B12 scFv aa EVQLVEESGGGLVQPGRSLKLSCAASGFTFSNFDMAWVRQAPTRGLEWVASITTGGGDTYYRDSVKG RFTISRDNAKSTLYLQMDSLRSEDTATYYCVRHGYYDGYHLFDYWGQGVMVIVSSGGGGSGGGGSGG GGSELVMTQTPSSMPASLGERVTISCRASQGISNNLNWYQQKPDGTIKPLIYYTSNLQSGVPSRFSG SGSGTDYSLTISSLEPEDFAMYYCQQFDTSPYTFGAGTKLEIK 1076 BCMA-107 BC 247-A4 VH CDR1 aa GYSFPDYYIN 1077 BCMA-107 BC 247-A4 VH CDR2 aa WIYFASGNSEYNE 1078 BCMA-107 BC 247-A4 VH CDR3 aa LYDYDWYFDV 1079 BCMA-107 BC 247-A4 VL CDR1 aa RSSQSLVH SNGNTYLH 1080 BCMA-107 BC 247-A4 VL CDR2 aa KVSNRFS 1081 BCMA-107 BC 247-A4 VL CDR3 aa SQSTHVPYT 1082 BCMA-107 BC 247-A4 VH aa EVQLVEQSGPELVKPGASVKISCKVSGYSFPDYYINWVKQRPGQGLEWIGWIYFASGNSEYNERFTG KATLTVDTSSNTAYMQLSSLTSEDTAVYFCASLYDYDWYFDVWGQGTTVTVSS 1083 BCMA-107 BC 247-A4 VL aa ELVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRF SGSGSGADFTLKISRVEAEDLGVYFCSQSTHVPYTFGGGTKLEIK 1084 BCMA-107 BC 247-A4 scFv aa EVQLVEQSGPELVKPGASVKISCKVSGYSFPDYYINWVKQRPGQGLEWIGWIYFASGNSEYNERFTG KATLTVDTSSNTAYMQLSSLTSEDTAVYFCASLYDYDWYFDVWGQGTTVTVSSGGGGSGGGGSGGGG SELVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDR FSGSGSGADFTLKISRVEAEDLGVYFCSQSTHVPYTFGGGTKLEIK 1085 BCMA-108 BC 246-B6 VH CDR1 aa GYSFPDYYIN 1086 BCMA-108 BC 246-B6 VH CDR2 aa WIYFASGNSEYNE 1087 BCMA-108 BC 246-B6 VH CDR3 aa LYDYDWYFDV 1088 BCMA-108 BC 246-B6 VL CDR1 aa RSSQSLVHSNGNTYLH 1089 BCMA-108 BC 246-B6 VL CDR2 aa KVSNRFS 1090 BCMA-108 BC 246-B6 VL CDR3 aa FQGSHVPWT 1091 BCMA-108 BC 246-B6 VH aa EVQLVEQSGPQLVKPGASVKISCKVSGYSFPDYYINWVKQRPGQGLEWIGWIYFASGNSEYNERFTG KATLTVDTSSNTAYMQLSSLTSEDTAVYFCASLYDYDWYFDVWGQGTTVTVSS 1092 BCMA-108 BC 246-B6 VL aa ELVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPGRF SGSGSGTDFTLKINRVEAEDLGVYYCFQGSHVPWTFGGGTKLEIK 1093 BCMA-108 BC 246-B6 scFv aa EVQLVEQSGPQLVKPGASVKISCKVSGYSFPDYYINWVKQRPGQGLEWIGWIYFASGNSEYNERFTG KATLTVDTSSNTAYMQLSSLTSEDTAVYFCASLYDYDWYFDVWGQGTTVTVSSGGGGSGGGGSGGGG SELVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPGR FSGSGSGTDFTLKINRVEAEDLGVYYCFQGSHVPWTFGGGTKLEIK